DRUG-ANTIBODY CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES

Abstract

Drug conjugates having the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab where: D is a drug fraction having the following formula (I) or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, (see formula) where D is covalently linked by a hydroxy or amine group to (X)b if any, to (AA)w if any or to (T)g if any, or (L); which are useful in the treatment of cancer.

Description

DRUG-ANTIBODY CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES field of invention The present invention relates to novel drug conjugates, drug binding compounds, methods for their preparation, pharmaceutical compositions containing such drug conjugates, and their use as antitumor agents. Background of the invention The international patent application number PCT / EP2018 / 060868 refers to new ecteinascidin derivatives that show very promising antitumor activity. One of the compounds described in said patent application is currently in Phase I clinical trials for the prevention and treatment of solid tumors. Cancer treatment has advanced significantly in recent years with the development of pharmaceutical entities that target and kill cancer cells more effectively. Researchers have taken advantage of cell surface receptors and antigens selectively expressed by target cells, such as cancer cells, to develop antibody-based pharmaceutical entities that bind, in the example of tumors, antigens. tumor-associated or tumor-specific. In order to achieve this, cytotoxic molecules such as chemotherapeutic drugs, bacteria and plant and bacterial toxins, and radionuclides have been chemically linked to monoclonal antibodies that bind to tumor-associated or tumor-specific cell surface antigens. Therefore, antibody-drug conjugates (ADCs) represent a challenging development area given the complex charge, antibody structure, and binder, but the need to develop other antibody-drug conjugates remains. Brief description of the invention There is a need for new active drug conjugates. The present invention addresses this need. Furthermore, it provides novel drug binding compounds for use in the preparation of drug conjugates of the present invention, processes for the preparation of the novel drug conjugates of the present invention, pharmaceutical compositions containing such drug conjugates, and their use as agents. antitumor agents, as well as a set comprising the drug conjugate of the present invention for use in the treatment of cancer. In a first aspect of the present invention, a drug conjugate is provided that contains a drug moiety covalently linked to the remainder of the drug conjugate, and the drug conjugate has the formula [D-(X)b-(AA)w -(T)g-(L)-]n-Ab where: D is a drug moiety possessing the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, I PQQCn / 1 7Π7 / 3 / ΥΙΛΙ LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ where: D is covalently linked via a hydroxy or amine group to (X)b, if any, to (AA)W if any, or to (T)g if any, or to (L); Yes-NH-u-O-; Ri is -OH or -CN; R2 is a group -C(=O)Ra; Rs is hydrogen or a -ORb group; R4 is selected from hydrogen, -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH; Rase is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Re is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNHe is a protecting group for amino, with the optional proviso that when R4 is hydrogen, then Y is -O-; X and T are extension groups that can be the same or different; each AA is independently an amino acid unit; L is a linking group; w is an integer from 0 to 12; b is an integer of 0 or 1; g is an integer of 0 or 1; Ab is a moiety comprising at least one antigen binding site; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the fraction that comprises at least one antigen-binding site and is in the range of 1 to 20. In another aspect of the present invention, a drug conjugate is provided comprising a drug moiety covalently linked to the remainder of the drug conjugate, and the compound has the formula [D-(X)b-(AA)w-(T )g-(L)-]n-Ab, where: D is a drug moiety having the following formula (IH) or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, r3 (IH) LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: the wavy line indicates the point of covalent attachment to (X)b if any, (AA)W if any, (T)g if any, or to (L); each Y and Z is independently selected from -NH- and -O-; Ri is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb; Rase is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl, where optional substituents are one or more R x substituents; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl, where the optional substituents are one or more Rx substituents; The Rx substituents are selected from the group consisting of C1-C12 alkyl groups that may be optionally substituted with at least one Ry group, C2-C12 alkenyl groups that may be optionally substituted with at least one Ry group, C2-C12 alkynyl groups that may be optionally substituted with at least one Ry group, halogen atoms, oxo groups, thio groups, cyano groups, nitro groups, ORy, OCORy, OCOORy, CORy, COORy, OCONRyRz, CONRyRz, S(O)Ry, SO2Ry, P( O)(Ry)ORz, NRyRz, NRyCORz, NRyC(=O)NRyRz, NRyC(=NRy)NRyRz, aryl groups having 6 to 18 carbon atoms in one or more rings that may be optionally substituted with one or more substituents, which may be the same or different selected from the group consisting of Ry, ORy, OCORy, OCOORy, NRyRz, NRyCORz, and NRyC(=NRy)NRyRz, aralkyl groups comprising an alkyl group having 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, aralkyloxy groups comprising an alkoxy group having 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, and a saturated heterocyclic group or unsaturated from 5 to 14 members having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, the heterocyclic group is optionally substituted with one or more Ry substituents, and where there are more of an optional substituent on any given group and the optional substituents R and may be the same or different; each Ry and Rz are independently selected from the group consisting of hydrogen, C1-C12 alkyl groups, C1-C12 alkyl groups that are substituted with at least one hydrogen atom, aralkyl groups that comprise a C1-C12 alkyl group that is substituted with an aryl group having 6 to 18 carbon atoms in one or more rings and heterocycloalkyl groups comprising a C1-C12 alkyl group that is substituted with a 5- to 14-membered saturated or unsaturated heterocyclic group having one or more rings and comprises at least one oxygen, nitrogen or sulfur atom in said one or more rings; X and T are extension groups that can be the same or different; each AA is independently an amino acid unit; L is a linking group; w is an integer from 0 to 12; b is an integer of 0 or 1; g is an integer of 0 or 1; where b+g+w is optionally not 0; Ab is a moiety comprising at least one antigen binding site; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the fraction that comprises at least one antigen-binding site and is in the range of 1 to 20. In another aspect of the present invention, a drug conjugate is provided comprising a drug moiety covalently linked to the remainder of the drug conjugate and the drug conjugate has the formula [D-(X)b-(AA)w-( T)g-(L)-]n-Ab, where: D is a drug moiety possessing the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, LPQQCn / Lznz / Σΐ / ΥΙΛΙ R3 where: D is covalently attached via a hydroxy or amine group to (X)b if any, (AA)w if any, (T)g if any, or to (L); Yes-NH-u-O-; Ri is -OH or -CN; R2 is a group -C(=O)Ra; Rs is hydrogen or a -ORb group; R4 is selected from hydrogen, -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH; Ra is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Re is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNHe is a protecting group for amino, with the optional proviso that when R4 is hydrogen, then Y is -O-; X and T are extension groups that can be the same or different; each AA is independently an amino acid unit; L is a linking group; w is an integer from 0 to 12; b is 1; g is an integer of 0 or 1; Ab is a moiety comprising at least one antigen binding site; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the fraction that comprises at least one antigen-binding site and is in the range of 1 to 20. In another aspect of the present invention, a drug conjugate is provided comprising a drug moiety covalently linked to the remainder of the drug conjugate, and the drug conjugate has the formula [D-(X)b-(AA)w- (T)g-(L)-]n-Ab, where: D is a drug moiety possessing the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, LPQQCn / I 7Π7 / 3 / ΥΙΛΙ (I where: D is covalently attached via a hydroxy or amine group to (X)b if any, (AA)W if any, (T)g if any, or to (L); Yes-NH-u-O-; Ri is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb; R4 is selected from hydrogen, -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH; Rase is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rcse is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNHe is a protecting group for amino, with the optional proviso that when R4 is hydrogen, then Y is -O-; X and T are extension groups that can be the same or different; each AA is independently an amino acid unit; L is a linking group; w is 2; b is 1; g is an integer of 0 or 1; Ab is a moiety comprising at least one antigen binding site; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the fraction that comprises at least one antigen-binding site and is in the range of 1 to 20. As we will explain and exemplify in more detail below, the drug conjugates of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab of the present invention represent a discovery in addressing the problems outlined above that require other drug conjugates than those based on the three main families of cytotoxic drugs that have been used as payloads to date, showing excellent antitumor activity. In preferred embodiments of the present invention, a drug conjugate as defined herein, or a pharmaceutically acceptable salt, ester, solvate, tautomer, or stereoisomer thereof, is provided, wherein D is a drug moiety selected from the following: formulas (IHa) and (IHb): LPQQCn / I 7Π7 / 3 / ΥΙΛΙ (IHa) (IHb) LPQQCn / Lznz / Σΐ / ΥΙΛΙ where the wavy lines, Ri, R2, R3, Y, and Z are as defined for formula (IH). In another aspect of the present invention, there is provided a compound of the formula D-(X)b-(AA)w-(T)g-Li or of the formula D-(X)b-(AA)w-(T) g-H, where: L1 is a linker selected from the group of formulas consisting of: O ^-6- r19-NH-NH2 O ó-R19-N=O0 , or oHo ^_(5-R19_N=C=S d-R19-N-ó-CH2-G , O O O n=x ^_¿}_r19_¿_j , (5-r19-s-s^ \ o ^_<5_r19-o-nh2each of the wavy lines indicates the point of covalent attachment to (T)g if any, (AA)W if any, (X)b if any, or to D; G is selected from halo, -0-mesyl, and -O-tosyl; J is selected from halo, hydroxy, - / V-succinimidoxy, -O-(4-nitrophenyl), -O-pentafluorophenyl, -0-tetrafluorophenyl, and -0-C(0)-OR2o; R19 is selected from C1-C12 alkylene, Cb-Cb carbocyclo, -O-(C1-C12 alkylene), Ce-Cis arylene on one or more rings which may be optionally substituted with one or more substituents Rx, C1-C12 alkylene- Cs-Cis arylene, where the arylene group is on one or more rings that may be optionally substituted with one or more Rx substituents, Ce-Cis-arylene-C1-C12 alkylene, where the arylene group is on one or more rings that may be optionally substituted with one or more substituents Rx, C1-C12 alkylene-carbocyclo(Cs-Cs)-, -(carbocyclo Cs-Cs)-C1-C12 alkylene-, C5-C14 heterocycle, wherein said heterocycle group may be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom on said one or more rings, said group being optionally substituted with one or more substituents Rx, C1-C12 alkylene-(C5 heterocycle -C14)- where said heterocyclo group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -(C5-C14 heterocycle)-C1-C12 alkylene-, where the heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more Rx substituents, -(OCH2CH2)r- and -CH2-(OCH2CH2)r-, where each of the aforementioned alkylene substituents, either alone or attached to another moiety on the carbon chain it can be optionally substituted by one or more Rx substituents; R20 is C1-C12 alkyl or an aryl group having 6 to 18 carbon atoms in one or more aromatic rings, said aryl groups being optionally substituted with one or more Rx substituents; r is an integer from 1-10; g is an integer of 0 or 1; b is an integer of 0 or 1; w is an integer from 0 to 12; and each of D, Rx, X, T, and AA is as defined in the first aspect of the invention. In preferred embodiments of the present invention, b+g+w is not 0. In other embodiments, b+w is not 0. In still other embodiments, when w is not 0, then b is 1. In another embodiment, when w is 0, so b is 1. In another aspect of the present invention, there is provided a compound of the formula D-(X)b-(AA)w-(T)g-Li or of the formula D-(X)b-(AA)w-(T) g-H, or a pharmaceutically acceptable salt, ester, solvate, tautomer, or stereoisomer thereof; where each of D, X, AA, T, L1, b, g and w are as defined herein; but, furthermore, where if the compound is a compound of formula D-(X)b-(AA)w-(T)g-H, then b+w+g^0. In a preferred embodiment according to aspects of the present invention, n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the fraction comprising the least one antigen binding site and is in the range of 1 to 20. In other embodiments, n is in the range of 1-12, 1-8, 3-8, 3-6, 3-5 or is 1, 2, 3, 4, 5 or 6 preferably 3, 4, or 5 or 4. In another aspect of the present invention, a drug D moiety is provided for use in a drug-antibody conjugate. In another aspect of the present invention, a drug fraction D is provided for use as a payload in a drug-antibody conjugate. In another aspect of the present invention, there is provided the use of a drug fraction D as described herein, in the preparation of a drug-antibody conjugate. In another aspect of the present invention, a drug conjugate according to the present invention is provided for use as a medicament. In another aspect of the present invention, there is provided a drug conjugate according to the LPQQCn / Lznz / Σΐ / ΥΙΛΙ present invention for use in the treatment of cancer, and, more preferably, a cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma , gastric and ovarian cancer. The most preferred cancer is breast cancer. In another aspect of the present invention, there is provided a pharmaceutical composition comprising a drug conjugate according to the present invention and a pharmaceutically acceptable carrier. In another aspect of the present invention, a method for the prevention or treatment of cancer is provided, comprising administering an effective amount of a drug conjugate according to the present invention to a patient in need thereof. Preferably, the cancer is selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer. The most preferred cancer is breast cancer. In another aspect of the present invention, there is provided the use of a drug conjugate according to the present invention in the preparation of a medicament for the treatment of cancer and, more preferably, a cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer. The most preferred cancer is breast cancer. In another aspect of the present invention, there is provided a kit comprising a therapeutically effective amount of a drug conjugate according to the present invention and a pharmaceutically acceptable carrier. The kit is to be used in the treatment of cancer and, more preferably, a cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer. The most preferred cancer is breast cancer. A kit according to the present invention may comprise a therapeutically effective amount of a drug conjugate according to the present invention and, optionally, instructions for using the drug conjugate in the treatment of cancer, particularly a cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer; with the greatest preference to use the drug conjugate in the treatment of breast cancer. In another aspect of the present invention, there is provided a process for the preparation of a drug conjugate according to the present invention comprising conjugating an Ab moiety comprising at least one antigen binding site and a drug D, Ab and D which are as defined herein. Detailed description of preferred modalities The following applies to all aspects of the present invention: In the compounds of the present invention, alkyl groups may be branched or unbranched and preferably have from 1 to about 12 carbon atoms. A more preferred class of alkyl groups have from 1 to about 6 carbon atoms. are preferred LPQQCn / LZnZ / q / YIAI further alkyl groups having 1, 2, 3 or 4 carbon atoms. Methyl, ethyl, n-propyl, isopropyl, and butyl, including n-butyl, isobutyl, sec-butyl, and tert-butyl, are particularly preferred alkyl groups in the compounds of the present invention. In the compounds of the present invention, alkenyl groups may be branched or unbranched, have one or more double bonds, and have 2 to about 12 carbon atoms. A more preferred class of alkenyl groups have from 2 to about 6 carbon atoms. Even more preferred are alkenyl groups having 2, 3 or 4 carbon atoms. Ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, and 3-butenyl are particularly preferred alkenyl groups in the compounds of the present invention. In the compounds of the present invention, alkynyl groups may be branched or unbranched, have one or more triple bonds, and have 2 to about 12 carbon atoms. A more preferred class of alkynyl groups have from 2 to about 6 carbon atoms. Alkynyl groups having 2, 3 or 4 carbon atoms are even more preferred. Suitable aryl groups in the compounds of the present invention include single-ring and multi-ring compounds, including multi-ring compounds containing separate and / or fused aryl groups. Typical aryl groups contain 1 to 3 separate and / or fused rings and 6 to about 18 carbon ring atoms. Preferably, the aryl groups contain from 6 to about 10 carbon ring atoms. Especially preferred aryl groups included substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl, substituted or unsubstituted phenanthryl, and substituted or unsubstituted anthryl. Suitable heterocyclic groups include heteroaromatic and heteroalicyclic groups containing 1 to 3 separate and / or fused rings and 5 to about 18 ring atoms. Preferably, the heteroaromatic and heteroalicyclic groups contain from 5 to about 10 ring atoms, most preferably 5, 6, or 7 ring atoms. Suitable heteroaromatic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, for example, coumarinyl, including 8-coumarinyl, quinolyl, including 8-quinolyl, isoquinolyl , pyridyl, pyrazinyl, pyrazolyl, pyrimidinyl, furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, imidazolyl, indolyl, isoindolyl, indazolyl, indolizinyl, phthalazinyl, pteridyl, purinyl, oxadiazolyl, thiadiazolyl, furazan ilo, pyridazinyl , triazinyl, cinnolinyl, benzimidazolyl, benzofuranyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridyl. Suitable heteroalicylic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S and include, for example, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, azetidinyl , oxetanyl, thietanyl, homopiperidyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2 / 7-pyranyl, 4 / 7-pyranyl, dioxanyl , 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexyl, 3azabicyclo[4.1.0]heptyl, 3H-indolyl, and quinolizinyl. LPQQCñ / Lznz / Σΐ / ΥΙΛΙ The aforementioned groups may be substituted at one or more available positions with one or more suitable groups, such as OR', =O, SR', SOR', SO2R', NO2, NHR', NR'R', =N- R', NHCOR', N(COR')2, NHSO2R', NR'C(=NRjNR'R', CN, halogen, COR', COOR', OCOR', OCONHR', OCONR'R', CONHR', CONR'R', protected OH, protected amino, protected SH, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, and heterocyclic group substituted or unsubstituted, where each of the R' groups is independently selected from the group consisting of hydrogen, OH, NO2, NH2, SH, CN, halogen, COH, COalkyl, CO2H, C1-C12 alkyl substituted or unsubstituted substituted, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group Where such groups are substituted for themselves, the substituents may be selected from the following: preceding list. Also, when there is more than one R' group on the substituent, each R' may be the same or different. In the compounds for the present invention, halogen substituents include F, Cl, Br, and I. More particularly, in the compounds of the present invention, the alkyl groups in the definitions of R20, Ra, Rb, Re, Rx, Ry, and Rz may be straight chain or branched chain alkyl groups having 1 to 12 carbon atoms. carbon and are preferably an alkyl group having 1 to 6 carbon atoms, more preferably a methyl group, an ethyl group, or a / -propyl group, and most preferably a methyl group. In the definitions of M and Q, they can be straight chain or branched chain alkyl groups having 1 to 6 carbon atoms. Methyl, ethyl, n-propyl, isopropyl, and butyl, including n-butyl, isobutyl, sec-butyl, and tert-butyl, are particularly preferred alkyl groups in the compounds of the present invention. In the compounds of the present invention, alkenyl groups in the definitions of Ra, Rb, Re and Rx are branched or unbranched, and may have one or more double bonds and 2 to 12 carbon atoms. Preferably they have 2 to 6 carbon atoms, and more preferably they are branched or unbranched alkenyl groups having 2, 3 or 4 carbon atoms. Ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, and 3-butenyl are particularly preferred alkenyl groups in the compounds of the present invention. In the compounds of the present invention, alkynyl groups in the definitions of Ra, Rb, Re and Rx are branched or unbranched, and may have one or more triple bonds and 2 to 12 carbon atoms. Preferably they have 2 to 6 carbon atoms, and more preferably they are branched or unbranched alkynyl groups having 2, 3 or 4 carbon atoms. In the compounds of the present invention, halogen substituents in the definitions of Rx, Ry, and Rz include F, Cl, Br, and I, preferably Cl. In the compounds of the present invention, the saturated or unsaturated heterocyclic group, from 5 to 14 members, in the definitions of Rx, is a heterocyclic group possessing one or more rings, comprising at least one oxygen, nitrogen or sulfur atom. in said one or more rings. The heterocyclic group is a group that may be a heteroaromatic group or a heteroalicyclic group, of which LPQQCn / Lznz / Σΐ / ΥΙΛΙ the last mentioned may be partially unsaturated, and both the aromatic and also alicyclic heterocyclic groups contain 1 to 3 separate or fused rings. Preferably, the heteroaromatic and heteroalicyclic group contain 5 to 10 ring atoms. Suitable heteroaromatic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O and S atoms and include, for example, quinolyl including 8-quinolyl, isoquinolyl, coumarinyl including 8-coumarinyl, pyridyl, pyrazinyl, pyrazolyl, pyrimidinyl, furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, imidazolyl, indolyl, isoindolyl, indazolyl, indolizinyl, phthalazinyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazan ilo, pyridazinyl, triazinyl, cinnolinyl, benzimidazolyl, benzofuranyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridyl. Suitable heteroalicyclic groups in the compounds of the present invention contain one, two, or three heteroatoms selected from N, O, and S atoms and include, for example, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexyl, 3azabicyclo[4.1.0]heptyl, 3H-indolyl, and quinolizinyl . In the compounds of the present invention, the aryl group in the definition of Rxy R20 is a single-ring or multi-ring compound containing separate and / or fused aryl groups, possessing 6 to 18 ring atoms, and is optionally substituted. . Typical aryl groups contain 1 to 3 separate or fused rings. Preferably, aryl groups contain from 6 to 12 carbon ring atoms. Particularly preferred aryl groups include substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl, substituted or unsubstituted phenanthryl, and substituted or unsubstituted anthryl, and most preferably substituted or unsubstituted phenyl, where the substituents are as indicated above. In the compounds of the present invention, aralkyl groups in the definitions of Rx, Ry, and Rz comprise an alkyl group as defined and exemplified above that is substituted by one or more aryl groups as defined and exemplified above. Preferred examples include optionally substituted benzyl, optionally substituted phenylethyl, and optionally substituted naphthylmethyl. In the compounds of the present invention, aralkyloxy groups in the definitions of R x comprise an alkoxy group having 1 to 12 carbon atoms that is substituted with one or more aryl groups as defined and exemplified above. Preferably, the alkoxy moiety has 1 to 6 carbon atoms and the aryl group contains 6 to about 12 carbon ring atoms, and most preferably, the aralkyloxy group is optionally substituted benzyloxy, optionally substituted phenylethoxy, and optionally naphthylmethoxy. substituted. In the compounds of the present invention, heterocycloalkyl groups in the definitions of Ry and Rz comprise an alkyl group as defined and exemplified above which is substituted with LPQQCn / Lznz / Σΐ / ΥΙΛΙ one or more heterocyclyl groups as defined and exemplified above. Preferably, heterocycloalkyl groups comprise an alkyl group having 1 to 6 carbon atoms and which is substituted with a heterocyclyl group having 5 to 10 ring atoms on 1 or 2 ring atoms and may be aromatic, partial or totally saturated. More preferably, heterocycloalkyl groups comprise a methyl or ethyl group substituted with a heterocyclyl group selected from the group consisting of pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, oxanyl, thianyl, 8-quinolyl, isoquinolyl, pyridyl, pyrazinyl, pyrazolyl, pyrimidinyl, furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl and benzimidazole. In the compounds of the present invention, the alkylene groups in the definition of R19 are straight or branched alkylene groups having 1 to 12 carbon atoms and the alkylene groups in the definitions of Μ, X, T, and R30 are alkylene groups. straight or branched having from 1 to 6 carbon atoms. Preferably, the alkylene groups in the definition of R19 are straight or branched alkylene groups having 1 to 8 carbon atoms, more preferably straight or branched alkylene groups having 1 to 6 carbon atoms. For M, straight or branched alkylene groups having 1 to 3 carbon atoms are preferred. In the definition of X, the alkylene groups in the definition of X are preferably straight or branched alkylene groups having 2 to 4 carbon atoms. For T, straight or branched alkylene groups having 2 to 4 carbon atoms are preferred. In the definition of R30, straight or branched alkylene groups having 2 to 4 carbon atoms are preferred, most preferably a straight alkylene group having 3 carbon atoms. For the avoidance of doubt, the term alkylene is used to refer to alkandiyl groups. In the compounds of the present invention, the carbocyclo groups in the definitions of R19 and M are cycloalkyl groups having 3 to 8 carbon atoms having two covalent bonds at any position on the cycloalkyl ring connecting the cycloalkyl group to the rest of the drug conjugate. Preferably, the carbocyclo groups in the definitions of R19 and M are cycloalkyl groups having 3 to 7 carbon atoms, and more preferably carbocyclo groups having 5 to 7 carbon atoms. In the compounds of the present invention, arylene groups in the definition of R19 are aryl groups possessing from 6 to 18 carbon atoms in one or more rings possessing two covalent bonds at any position in the aromatic ring system connecting the arylene groups with the remainder of the drug conjugate. Preferably, the arylene groups in the definition of R19 are aryl groups having from 6 to 12 carbon atoms in one or more rings having two covalent bonds at any position in the aromatic ring system, and most preferably are phenylene groups. In the compounds of the present invention, heterocyclo groups in the definition of R19 are heterocyclyl groups containing 1 to 3 separate or fused rings having 5 to 14 ring atoms and comprising at least one oxygen, nitrogen or sulfur in said one or more rings, where there are two covalent bonds at any position on the ring system of said heterocyclic groups. Heterocyclic groups are groups that may be heteroaromatic groups or heteroalicyclic groups (of which the heteroalicyclic groups may be partially unsaturated). LPQQCn / I 7Π7 / 3 / ΥΙΛΙ Preferably, heterocyclo groups in the definition of R19 are heterocyclic groups containing 1 to 3 separate or fused rings having 5 to 12 ring atoms and comprising at least one oxygen, nitrogen or sulfur atom in said one or more. rings, where there are two covalent bonds at any position in the ring system of said heterocyclic groups. When more than one Rx, R, or Rz optional substituent exists on a substituent, each Rx substituent may be the same or different, each Ry substituent may be the same or different, and each Rz may be the same or different. In one embodiment, D can be a compound of formula I or a pharmaceutically acceptable salt or ester thereof: LPQQCn / I 7Π7 / 3 / ΥΙΛΙ r3 I where: Yes-NH-u-O-; R1 is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb; R4 is selected from hydrogen, -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH; Rase is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rcse is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNH is a protecting group for amino. In one embodiment, the compound of formula I has the proviso that when R4 is hydrogen, then Y is -O-. In another embodiment, the compound of formula I can be a compound of formula IC, or a pharmaceutically acceptable salt or ester thereof: LPQQCn / Lznz / Σΐ / ΥΙΛΙ ,Η° Η > where: Yes -ΝΗ-; Ri is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb¡ R4 is selected from -CH2OH, -CH2O-(C=O)Rc, -CH2NH2 and -CH2NHProtNH; Rase is selected from hydrogen, substituted or unsubstituted Ci-Ci2 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-Ci2 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rcse is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNH is a protecting group for amino. In yet another embodiment, the compound of formula I may be a compound of formula ID, or a pharmaceutically acceptable salt or ester thereof: ,H° H > where: And so-; R1 is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb; R4 is selected from hydrogen, -CH2OH, -CH2O-(C=O)Rc, -CH2NH2 and -CH2NHProtNH; Ra is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Re is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNH is a protecting group for amino. In yet another embodiment, the compound of formula I may be a compound of formula IE, or a pharmaceutically acceptable salt or ester thereof: LPQQCn / Lznz / Σΐ / ΥΙΛΙ IE where: Yes -NH- or -O-; R1 is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Rase is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNH is a protecting group for amino. In yet another embodiment, the compound of formula I can be a compound of formula IA or a pharmaceutically acceptable salt or ester thereof: I PQQCn / 1 7Π7 / 3 / ΥΙΛΙ where: Yes -NH-u-O-; Ri is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen; R4 is selected from hydrogen, -CH2OH, -CH2O-(C=O)Rc, -CH2NH2 and -CH2NHProtNH; Rase is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rcse is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNH is a protecting group for amino. In one embodiment, the compound of formula IA has the proviso that when R4 is hydrogen, then Y is -O-. In yet another embodiment, the compound of formula I can be a compound of formula IB or a pharmaceutically acceptable salt or ester thereof: R3 IB where: Yes -NH-u-O-; R1 is -OH or -CN; R2 is a group -C(=O)Ra; R3 is a -ORb group; R4 is selected from hydrogen, -CH2OH, -CH2O-(C=O)Rc, -CH2NH2 and -CH2NHProtNH; Ra is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; Re is selected from substituted or unsubstituted Ci-Ci2 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNH is a protecting group for amino. In one embodiment, the compound of formula IB has the proviso that when R4 is hydrogen, then Y is -O-. In yet another embodiment, the compound of formula I may be a compound of formula IF or a pharmaceutically acceptable salt or ester thereof: LPQQCn / Lznz / Σΐ / ΥΙΛΙ r3 where: Yes-NH-u-O-; R1 is -OH; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb¡ R4 is selected from hydrogen, -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH; Rase is selected from hydrogen, substituted or unsubstituted Ci-Ci2 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-Ci2 alkynyl; Rb is selected from substituted or unsubstituted Ci-Ci2 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-Ci2 alkynyl; Re is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-Ci2 alkynyl; and ProtNH is a protecting group for amino. In one embodiment, the compound of formula IF possesses the proviso that when R4 is hydrogen, then Y is -O-. In yet another embodiment, the compound of formula I may be a compound of formula IG or a pharmaceutically acceptable salt or ester thereof: LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: Yes -NH-u-O-; Ri is -OH or -CN; R2 is acetyl; R3 is hydrogen or a group -ORb¡ R4 is selected from hydrogen, -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH; Rb is selected from substituted or unsubstituted Ci-Ci2 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-Ci2 alkynyl; Re is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and ProtNH is a protecting group for amino In one embodiment, the compound of formula IG possesses the proviso that when R4 is hydrogen, then Y is -O-. Preferred compounds of the compounds of formula I, IA, IB, IC, ID, IE, IF, or IG, are those having the general formula a or b, or a pharmaceutically acceptable salt or ester thereof: r3r3 Note that when compounds have the general formula a or b, R4 cannot be hydrogen. Preferred compounds of the compounds of formula I, IA, IB, ID, IF, or IG may be those possessing formula c or a pharmaceutically acceptable salt or ester thereof: r3 LPQQCn / I 7Π7 / 3 / ΥΙΛΙ where: Ri is -OH or -CN; R2 is a group -C(=O)Ra; R3 is hydrogen or a group -ORb; Rase is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl. For the avoidance of doubt, the above-mentioned compounds may be drug moiety D and are covalently linked via a hydroxy or amine group to (X)b if any, (AA)W if any, (T )g if any, or to (L). Thus, when conjugated, a covalent bond replaces a proton on a hydroxy or amine group in the compound. Preferred compounds include compounds of general formula I, IA, IB, IE, IF, IG, la, lAa, IBa, lEa, IFa, IGa, Ib, lAb, IBb, lEb, IFb, and IGb, where: Yes-NH-; and R1; R2; R3; R4; ra; Rb; rc; and ProtNH are as defined above. Preferred compounds include compounds of general formula I, IA, IB, IE, IF, IG, la, lAa, IBa, lEa, IFa, IGa, Ib, lAb, IBb, lEb, IFb, and IGb, where: And so-; and R1; R2; R3; R4; ra; Rb; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, ID, IE, IG, la, lAa, IBa, ICa, IDa, lEa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, e IGB, where: R1 is -OH; Hey; R2; R3; R4; ra; Rb; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, ID, IE, IF, la, lAa, IBa, ICa, IDa, lEa, IFa, Ib, lAb, IBb, ICb, IDb, lEb, e IFb, where: R2 is a group -C(=O)R where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. more preferred R2 is acetyl; Hey; R1; R3; R4; Rb; Re; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IB, IC, ID, IE, IF, IG, la, IBa, ICa, IDa, lEa, IFa, IGa, Ib, IBb, ICb, IDb, lEb, IFb, e IGB, where: Ra is hydrogen or a group -ORb for compounds of formula I, IC, ID, IE, IF, IG, la, ICa, IDa, IEa, IFa, IGa, Ib, ICb, IDb, IEb, IFb, or IGb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec-butyl substituted or unsubstituted and substituted or unsubstituted tert-butyl. The most preferred R3's are hydrogen and methoxy, of which hydrogen is the most preferred R3 group; Hey; R1; R2; R4; ra; Re; and ProtNH are as defined above. Other preferred compounds include compounds of general formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb , lEb, IFb, and IGb, where: R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, ID, IF, IG, la, lAa, IBa, ICa, IDa, IFa , IGa, Ib, IAb, IBb, ICb, IDb, IFb, or IGb; and R4 is selected from -CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Rc is a substituted or unsubstituted C1-C6 alkyl. Particularly preferred is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted sec-butyl or unsubstituted, and substituted or unsubstituted tert-butyl. More preferred Rc is methyl. More preferred R4 is selected from -CH2OH and -CH2NH2. More preferably, R4 can be -CH2NH2. The most preferred R4 is -CH2OH; Hey; R1; R2; R3; ra; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R1 is -OH; and R2; R3; R4; ra; Rb; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R2 is -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred R is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec-butyl replaced or not substituted and unsubstituted or substituted tert-butyl LPQQCn / Lznz / Σΐ / ΥΙΛΙ. more preferred R2 is acetyl; and R1; R3; R4; Rb; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB where: Yes-NH-; Ra is hydrogen or a group -ORb for compounds of formula I, IC, IE, IF, IG, la, ICa, lEa, IFa, IGa, Ib, ICb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferably Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec-butyl substituted or unsubstituted and substituted or unsubstituted tert-butyl. More preferred R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R1; R2; R4; ra; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes -NH-; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib , IAb, IBb, ICb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where R is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rc is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl substituted, or substituted or unsubstituted tert-butyl. More preferred Rc is methyl. More preferably R4 is selected from CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. More preferably, R4 is -CH2OH; and R1; R2; R3; ra; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R1 is -OH; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. More preferably, R2 is acetyl; and R3; R4; Rb; rc; and ProtNH are as defined above. LPQQCn / Lznz / Σΐ / ΥΙΛΙ Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; Ri is -OH; Rs is hydrogen or a -ORb group for compounds of formula I, IC, IE, IF, IG, la, ICa, lEa, IFa, IGa, Ib, ICb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted sec-butyl or unsubstituted and substituted or unsubstituted tert-butyl. Most preferred R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R2; R4; ra; Re; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R1 is -OH; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib , IAb, IBb, ICb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where R is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rc is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl substituted, and substituted or unsubstituted tert-butyl. More preferred Rc is methyl. More preferably R4 is selected from CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. The most preferred R4 is -CH2OH; and R2; R3; ra; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Cs alkyl. Particularly preferred R is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or sec-butyl unsubstituted and substituted or unsubstituted tert-butyl. more preferred R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula I, IC, IE, IF, IG, la, ICa, IEa, IFa, IGa, Ib, ICb, IEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ -ORb group for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec-butyl substituted or unsubstituted and substituted or unsubstituted tert-butyl. Most preferred Ra is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R1; R4; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Cs alkyl. Particularly preferred R is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or sec-butyl unsubstituted and substituted or unsubstituted tert-butyl. R2 more preferably is acetyl; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib , IAb, IBb, ICb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Rc is a substituted or unsubstituted C1-C6 alkyl. Particularly preferred is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl , and substituted or unsubstituted tert-butyl. More preferred Rc is methyl. More preferably R4 is selected from CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. More preferred R4 is -CH2OH; and R1; R3; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R3 is hydrogen or a group -ORb for compounds of formula I, IC, IE, IF, IG, la, ICa, IEa, IFa, IGa, Ib, ICb, IEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted sec-butyl or unsubstituted and substituted or unsubstituted tert-butyl. The most preferred R3's are hydrogen and methoxy, of which hydrogen is the most preferred R3 group; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for compounds of LPQQCn / Lznz / Σΐ / ΥΙΛΙ formula I, ΙΑ, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib, lAb, IBb, ICb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where R is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rc is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted sec-butyl or unsubstituted, and substituted substituted or unsubstituted ferr-butyl. Most preferred rc is methyl. More preferably R4 is selected from CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. More preferred R4 is -CH2OH; and Ri; R2; and Ra; are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R1 is -OH; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferably, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl and substituted or unsubstituted ferr-butyl. More preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula I, IC, IE, IF, IG, la, ICa, IEa, IFa, IGa, Ib, ICb, IEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted ferr-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred Rs group; and R4; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R1 is -OH; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl and substituted or unsubstituted ferr-butyl. Most preferably R2 is acetyl; LPQQCn / Lznz / Σΐ / ΥΙΛΙ R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib , IAb, IBb, ICb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Re is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rcse is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl, and substituted or unsubstituted ferr-butyl. Most preferably, Rces methyl. More preferably, R4 is selected from CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. More preferably, R4 is -CH2OH; and R3; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, e IGB, where: Yes-NH-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl and substituted or unsubstituted ferr-butyl. Most preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula I, IC, IE, IF, IG, la, ICa, IEa, IFa, IGa, Ib, ICb, IEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted ferr-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib , IAb, IBb, ICb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where R is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rc is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted sec-butyl or unsubstituted, and substituted or unsubstituted ferr-butyl. Most preferably, Rces methyl. More preferably, R4 is selected from CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH; and R1 is as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, IC, IE, IF, IG, LPQQCn / I 7Π7 / 3 / ΥΙΛΙ la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, and IGb, where: Yes-NH-; Ri is -OH; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula I, IC, IE, IF, IG, la, ICa, IEa, IFa, IGa, Ib, ICb, IEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib, IAb, IBb, ICb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where R is a substituted or unsubstituted C1-C6 alkyl. With particular preference, Rcse is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl, and substituted or unsubstituted tert-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R1 is -OH; and R2; R3; R4; ra; Rb; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted C1-C6 alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, isopropyl LPQQCn / I 7Π7 / 3 / ΥΙΛΙ substituted or unsubstituted, n-butyl substituted or unsubstituted, isobutyl substituted or unsubstituted, sec-butyl substituted or unsubstituted and tert-butyl substituted or unsubstituted. Most preferably R2 is acetyl; and R1; R3; R4; Rb; Re; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R3 is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted terebutyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R1; R2; R4; ra; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib , IAb, IBb, IDb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Rc is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rc is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl, and substituted or unsubstituted tert-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from -CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH; and R-i; R2; R3; ra; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R1 is -OH; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb ; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; LPQQCn / Lznz / Σΐ / ΥΙΛΙ and R3; R4; Rb; Re; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R1 is -OH; Ra is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R2; R4; ra; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R1 is -OH; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib , IAb, IBb, IDb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where R is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rcse is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl, and substituted or unsubstituted tert-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from -CH2OH and CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH; and R2; R3; ra; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, LPQQCn / Lznz / Σΐ / ΥΙΛΙ IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted terebutyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R1; R4; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib , IAb, IBb, IDb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Rc is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rcse is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl, and substituted or unsubstituted tert-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from -CH2OH and -CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH; and R1; R3; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R3 is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; LPQQCn / I 7Π7 / 3 / ΥΙΛΙ R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib , IAb, IBb, IDb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Re is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rcse is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl, and substituted or unsubstituted ferr-butyl. Most preferably, Rces methyl. More preferably, R4 is selected from -CH2OH and -CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH; and R1; R2; and Ra; are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R1 is -OH; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Ra is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted ferr-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R4; rc; and ProtNH are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R1 is -OH; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -butyl LPQQCn / I 7Π7 / 3 / ΥΙΛΙ substituted or unsubstituted and tert-butyl substituted or unsubstituted. Most preferably R2 is acetyl; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib , IAb, IBb, IDb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Re is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rcse is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl, and substituted or unsubstituted tert-butyl. Most preferably, Re is methyl. More preferably, R4 is selected from -CH2OH and -CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH; and R3; and Rb are as defined above. Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Ra is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted terebutyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred Rs group; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib , IAb, IBb, IDb, IFb, or IGb; and R4 is selected from CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Rc is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rc is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl, and substituted or unsubstituted ferr-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from -CH2OH and -CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH; and R1 is as defined above. LPQQCn / Lznz / Σΐ / ΥΙΛΙ Other preferred compounds include the compounds of general formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, e IGB, where: And so-; Ri is -OH; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb, or IFb ; and R2 is acetyl for compounds of formula IG, IGa or IGb; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; Rs is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa, or IAb; and R3 is a group -ORb for compounds of formula IB, IBa or IBb; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; R4 is selected from -CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib , IAb, IBb, IDb, IFb, or IGb; and R4 is selected from CH2NH2, y-CH2NHProtNH for compounds of formula IE, IEa or IEb; where Rc is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rcse is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl, and substituted or unsubstituted tert-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from -CH2OH and -CH2NH2. More preferably, R4 can be -CH2NH2. Most preferably, R4 is -CH2OH. Other preferred compounds include the compounds of the general formula le, lAc, IBc, IDc, and IGc, where: R1 is -OH; and R2; R3; Ra and Rb are as defined above. Other preferred compounds include the compounds of the general formula le, lAc, IBc, IDc, IFc, and IGc, where: R2 is a group -C(=O)Ra for compounds of formula le, lAc, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -butyl substituted or unsubstituted and tert-butyl substituted or not LPQQCn / Lznz / Σΐ / ΥΙΛΙ substituted. Most preferably R2 is acetyl; and R1; R3; Rbson as defined above. Other preferred compounds include the compounds of the general formula le, lAc, IBc, IDc, IFc, and IGc, where: Rs is hydrogen or a -ORb group for compounds of formula le, IDc, IFc, or IGc; R3 is hydrogen for compounds of formula 1Ac; and R3 is a group -ORb for compounds of formula IBc; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R1; R2; and Ra are as defined above. Other preferred compounds include the compounds of the general formula le, lAc, IBc, IDc, IFc, and IGc, where: R1 is -OH; R2 is a group -C(=O)Ra for compounds of formula le, ¡Ac, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; and R3; and Rb are as defined above. Other preferred compounds include the compounds of the general formula le, lAc, IBc, IDc, IFc, and IGc, where: R1 is -OH; R3 is hydrogen or a group -ORb for compounds of formula le, IDc, IFc, or IGc; R3 is hydrogen for compounds of formula 1Ac; and R3 is a group -ORb for compounds of formula IBc; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R2 and Rason as defined above. Other preferred compounds include the compounds of the general formula le, lAc, IBc, IDc, IFc, and IGc, where: R2 is a group -C(=O)Ra for compounds of formula le, ¡Ac, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rase is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl LPQQCn / Lznz / Σΐ / ΥΙΛΙ substituted, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl, and substituted or tert-butyl not substituted. Most preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula le, IDc, IFc, or IGc; R3 is hydrogen for compounds of formula 1Ac; and R3 is a group -ORb for compounds of formula IBc; where Rb is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group; and R1 is as defined above. Other preferred compounds include the compounds of the general formula le, lAc, IBc, IDc, IFc, and IGc, where: R1 is -OH; R2 is a group -C(=O)Ra for compounds of formula le, lAc, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; where Ra is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Ra is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl; R3 is hydrogen or a group -ORb for compounds of formula le, IDc, IFc, or IGc; R3 is hydrogen for compounds of formula 1Ac; and R3 is a group -ORb for compounds of formula IBc; where Rb is a substituted or unsubstituted alkyl Οι-Ce. With particular preference, Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. More preferably R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group. The following preferred substituents (where possible substituent groups allow) apply to compounds of formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa , IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, IGb, le, lAc, IBc, IDc, IFc, and IGc: In compounds of the present invention, particularly preferred R1 is -OH. In the compounds of the present invention, particularly preferred R2 is a group -C(=O)R where Ra is a substituted or unsubstituted C1-C6 alkyl. Particularly preferred R is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or sec-butyl unsubstituted and substituted or unsubstituted tert-butyl. Most preferably R2 is acetyl. In the compounds of the present invention, particularly preferred R3 is hydrogen or a group -ORb, where Rb is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rb is selected LPQQCn / Lznz / Σΐ / ΥΙΛΙ of substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, seo -substituted or unsubstituted butyl and substituted or unsubstituted tert-butyl. More preferably, R3 is hydrogen and methoxy, of which hydrogen is the most preferred R3 group. In the compounds of the present invention, particularly preferred R4 is selected from H, CH2OH, -CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH where R is a substituted or unsubstituted Ci-Ce alkyl. Particularly preferred Rc is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted sec-butyl or unsubstituted, and substituted or unsubstituted tert-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from H, CH2OH, and CH2NH2. Most preferably, R4 is -CH2OH. In the compounds of general formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, and IGb, with particular preference, R4 is selected from -CH2OH, CH2OC(=O)Rc, -CH2NH2, and -CH2NHProtNH for the compounds of formula I, IA, IB, IC, ID, IF, IG, la, lAa , IBa, ICa, IDa, IFa, IGa, Ib, IAb, IBb, ICb, IDb, IFb, or IGb; and R4 is selected from -CH2NH2, and -CH2NHProtNH for compounds of formula IE, IEa or IEb; where Rc is a substituted or unsubstituted Ci-Ce alkyl. With particular preference, Rc is a substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, sec- substituted or unsubstituted butyl, and substituted or unsubstituted tert-butyl. Most preferably, Rc is methyl. More preferably, R4 is selected from CH2OH and CH2NH2. Most preferably, R4 is -CH2OH. Particularly preferred are compounds of formula la, IAa, IBa, ICa, IDa, IFa, IGa when R4 is -CH2OH or -CH2OC(=O)Rc and compounds of formula Ib, IAb, IBb, ICb, IDb, IEb, IFb, IGb when R4 is -CH2NH2 or -CH2NHProtNH. In the compounds of the present invention, with particular preference, Y is -NH-. Alternatively, in the compounds of the present invention, with particular preference, Y is -O-. Preferred compounds according to the present invention include; • Compounds of formula I, IA, IB, IC, ID, IF, IG, la, lAa, IBa, ICa, IDa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, IFb, and IGb, where; R4 is selected from -CH2OH and -CH2OC(=O)Rc; Particularly preferred are compounds of formula la, IAa, IBa, ICa, IDa, IFa, and IGa and / or compounds wherein R4 is -CH2OH. • Compounds of formula I, IA, IB, IC, ID, IE IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, e IGB, where: R4 is selected from -CH2NH2 and -CH2NHProtNH; and ProtNH is a protecting group for amino. Particularly preferred are compounds of formula Ib, IAb, IBb, ICb, IDb, IEb, IFb, e LPQQCn / I 7Π7 / 3 / ΥΙΛΙ IGb and / or the compounds in which R4 is -CH2NH2. • Compounds of formula le, lAc, IBc, IDc, IFc, IGc, where R2 is a group -C(=O)Ra for compounds of formula le, lAc, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; R3 is hydrogen or a group -ORb for compounds of formula le, IDc, IFc, IGc; R3 is hydrogen for compounds of formula 1Ac; or R3 is a group -ORb for compounds of formula IBc; Rase is selected from hydrogen, and substituted or unsubstituted Ci-Cs alkyl; and Rb is substituted or unsubstituted Ci-Ce alkyl. Particularly preferred compounds according to the present invention include: • Compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib, lAb, IBb, ICb, IFb, and IGb, where: Yes -NH-; R4 is selected from -CH2OH, and -CH2OC(=O)Rc; and Re is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl. Even more preferred are compounds of formula la, lAa, IBa, ICa, IFa, IGa and / or compounds in which R4 is -CH2OH. • Compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib, lAb, IBb, IDb, IFb, and IGb, where: And so-; R4 is selected from -CH2OH and -CH2OC(=O)Rc; and Re is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl. Even more preferred are compounds of formula la, lAa, IBa, IDa, IFa, IGa and / or compounds in which R4 is -CH2OH. • Compounds of formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, and IGb, where: Yes -NH-; R4 is selected from -CH2NH2 and -CH2NHProtNH; and ProtNH is a protecting group for amino. Even more preferred are compounds of formula Ib, IAb, IBb, ICb, IEb, IFb, IGb and / or compounds in which R4 is -CH2NH2. • Compounds of formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, and IGb, where: LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ And so-; R4 is selected from -CH2NH2 and -CH2NHProtNH; and ProtNH is a protecting group for amino. Even more preferred are compounds of formula Ib, IAb, IBb, IDb, IEb, IFb, IGb and / or compounds in which FU is -CH2NH2. • Compounds of formula I, IA, IB, IC, ID, IF, IG, la, lAa, IBa, ICa, IDa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, IFb, IGb, where: R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, ID, IF, la, IAa, IBa, ICa, IDa, IFa, Ib, IAb, IBb, ICb, IDb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a group -ORb for compounds of formula I, IC, ID, IF, IG, la, ICa, IDa, IFa, IGa, Ib, ICb, IDb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is selected from -CH2OH, and -CH2OC(=O)Rc; Rase is selected from hydrogen, and substituted or unsubstituted Ci-Ce alkyl; Rb is substituted or unsubstituted Ci-Ce alkyl; and Re is substituted or unsubstituted Ci-Ce alkyl. Even more preferred are compounds of formula la, lAa, IBa, ICa, IDa, IFa, IGa and / or compounds in which R4 is -CH2OH. • Compounds of formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, and IGb, where: R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, ID, IF, la, IAa, IBa, ICa, IDa, IFa, Ib, IAb, IBb, ICb, IDb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a group -ORb for compounds of formula I, IC, ID, IE, IF, IG, la, ICa, IDa, IEa, IFa, IGa, Ib, ICb, IDb, IEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Ra is selected from hydrogen, and substituted or unsubstituted Ci-Ce alkyl; Rb is substituted or unsubstituted Ci-Ce alkyl; and ProtNH is a protecting group for amino. Even more preferred are compounds of formula Ib, IAb, IBb, ICb, IDb, IEb, IFb, IGb and / or compounds in which R4 is -CH2NH2. • Compounds of formula le, lAc, IBc, IDc, IFc, IGc, where: R2 is a group -C(=O)Ra for compounds of formula le, lAc, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; R3 is hydrogen or a group -ORb for compounds of formula le, IDc, IFc, IGc; R3 is LPQQCn / Lznz / Σΐ / ΥΙΛΙ hydrogen for compounds of formula 1Ac; or R3 is a group -ORb for compounds of formula IBc; Ra is substituted or unsubstituted Ci-Ce alkyl; and Rb is substituted or unsubstituted Ci-Ce alkyl. Most preferred compounds according to the present invention include: • Compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib, lAb, IBb, ICb, IFb, and IGb, where: Yes-NH-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, IC, IF, la, lAa, IBa, ICa, IFa, Ib, lAb, IBb, ICb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a group -ORb for compounds of formula I, IC, IF, IG, la, ICa, IFa, IGa, Ib, ICb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is -CH2OH; Rase is selected from hydrogen and substituted or unsubstituted Ci-Ce alkyl; and Rb is substituted or unsubstituted Ci-Ce alkyl. More particularly preferred are the compounds of formula la, la, or IBa, ICa, IFa, IGa. • Compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib, lAb, IBb, IDb, IFb, and IGb, where: And so-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IF, la, lAa, IBa, IDa, IFa, Ib, lAb, IBb, IDb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; Rs is hydrogen or a -ORb group for compounds of formula I, ID, IF, IG, la, IDa, IFa, IGa, Ib, IDb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is -CH2OH; Rase is selected from hydrogen and substituted or unsubstituted Ci-Ce alkyl; and Rb is substituted or unsubstituted Ci-Ce alkyl. More particularly preferred are compounds of formula la, la, IBa, IDa, IFa, or IGa. • Compounds of formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, and IGb, where: Y is -NH-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, IEb or IFb ; and R2 is acetyl for compounds of formula IG, IGa or IGb; LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ R3 is hydrogen or a group -ORb for compounds of formula I, IC, IE, IF, IG, la, ICa, IEa, IFa, IGa, Ib, ICb, IEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Ra is selected from hydrogen and substituted or unsubstituted Ci-Cs alkyl; Rb is substituted or unsubstituted Ci-Ce alkyl; and ProtNH is a protecting group for amino. More particularly preferred are the compounds of formula Ib, IAb, IBb, ICb, IEb, IFb, IGb and / or the compounds in which R4 is -CH2NH2. • Compounds of formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, and IGb, where: And so-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, IEb or IFb ; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a group -ORb for compounds of formula I, ID, IE, IF, IG, la, IDa, lEa, IFa, IGa, Ib, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Rase is selected from hydrogen and substituted or unsubstituted C1-C6 alkyl; Rb is substituted or unsubstituted Ci-Ce alkyl; and ProtNH is a protecting group for amino. More particularly preferred are compounds of formula Ib, IAb, IBb, IDb, IEb, IFb, IGb and / or compounds in which R4 is CH2NH2. • Compounds of formula I, IA, IB, IC, ID, IF, IG, la, lAa, IBa, ICa, IDa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, IFb, and IGb, where: R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, ID, IF, la, IAa, IBa, ICa, IDa, IFa, Ib, IAb, IBb, ICb, IDb or IFb ; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a group -ORb for compounds of formula I, IC, ID, IF, IG, la, ICa, IDa, IFa, IGa, Ib, ICb, IDb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is -CH2OH; Ra is a substituted or unsubstituted Ci-Ce alkyl; and Rb is substituted or unsubstituted Ci-Cs alkyl. More particularly preferred are compounds of formula la, la, IBa, ICa, IDa, IFa, or IGa. • Compounds of formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, and IGb, where: LPQQCn / LZnZ / q / YIAI R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, ID, IE, IF, la, lAa, IBa, ICa, IDa, lEa, IFa, Ib, lAb, IBb, ICb , IDb, lEb or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a group -ORb for compounds of formula I, IC, ID, IE, IF, IG, la, ICa, IDa, lEa, IFa, IGa, Ib, ICb, IDb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Ra is substituted or unsubstituted Ci-Ce alkyl; Rb is substituted or unsubstituted Ci-Ce alkyl; and ProtNH is a protecting group for amino. More particularly preferred are the compounds of formula Ib, IAb, IBb, ICb, IDb, IEb, IFb, IGb and / or compounds in which R4 is -CH2NH2. • Compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib, lAb, IBb, ICb, IFb, and IGb, where: Yes-NH-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, IC, IF, la, lAa, IBa, ICa, IFa, Ib, lAb, IBb, ICb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a group -ORb for compounds of formula I, IC, IF, IG, la, ICa, IFa, IGa, Ib, ICb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is a group -ORb for compounds of formula IB, IBa or IBb; R4 is -CH2OC(=O)Rc; Rase is selected from hydrogen and substituted or unsubstituted Ci-Ce alkyl; Rb is substituted or unsubstituted Ci-Ce alkyl; and Rc is substituted or unsubstituted Ci-Ce alkyl. Most preferred are compounds of formula la, la, IBa, ICa, IFa, or IGa. • Compounds of formula le, lAc, IBc, IDc, IFc, and IGc, where: R2 is a group -C(=O)Ra for compounds of formula le, lAc, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; R3 is hydrogen or methoxy for compounds of formula le, IDc, IFc, or IGc; R3 is hydrogen for compounds of formula 1Ac; or R3 is methoxy for compounds of formula IBc; and Ra is substituted or unsubstituted Ci-Ce alkyl. Particularly preferred compounds according to the present invention include: • Compounds of formula I, IA, IB, IC, IF, IG, la, lAa, IBa, ICa, IFa, IGa, Ib, lAb, IBb, ICb, IFb, and IGb, where: Yes-NH-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IF, la, lAa, IBa, ICa, LPQQCn / Lznz / Σΐ / ΥΙΛΙ IFa, Ib, IAb, IBb, ICb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or methoxy for compounds of formula I, IC, IF, IG, la, ICa, IFa, IGa, Ib, ICb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; and R3 is methoxy for compounds of formula IB, IBa or IBb; R4 is -CH2OH; and Ra is substituted or unsubstituted Ci-Ce alkyl. Even more preferred are compounds of formula la, la, IBa, ICa, IFa, IGa. • Compounds of formula I, IA, IB, ID, IF, IG, la, lAa, IBa, IDa, IFa, IGa, Ib, lAb, IBb, IDb, IFb, and IGb, where: And so-; R2 is a group -C(=O)Ra for compounds of formula I, IA, IB, ID, IF, la, lAa, IBa, IDa, IFa, Ib, lAb, IBb, IDb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or methoxy for compounds of formula I, ID, IF, IG, la, IDa, IFa, IGa, Ib, IDb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is methoxy for compounds of formula IB, IBa or IBb; R4 is -CH2OH; and Ra is substituted or unsubstituted Ci-Ce alkyl. Even more preferred are compounds of formula la, lAa, IBa, IDa, lEa, IFa, IGa. • Compounds of formula I, IA, IB, IC, IE, IF, IG, la, lAa, IBa, ICa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, lEb, IFb, and IGb, where: Y is -NH-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, IE, IF, la, lAa, IBa, ICa, lEa, IFa, Ib, lAb, IBb, ICb, IEb or IFb ; and R2 is acetyl for compounds of formula IG, IGa or IGb; Rs is hydrogen or methoxy for compounds of formula I, IC, IE, IF, IG, la, ICa, lEa, IFa, IGa, Ib, ICb, lEb, IFb, or IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is methoxy for compounds of formula IB, IBa or IBb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Ra is substituted or unsubstituted Ci-Ce alkyl; and ProtNH is a protecting group for amino. Even more preferred are compounds of formula Ib, IAb, IBb, ICb, IEb, IFb, IGb and / or compounds in which R4 is -CH2NH2. • Compounds of formula I, IA, IB, ID, IE, IF, IG, la, lAa, IBa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, IDb, lEb, IFb, and IGb, where: And so-; R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, ID, IE, IF, la, lAa, IBa, IDa, lEa, IFa, Ib, lAb, IBb, IDb, lEb or IFb ; and R2 is acetyl for compounds of formula IG, IGa or IGb; LPQQCn / LZnZ / q / YIAI Rs is hydrogen or methoxy for compounds of formula I, ID, IE, IF, IG, la, IDa, IEa, IFa, IGa, Ib, IDb, IEb, IFb, or IGb; Rs is hydrogen for compounds of formula IA, IAa or IAb; or Rs is methoxy for compounds of formula IB, IBa or IBb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Ra is substituted or unsubstituted Ci-Ce alkyl; and ProtNH is a protecting group for amino. Even more preferred are compounds of formula Ib, IAb, IBb, IDb, IEb, IFb, IGb and / or compounds in which R4 is -CH2NH2. • Compounds of formula I, IA, IB, IC, ID, IF, IG, la, lAa, IBa, ICa, IDa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, IFb, and IGb, where: R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, ID, IF, la, IAa, IBa, ICa, IDa, IFa, Ib, IAb, IBb, ICb, IDb, or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or methoxy for compounds of formula I, IC, ID, IF, IG, la, ICa, IDa, IFa, IGa, Ib, ICb, IDb, IFb, and IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is methoxy for compounds of formula IB, IBa or IBb; R4 is -CH2OH; and Rase is selected from methyl, ethyl, n-propyl, isopropyl, and butyl, including n-butyl, secbutyl, isobutyl, and tert-butyl. Even more preferred are compounds of formula la, lAa, IBa, ICa, IDa, lEa, IFa, or IGa. • Compounds of formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, and IGb, where: R2 is a group -C(=O)Ra for the compounds of formula I, IA, IB, IC, ID, IE, IF, la, lAa, IBa, ICa, IDa, lEa, IFa, Ib, lAb, IBb, ICb, IDb, lEb or IFb; and R2 is acetyl for compounds of formula IG, IGa or IGb; R3 is hydrogen or a methoxy for compounds of formula I, IC, ID, IE, IF, IG, la, ICa, IDa, IEa, IFa, IGa, Ib, ICb, IDb, IEb, IFb, and IGb; R3 is hydrogen for compounds of formula IA, IAa or IAb; or R3 is methoxy for compounds of formula IB, IBa or IBb; R4 is selected from -CH2NH2 and -CH2NHProtNH; Rase is selected from methyl, ethyl, n-propyl, isopropyl, and butyl, including n-butyl, secbutyl, isobutyl, and tert-butyl; and ProtNH is a protecting group for amino. Even more preferred are compounds of formula Ib, IAb, IBb, ICb, IDb, IEb, IFb, IGb and / or compounds in which R4 is -CH2NH2. • Compounds of the formula le or lAc, IDc, IFc, and IGc, where: R2 is a group -C(=O)Ra for compounds of formula le, lAc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; R3 is hydrogen; and LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ Ra is selected from methyl, ethyl, n-propyl, isopropyl, and butyl, including n-butyl, secbutyl, isobutyl, and tert-butyl. • Compounds of the formula le, IBc, IDc, IFc, and IGc, where: R2 is a group -C(=O)Ra for compounds of formula le, IBc, IDc, or IFc; and R2 is acetyl for compounds of formula IGc; Ra is methoxy; and Rase is selected from methyl, ethyl, n-propyl, isopropyl, and butyl, including n-butyl, secbutyl, isobutyl, and tert-butyl. Still more preferred compounds according to the present invention include: • Compounds of formula I, IA, IC, IF, IG, la, lAa, ICa, IFa, IGa, Ib, lAb, ICb, IFb, and IGb, where: Yes -NH-; R2 is acetyl; Ra is hydrogen; and R4 is -CH2OH. Even more preferred are the compounds of formula la, la, ICa, IFa, or IGa. • Compounds of formula I, IA, ID, IF, IG, la, lAa, IDa, IFa, IGa, Ib, lAb, IDb, IFb, and IGb, where: And so-; R2 is acetyl; R3 is hydrogen; and R4 is -CH2OH. Even more preferred are the compounds of formula la, la, IDa, IFa, or IGa. • Compounds of formula I, IA, IC, IE, IF, IG, la, lAa, ICa, lEa, IFa, IGa, Ib, lAb, ICb, lEb, IFb, and IGb, where: Y is -NH-; R2 is acetyl; R3 is hydrogen; and R4 is -CH2NH2. Even more preferred are the compounds of formula Ib, IAb, ICb, IEb, IFb, or IGb. • Compounds of formula I, IA, ID, IE, IF, IG, la, lAa, IDa, lEa, IFa, IGa, Ib, lAb, IDb, lEb, IFb, and IGb, where: And so-; R2 is acetyl; R3 is hydrogen; and R4 is -CH2NH2. Even more preferred are compounds of formula Ib, IAb, IDb, IEb, IFb, or IGb. LPQQCn / Lznz / Σΐ / ΥΙΛΙ • Compounds of formula I, IA, IC, ID, IF, IG, la, lAa, ICa, IDa, IFa, IGa, Ib, lAb, ICb, IDb, IFb, and IGb, where: R2 is acetyl; R3 is hydrogen; and R4 is -CH2OH. Even more preferred are compounds of formula la, lAa, ICa, IDa, IFa or IGa. • Compounds of formula I, IA, IC, ID, IF, IG, la, lAa, ICa, IDa, IFa, IGa, Ib, lAb, ICb, IDb, IFb, and IGb, where: R1 is -OH; R2 is acetyl; R3 is hydrogen; and R4 is -CH2OH. Even more preferred are compounds of formula la, lAa, ICa, IDa, IFa or IGa. • Compounds of formula I, IA, IC, ID, IE, IF, IG, la, lAa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, ICb, IDb, lEb, IFb, and IGb, where: R2 is acetyl; R3 is hydrogen; and R4 is -CH2NH2. Even more preferred are compounds of formula Ib, IAb, ICb, IDb, IEb, IFb, or IGb. • Compounds of formula le or lAc, IDc, IFc, IGc where R2 is acetyl; and R3 is hydrogen. • Compounds of formula le or IBc, IDc, IFc, IGc where R2 is acetyl; and Rs is methoxy. • A compound according to the present invention of the formula: LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ MeO I ΓΟΟΟΩ / 1 7Π7 / 3 / ΥΙΛΙ LPQQCn / Lznz / Σΐ / ΥΙΛΙ MeO MeO MeOMeO or one of its pharmaceutically acceptable salts or esters. Particularly preferred is a compound of the formula: MeO MeO I PQQCn / 1 7Π7 / 3 / ΥΙΛΙ or a pharmaceutically acceptable salt or ester thereof. • A compound according to the present invention of the formula: MeO LPQQCn / Lznz / Σΐ / ΥΙΛΙ LPQQCn / Lznz / Σΐ / ΥΙΛΙ or a pharmaceutically acceptable salt or ester thereof. Particularly preferred is a compound of the formula: or one of its pharmaceutically acceptable salts or esters. Even more preferred is a compound of the formula: MeO MeO MeO LPQQCn / Lznz / Σΐ / ΥΙΛΙ or a pharmaceutically acceptable salt or ester thereof. Still more preferred compounds according to the present invention are those compounds of the formula: LPQQCn / I 7Π7 / 3 / ΥΙΛΙ or a pharmaceutically acceptable salt or ester thereof. Other preferred compounds according to the present invention are compounds of the formula: or one of its pharmaceutically acceptable salts or esters. In another embodiment, according to the present invention, preferred compounds are compounds of the formula: or one of its pharmaceutically acceptable salts or esters. Other preferred compounds include a compound of the formula: LPQQCn / Lznz / Σΐ / ΥΙΛΙ LPQQCn / Lznz / Σΐ / ΥΙΛΙ or a pharmaceutically acceptable salt or ester thereof. Other preferred compounds include a compound of the formula: LPQQCn / I 7Π7 / 3 / ΥΙΛΙ or a pharmaceutically acceptable salt or ester thereof. In additional preferred embodiments, the preferences described above for the different substituents are combined. The present invention also relates to such preferred combinations of substitutions (when possible substituent groups allow) in compounds of formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, IGb, le, lAc, IBc, IDc, IFc or IGc according to the present invention. For the avoidance of doubt, the above-mentioned compounds may be drug moiety D and are covalently linked via a hydroxy or amine group to (X)b if any, (AA)Wif any, (T) gif any, or to (L). Thus, when conjugated, a covalent bond replaces a proton on a hydroxy or amine group in the compound. Preferred drug conjugates in accordance with the present invention are listed below. The preferred definitions of (X)b, (AA)W, (T)g, and (L) as set forth below are applicable to all of the drug moiety D compounds described above. Preferred drug conjugates according to the present invention include: • a drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, where L is a linking group selected from the group that consists of: LPQQCn / Lznz / Σΐ / ΥΙΛΙ O O ^-d-R19-S—’ ^-¿}-R19-O-N=^ where: the wavy lines indicate the point of covalent attachments to Ab (the wavy line to the right) and to (T)g if any, or (AA)W if any, or to (X)b if any, or to D (the wavy line toward the left); R19 is selected from -C1-C12 alkylene-, -C3-C8 carbocyclo, -O-(C1-C12 alkylene), Cs-Cis arylene on one or more rings which may be optionally substituted with one or more Rx substituents, -alkylene C1-C12 -arylene Ce-C-is - where the arylene group is on one or more rings which may be optionally substituted with one or more substituents Rx, -arylene CeC18 -C1-C12 alkylene - where the arylene group is on one or more rings that may be optionally substituted with one or more substituents Rx, -C1-C12 alkylene -(Cs-Cs carbocycle)-, (Cs-Csj carbocycle-C1-C12 alkylene-, -C5-C14 heterocycle - where said heterocyclo group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group being optionally substituted with one or more substituents Rx, -alkylene Ci -Ci2-(C5-C14 heterocycle)- where said heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -(C5-C14 heterocycle)C1-C12 alkylene - where said heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur on said one or more rings, said group is optionally substituted with one or more substituents Rx, -(OCH2CH2)r-, and -CH2-(OCH2CH2)r-, where each of the above-mentioned alkylene substituents, whether found alone or attached to another moiety, the carbon chain can be optionally substituted with one or more Rx substituents; R3o is a Ci-Ce alkylene group; M is selected from the group consisting of -Ci-Ce alkylene -, -Ci-C6 alkylene-(Cs-Cs carbocycle)-, -(CH2CH2O)s-, -Ci-Ce alkylene -(C3-Cs carbocycle)-CON (H or Ci-Ce alkyl)-CiCe alkylene-, phenylene, which may be optionally substituted by one or more Rx substituents, phenylene-Ci-Ce alkylene- where the phenylene moiety may optionally be substituted by one or more Rxy alkylene Ci- substituents Ce -CON(H or Ci-Ce alkyl) Ci-Ce alkylene -; Q is selected from the group consisting of -N(H or Ci-Cs alkyl)phenylene- and -N(H or CiCe alkyl)-(CH2)s; r is an integer from 1 to 10; and s is an integer from 1 to 10. • a drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, where L is selected from the group consisting of: LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: the wavy lines indicate the point of covalent attachments to Ab (the wavy line to the right) and to (T)g if any, or (AA)W if any, or to (X)b if any, or to D (the wavy line toward the left); Ría is selected from -C1-C12 alkylene-, -O-(C1-C12 alkylene), -C6-C12 arylene on one or more rings which may be optionally substituted with one or more Rx substituents, -Ci-Ci2-arylene alkylene C6-C12 - where the arylene group is on one or more rings that may be optionally substituted with one or more Rx substituents, - Ce-Ci2 arylene-Ci-Ci2 alkylene where the arylene group is on one or more rings that may be optionally substituted with one or more substituents Rx, -heterocycle O5-Ci2- where the heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -C1-C12 alkylene -(C5-C12 heterocycle)- where said heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -(C5-Ci2 heterocycle)-C1-C12 alkylene - where said heterocycle group may be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, (OCH2CH2)r-, and -CH2-(OCH2CH2 )r- where in each of the alkylene substituents, whether found alone or attached to another moiety, the carbon chain can be optionally substituted by one or more Rx substituents; Rso is a -Ci-Ce-alkylene group; M is selected from the group consisting of -Ci-Ce alkylene -Ci-Ce alkylene -(Cs-Cs carbocycle)- and phenylene which may be optionally substituted with one or more Rx substituents; and r is an integer from 1-6. • a drug conjugate of formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention selected from formulas (IV), (V) and I saw): LPQQCn / Lznz / Σΐ / ΥΙΛΙ (IV) (V) (VI) where: X and T are extension groups as defined herein; each AA is, independently, an amino acid unit as defined herein; w is an integer from 0 to 12; b is an integer of 0 or 1; g is an integer of 0 or 1; where b+g+w is optionally not 0; D is a drug fraction; Ab is a moiety comprising at least one antigen binding site; n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), (V) or (VI) for the fraction that comprises at least one antigen binding site and is in the range of 1 to 20; R19 is selected from -Ci-Cs alkylene-, -O-(Ci-Ce alkylene), -Ci-Cs alkylene -CeC12 arylene - where the arylene group is found on one or more rings that may be optionally substituted with one or more substituents Rx, and -C6-C12 arylene -Ci-Cs alkylene - where the arylene group is found in one or more rings that may be optionally substituted with one or more Rx substituents, where in each of the aforementioned alkylene substituents, and either alone or attached to another moiety on the carbon chain may be optionally substituted by one or more Rx substituents; R30 is a -C2-C4 alkylene- group; and M is selected from the group consisting of -C1-C3 alkylene- and -C1-C3 alkylene -(C5-C7 carbocycle)-. • a drug conjugate of formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, selected from formulas (IV), (V ) and I saw): LPQQCn / I 7Π7 / 3 / ΥΙΛΙ (IV) (V) (VI) where: X and T are extension groups that can be the same or different; each AA is independently an amino acid unit; w is an integer from 0 to 12; b is an integer of 0 or 1; g is an integer of 0 or 1; where b+g+w is optionally not 0; D is a drug fraction; Ab is a moiety comprising at least one antigen binding site; n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), (V) or (VI) , for the fraction that comprises at least one antigen-binding site and is in the range of 1 to 20; R19 is selected from -Ci-Ce alkylene-, phenylene-Ci-Ce alkylene- where the phenylene group may be optionally substituted with one or more substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, groups alkoxy possessing 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, where each of the above-mentioned alkylene substituents, either alone or attached to another moiety in the carbon chain, may be optionally substituted by one or more Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, aryl groups having 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups, and preferably a Ci-Ce -alkylene group; R30 is a -C2-C4 alkylene- group; and M is -C1-C3 alkylene -(C5-C7 carbocyclo)-. • It is preferred that in the definition of the drug conjugate of formula [D-(X)b-(AA)w(T)g-(L)-]n-Ab, L be as defined in the preferred definitions for said group mentioned above and (AA)W is of formula (II): LPQQCn / Lznz / Σΐ / ΥΙΛΙ (II) where the wavy lines indicate the point of covalent attachments to (X)b if any, or to the drug moiety (the wavy line to the left) and to (T)g if any, or to the linker (the wavy line to the left). to the right); and R21, at each occurrence, is selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -CH(OH)CH3, CH2CH2SCH3, -CH2CONH2, -CH2COOH, - CH2CH2CONH2, -CH2CH2COOH, (CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, (CH2)4NHC(=NH)NH2, -(CH2)4NH2, - (CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl, phenyl, cyclohexyl, and w is an integer from 0 to 12. • a drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the first aspect of the present invention, where L is as defined in the preferred definitions for said group mentioned above and (AA)w is of formula (II), where: R2i is selected, at each occurrence, from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, -(CH2)3NHCONH2, -(CH2)4NH2, -(CH2)3NHC(=NH)NH2 and -(CH2)4NHC(=NH)NH2; and w is an integer from 0 to 6. • a drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the first aspect of the present invention, where L is as defined in the preferred definitions for said group mentioned above, where w is 0 or 2, and when w is 2, then (AA)Wes of formula (III) where: LPQQCn / Lznz / Σΐ / ΥΙΛΙ (III) wavy lines indicate the point of covalent attachments to (X)b if any, or to the drug fraction (wavy line to the left) and to (T)g if any, or to the linker (the wavy line to the right); R22 is selected from methyl, benzyl, isopropyl, sec-butyl, and indolylmethyl; and R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2 and -(CH2)3NHC(=NH)NH2. • In embodiments of the present invention, b+g+w is not 0. In other embodiments, b+w is not 0. In still other embodiments, when w is not 0, then b is 1. Furthermore, it is preferred that in the definition of the drug conjugate of formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab, L and (AA)W are as defined in the preferred definitions for those groups mentioned above and X is an extension group selected from: where D is conjugated via an amine group (for example, where Z is -NH-): -COO-(Ci-Ce alkylene)NH-; -COO-CH2-(phenylene which may be optionally substituted with one or more RX substituents)-NH-; -COO-(Ci-C6 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one or more Rx substituents)-NH-; -COCH2NH-COCH2-NH-; -COCH2NH-; -COO-(alkylene Ci-CejS-; -COO-(Ci-C6 alkylene)NHCO(Ci-Ce alkylene)S-; or where D is conjugated via a hydroxy group (for example, where Z is -O-): -CONH-(Ci-C6 alkylene)NH-; -COO-CH2-(phenylene which may be optionally substituted with one or more Rx substituents)-NH-; -CONH-(Ci-C6 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one or more Rx substituents)-NH-; -COCH2NH-COCH2-NH-; -COCH2NH-; -CONH-(Ci-C6 alkylene)S-; -CONH-(Ci-C6 alkylene)NHCO(Ci-Ce alkylene)S-; and b is 0 or 1, preferably 1. • a drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, where L and (AA)W are as defined in the preferred definitions for such groups mentioned above and X is an extension group selected from the group consisting of: where D is conjugated via an amine group (for example, where Z is -NH-): -COO-(C2-C4 alkylene)NH-; -COO-CH2-phenylene-NH-, where the phenylene group may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups; -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted by one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano)-NH- groups; -COCH2NH-COCH2-NH-; -COO-(C2-C4 alkylene)S-; -COO-(C2-C4 alkylene)NHCO(Ci-CsjS alkylene-; or where D is conjugated via a hydroxy group (for example, where Z is -O-): -CONH-(C2-C4 alkylene)NH-; -COO-CH2-phenylene-NH-, where the phenylene group may be optionally substituted by one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups; -CONH-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted by one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano)-NH- groups; -COCH2NH-COCH2-NH-; -CONH-(C2-C4 alkylene)S-; -CONH-(C2-C4 alkylene)NHCO(Ci-CsjS alkylene-; and b is 0 or 1, preferably 1. • a drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, where L and (AA)w are as follows. defined in the preferred definitions for LPQQCn / Lznz / Σΐ / ΥΙΛΙ said groups mentioned above and X is an extension group selected from the group consisting of: where D is conjugated via an amine group (for example, where Z is -NH-): -COO-CH2-phenylene-NH-COO(CH2)3NHCOOCH2-phenylene-NH-; -COO(CH2)3NH-; -COO(CH2)3-S-; -COO(CH2)3NHCO(CH2)2S-; or where D is conjugated via a hydroxy group (for example, where Z is -O-): -COO-CH2-phenylene-NH-CONH(CH2)3NHCOOCH2-phenylene-NH-; -CONH(CH2)3NH-; -CONH(CH2)3-S-; -CONH(CH2)3NHCO(CH2)2S-; and b is 0 or 1, preferably 1. • a drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, where L, (AA)w, and ( X)b are as defined in the preferred definitions for such groups mentioned above and T is an extension group selected from the group consisting of: -CO-(Ci-Ce alkylene)-NH-; -CO-(Ci-C6 alkylene)-[O-(C2-Ce alkylene)]j-NH-; -COO-(Ci-C6 alkylene)-[O-(C2-Ce alkylene)]j-NH-; where j is an integer from 1 to 25, and g is 0 or 1. • A drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, where L, (AA)», and ( X)b are as defined in the preferred definitions for such groups mentioned above and T is an extension group selected from the group consisting of: -CO-(Ci-C4 alkylene)NH-CO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-; -COO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-; where j is an integer from 1 to 10; and g is 0 or 1. • A drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention, where L, (AA)W, and ( X)b are as defined in the preferred definitions for such groups mentioned above and T is an extension group selected from the group consisting of: -CO-(Ci-C4 alkylene)NHLPQQCn / Lznz / Σΐ / ΥΙΛΙ -CO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-; -COO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-; where j is an integer from 1 to 5; and g is 0 or 1. • A preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, IGb, (IH), (IHa) or (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, where Ri is CN or OH in the compounds of formula I, IA, IB, IC, ID, IE, IG, la, lAa, IBa, ICa, IDa, lEa, IGa, Ib, lAb, IBb, ICb, IDb, lEb , IGb, (IH), (IHa) or (IHb); Ri is OH in the compounds of formulas IF, IFa and IFb, and, more preferably, Ri is CN. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula I, IA, IB, IC, ID, IE, IF, la, lAa, IBa, ICa, IDa, lEa, IFa, Ib, IAb, IBb, ICb, IDb, IEb, IFb, (IH), (IHa) or (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, where R2 is C(= O)Ra, where Rase is selected from hydrogen and substituted or unsubstituted Ci-Ce alkyl, where optional substituents are one or more Rx substituents, and, more preferably, R2 is acetyl. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, IGb, (IH), (IHa) or (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, where R3 is hydrogen or a group -ORb in the compounds of formula I, IC, ID, IE, IF, IG, la, ICa, IDa, lEa, IFa, IGa, Ib, ICb, IDb, lEb, IFb, IGb, (IH), (IHa) or (IHb); R3 is hydrogen in compounds of formula IA, IAa, or IAb; R3 is a group -ORb in compounds of formula IB, IBa, or IBb, where Rb is a substituted or unsubstituted Ci-Ce alkyl group, where optional substituents are one or more Rx substituents, and, more preferably, R3 is hydrogen or methoxy. Most preferably, R3 is hydrogen. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula (IH), (IHa) or (IHb), or a pharmaceutically pharmaceutical salt, ester, solvate, tautomer or stereoisomer thereof. acceptable, where Y is -NHu-O-. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula (IH), (IHa) or (IHb), or a salt thereof, LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ pharmaceutically acceptable esters, solvates, tautomers or stereoisomers, where Z is -NHu-O-, and more preferably Z is -NH-. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula (IHa) or (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, where: Ri is -CN or -OH; R2 is -C(=O)Ra, where Rase is selected from hydrogen and substituted or unsubstituted Ci-Ce alkyl, where optional substituents are one or more Rx substituents; R3 is hydrogen or a group -ORb where Rb is a substituted or unsubstituted Ci-Ce alkyl group, where optional substituents are one or more Rx substituents, Y is -NH- or -O-; and Z is -NH- or -O-. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula (IHa) or (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, where: Ri is -CN or -OH; R2 is acetyl; R3 is hydrogen or methoxy, more preferably hydrogen; Y is -NH- or -O-; and Z is -NH- or -O-. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is a compound of formula (IHa) or (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, where: R1 is -CN; R2 is acetyl: R3 is hydrogen; Y is -NH- or -O-; and Z is -NH-. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is selected from: LPQQCn / Lznz / Σΐ / ΥΙΛΙ LPQQCn / Lznz / Σΐ / ΥΙΛΙ or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; where the wavy lines indicate the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to (L). • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, and (T)g are as defined above and where D is selected from: or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; where the wavy lines indicate the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to (L). • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, (T)g and D are as defined above and where the Ab moiety comprising at least one antigen binding site is an antigen binding peptide. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, (T)g and D are as defined above and the Ab moiety comprising at least one antigen binding site is an antibody, a single antigen binding domain antibody or fragment thereof. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, (T)g and D are as defined above and the Ab moiety comprising at least one antigen binding site is a monoclonal, polyclonal or bispecific antibody and where the antibody or binding fragment The antigen thereof is derived from any species, preferably a human, mouse or rabbit. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, (T)g and D are as defined above and the Ab moiety comprising at least one antigen binding site is an antibody or an antigen binding fragment selected from the group consisting of a human antibody, an antigen-binding fragment of a human antibody, a humanized antibody, an antigen-binding fragment of a humanized antibody, a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a glycosylated antibody, and a binding to glycosylated antigen. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, (T)g and D are as defined above and the Ab moiety comprising at least one antigen-binding site is an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment The antigen-binding fragment thereof is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, an F(abj2 fragment, and an Fv fragment. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, (T)g and D are as defined above and the Ab moiety comprising at least one antigen binding site is an antibody or antigen binding fragment thereof where the antibody or antigen binding fragment thereof antigen-binding is a monoclonal antibody that binds immunospecifically to cancer cell antigens, viral antigens, antigens from cells that produce autoimmune antibodies associated with autoimmune disease, microbial antigens, and preferably a monoclonal antibody that binds immunospecifically to antigens of cancer cells. • Another preferred drug conjugate of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab according to the present invention is one in which L, (AA) W, (X)b, (T)g and D are as defined herein and the Ab moiety comprising at least one antigen binding site is an antibody selected from the group consisting of Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Coltuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, LPQQCn / Lznz / Σΐ / ΥΙΛΙ Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Lifastuzumab, Lorvotuzumab, Milatuzumab, Mirvetuximab, Naratu ximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Pinatuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Sofituzumab, Vadastuxinnab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, and an anti-CD 30 antibody, or a binding fragment thereof to antigen or an immunologically active part thereof, wherein, preferably, the antibody is selected from Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Vadastuximab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, and an anti-CD 30 antibody, or an antigen-binding fragment thereof or a part thereof immunologically active and, even more preferably, Abciximab, Alemtuzumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denosumab, Dinutuximab, Durvalumab, Elotuzumab, Gemtuzumab, Ibritumomab, In otuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuximab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-antibody CD13 and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof. Of those mentioned, Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof; or the antibody is selected from Trastuzumab and the anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof of the same. • Particularly preferred drug conjugates of the formula [D-(X)b-(AA)w-(T)g(L)-]n-Ab according to the present invention include the following: (a) a drug conjugate according to the present invention, wherein: L is selected from the group consisting of: LPQQCn / Lznz / Σΐ / ΥΙΛΙ LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: the wavy lines indicate the point of covalent attachments to an Ab (the wavy line to the right) and to (T)g if any, to (AA)W if any, to (X)b if any, or to (D) ( the wavy line to the left); R19 is selected from -C1-C12 alkylene-, -O-(C1-C12 alkylene), -C6-C12 arylene on one or more rings which may be optionally substituted with one or more substituents Rx, -C1-C12 alkylene-arylene CeC12 - where the arylene group is on one or more rings which may be optionally substituted with one or more Rx substituents, -C6-C12 arylene -C1-C12 alkylene - where the arylene group is on one or more rings which may be optionally substituted with one or more substituents Rx, -C5C12 heterocycle - where the heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -C1-C12 alkylene -(C5-C12 heterocycle) where the heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen atom , nitrogen or sulfur on said one or more rings, said group is optionally substituted with one or more substituents Rx, -(C5-C12 heterocycle)-C1-C12 alkylene where the heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -(OCH2CH2)r- and -CH2-(OCH2CH2)r-, where each of the aforementioned alkylene substituents, alone or together with another moiety, on the carbon chain, may be optionally substituted by one or more Rx substituents; R30 is a -Ci-Ce alkylene- group; M is selected from the group consisting of -O-Ce alkylene-, -Ci-Cs alkylene -(C3-C8 carbocycle)- and phenylene which may be optionally substituted with one or more Rx substituents; r is an integer from 1-6; (AA)w is of formula (II): (II) where the wavy lines indicate the point of covalent attachments to (X)b if any, to the drug fraction (wavy line to the left) and to (T)g if any, or to the linker (wavy line to the right); R21, at each occurrence, is selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH , CH2CH2CONH2, -CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, (CH2)4NHC(=NH)NH2, -(CH2)4NH2 , -(CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, (CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl, 3-pyrldylmethyl, 4-pyrldylmethyl, phenyl, cyclohexyl, LPQQCn / I 7Π7 / 3 / ΥΙΛΙ w is an integer from 0 to 12; where X is an extension group selected from: where D is conjugated via an amine group (for example, where Z is -NH-): -COO-(alkylene Ci-CejNH-, -COO-CH2-(phenylene which may be optionally substituted with one or more Rx substituents)- NH-, -COO-(Ci-Ce alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one or more Rx substituents)-NH-, -COCH2NH-COCH2-NH-, -COCH2-NH-, -COO-(Ci-Ce alkylene)S-, -COO(Ci-C6 alkylene)NHCO(Ci-Ce alkylene)S-, or where D is conjugated via a hydroxy group (for example, where Z is -O-) : -CONH-(Ci-CejNH-alkylene, -COO-CH2-(phenylene which can be optionally substituted with one or more Rx substituents)-NH-, -CONH-(Ci-C6 alkylene)NH-COO-CH2-( phenylene which may be optionally substituted with one or more substituents Rx)-NH-, -COCH2NH-COCH2-NH-, -COCH2NH-, -CONH-(Ci-Ce alkylene)S-, and CONH-(Ci-Cs alkylene) NHCO(Ci-Ce alkylene)S-; b is 0 or 1, preferably 1; where T is an extending group selected from -CO-(Ci-Cej alkylene-NH-, -CO-(C1C6 alkylene)-[O-(C2-C6 alkylene)]j-NH-, and -COO-(C1C6 alkylene Ci-C6)-[O-(C2-C6 alkylene)]j-NH-, where j is an integer from 1 to 25; g is 0 or 1; D is a drug fraction of formula I, IA, IB, IC, ID, IE, IF, IG, IH, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, IGb, (IHa) or (IHb), or one of their pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, where: R2 is C(=O)Ra, in compounds of formula I, IA, IB, IC, ID, IE, IF, la, lAa, IBa, ICa, IDa, lEa, IFa, Ib, lAb, IBb, ICb, IDb , IEb, IFb, (IH), (IHa) or (IHb); R2 is acetyl in compounds of formula IG, IGa or IGb, where Ra is selected from hydrogen and substituted or unsubstituted alkyl Ci-Ce, where optional substituents are one or more Rx substituents; R3 is hydrogen or a group -ORb in the compounds of formula I, IC, ID, IE, IF, IG, la, ICa, IDa, lEa, IFa, IGa, Ib, ICb, IDb, lEb, IFb, IGb, ( IH), (IHa) or (IHb); Rs is hydrogen in compounds of formula IA, IAa, or IAb; Rs is a -ORb group in compounds of formula IB, IBa, or IBb, where Rb is a substituted or unsubstituted Ci-Ce alkyl group, where optional substituents are one or more Rx substituents; the Ab moiety comprising at least one antigen-binding site is an antibody or an antigen-binding fragment thereof and is selected from the group consisting of a human antibody, an antigen-binding fragment of a human antibody, an antibody humanized, an antigen-binding fragment of a humanized antibody, a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a glycosylated antibody, a glycosylated antigen-binding fragment; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the Ab fraction that comprises at least one antigen-binding site and is in the range from 1 to 12. (b) a drug conjugate according to the present invention selected from formulas (IV), (V) and (VI): (IV) (V) LPQQCn / Lznz / Σΐ / ΥΙΛΙ -Ab n (VI) where: R19 is selected from -Ci-Ce alkylene-, -O-(Ci-Ce alkylene), -Ci-Cs alkylene-C6-C12 arylene where the arylene group is found on one or more rings that may be optionally substituted with one or more substituents Rxy -C6-C12 arylene -Ci-Ce alkylene - where the arylene group is found on one or more rings that may be optionally substituted with one or more Rx substituents, where each of the above-mentioned alkylene substituents, alone or attached to another moiety on the carbon chain, may be optionally substituted with one or more Rx substituents; R30 is a -C2-C4 alkylene- group; M is selected from the group consisting of -C1-C3 alkylene- and -C1-C3 alkylene-carbocyclo(C5-C7)-; (AA)w is of formula (II) (II) LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: the wavy lines indicate the point of covalent attachments to (X)b if any, to the drug moiety (wavy line to the left) and to (T)g if any, or to the linker (wavy line to the right) ; R21, at each occurrence, is selected from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, -(CH2)3NHCONH2, -(CH2)4NH2, -(CH2)3NHC(=NH)NH2y- (CH2)4NHC(=NH)NH2; w is an integer from 0 to 6; X is an extending group selected from the group consisting of where D is conjugated via an amine group (for example, where Z is -NH-): -COO-(C2-C4 alkylene)NH-, -COO-CH2-phenylene -NH-, where the phenylene group may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen, nitro groups and cyano groups, -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 atoms carbon, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO-(C2C4 alkylene)NHCO(Ci-C3 alkylene)S-; or where D is conjugated via a hydroxy group (for example, where Z is -O-): -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, where the phenylene group may be substituted optionally with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-( C2-C4alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms carbon atoms, halogen atoms, nitro groups, and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkylene)S-, and -CONH-(C2C4 alkylene)NHCO(Ci-alkylene) C3)S-; b is 0 or 1, preferably 1; where T is an extending group selected from -CO-(Ci-C4 alkylene)-NH-, -CO-(C1C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO-( C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 10; g is 0 or 1; D is a drug fraction of formula I, IA, IB, IC, ID, IE, IF, IG, IH, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, IEb, IFb, IGb, (IHa) or (IHb), or one of their pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, where: R2 is acetyl; R3 is hydrogen or methoxy in the compounds of formula I, IC, ID, IE, IF, IG, la, ICa, IDa, IEa, IFa, IGa, Ib, ICb, IDb, IEb, IFb, IGb, (IH), ( IHa) or (IHb); R3 is hydrogen in compounds of formula IA, IAa, or IAb; R3 is a methoxy group in compounds of formula IB, IBa, or IBb, preferably R3 is hydrogen; the Ab moiety comprising at least one antigen-binding site is an antigen-binding antibody or fragment thereof, wherein the antigen-binding antibody or fragment is a monoclonal antibody that immunospecifically binds cancer cell antigens, viral antigens, antigens from autoimmune antibody-producing cells associated with autoimmune disease, microbial agents, and, preferably, a monoclonal antibody that specifically binds to cancer cell antigens; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), (V) or (VI) , with respect to the Ab fraction that comprises at least one antigen-binding site and is in the range of 3 to 8. (c) a drug conjugate according to the present invention selected from formulas (IV), (V) and (VI): LPQQCn / I 7Π7 / 3 / ΥΙΛΙ or or (iv) (V) (VI) where: R19 is selected from -Ci-Ce alkylene-, -phenylene-Ci-Οβ alkylene- where the phenylene group may be optionally substituted with one or more substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, where each of the aforementioned alkylene substituents, alone or attached to another moiety in the carbon chain, can be optionally substituted with one or plus Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, aryl groups having 6 to 12 carbon atoms, halogen atoms, nitro and cyano groups, and preferably a Ci-Ce alkylene group; R3o is a -C2-C4 alkylene group M is -C1-C3 alkylene -(C5-C7 carbocycle)-; w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): LPQQCn / Lznz / Σΐ / ΥΙΛΙ (Hl) in which the wavy lines indicate the point of covalent attachments to (X)b if any, to the drug moiety (the wavy line to the left) and to (T)g if any, or to the linker (the wavy line to the right); R22 is selected from methyl, benzyl, isopropyl, sec-butyl, and indolylmethyl; R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2, and -(CH2)3NHC(=NH)NH2; X is an extending group selected from the group consisting of -COO-(C2-C4 alkylene)NH-, COO-CH2-phenylene-NH-, where the phenylene group may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups, -COO-(C2-C4 alkylene)NH-COO- CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups or cyano)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO-(C2C4 alkylene)NHCO(Ci-C3 alkylene)S- groups; b is 0 or 1, preferably 1; where T is an extending group selected from -CO-(Ci-C4 alkylene)-NH-, -CO-(C1C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO-( C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 5; g is 0 or 1; D is a fraction of drug of formula I, IA, IC, ID, IE, IG, IH, la, lAa, ICa, IDa, IEa, IGa, Ib, lAb, ICb, IDb, lEb, IGb, (IHa) or (IHb), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, where: R1 is CN; R2 is acetyl: R3 is hydrogen; Yes-NH-u-O-; Zes-NH-; • the Ab fraction comprising at least one antigen-binding site is a monoclonal antibody selected from the group consisting of Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Coltuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Lifastuzumab, Lorvotuzumab, Milatuzumab, Mirvetuximab, Naratu ximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Pinatuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Sofituzumab, Vadastuxinnab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, and an anti-CD 30 antibody, or a binding fragment thereof to antigen or an immunologically active part thereof, wherein, preferably, the antibody is selected from Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab , Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab , Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab , Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Vadastuximab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, and an anti-CD 30 antibody, or a fragment thereof antigen-binding portion thereof or an immunologically active portion thereof, and, even more preferably, Abciximab, Alemtuzumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denosumab, Dinutuximab, Durvalumab, Elotuzumab, Gemtuzumab, Ibritumomab, Inotuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuximab, Trastuzumab, an anti-CD4 antibody, an antibody anti-CD5, an anti-CD13 antibody and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof. Of these mentioned, Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an antigen-binding fragment thereof are particularly preferred. an immunologically active part thereof; or the antibody is selected from Trastuzumab and the anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), (V) or (VI) , with respect to the Ab fraction that comprises at least one antigen-binding site and is in the range of 3 to 5. (d) A drug conjugate according to the present invention selected from the formulas LPQQCn / Lznz / Σΐ / ΥΙΛΙ (IV), (V)y(VI): LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ (VI) where: R19 is -C2-C6 alkylene R30 is a -C2-C4 alkylene-; M is -C1-C3 alkylene -(C5-C7 carbocycle)-; w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): (lll) where R22 is isopropyl, R23 is selected from methyl, and -(CH2)3NHCONH2, where the wavy lines indicate the point of covalent attachments to (X)b if any, or to the drug fraction (wavy line to the left). left) and to (T)g if any, and to the linker (the wavy line to the right); X is an extending group selected from the group consisting of -COO-(C2-C4 alkylene)NH-, COO-CH2-phenylene-NH-, where the phenylene group may be substituted with one to four Rx substituents selected from the group that consists of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups, -COO(C2-C4 alkylene)NH-COO-CH2- (phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO-(C2-C4 alkylene)NHCO(Ci-C3 alkylene)S- groups; b is 0 or 1, preferably 1; where T is an extending group selected from -CO-(Ci-C4 alkylene)-NH-, -CO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO -(Ci-C4 alkylene)-[O-(C277 alkylene C4)]j-NH-, where j is an integer from 1 to 5; g is 0 or 1; D is a drug fraction selected from: LPQQCn / Lznz / Σΐ / ΥΙΛΙ or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; where the wavy line indicates the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to (L); the Ab fraction comprising at least one antigen binding site is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof, and, more preferably, is selected from Trastuzumab and the anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), (V) or (VI) , with respect to the Ab fraction that comprises at least one antigen-binding site and is in the range of 3 to 5. (e) A drug conjugate according to the present invention selected from formulas (IV), (V), and (VI): (VI) where: R19 is -C2-C6 alkylene-; R30 is -C2-C4 alkylene-; M is -C1-C3 alkylene -(C5-C7 carbocycle)-; w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): (III) where R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, and the wavy lines indicate the point of covalent attachments to (X)b, if any, to the drug fraction (wavy line to the left). left) and to (T)g if any, and to the linker (the wavy line to the right); X is an extending group selected from the group consisting of -COO-(C2-C4 alkylene)NH-, COO-CH2-phenylene-NH-, where the phenylene group may be substituted with one to four Rx substituents selected from the group that consists of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups, -COO(C2-C4 alkylene)NH-COO-CH2- (phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO-(C2-C4 alkylene)NHCO(Ci-C3 alkylene)S-; b is 0 or 1, preferably 1; where T is an extending group selected from -CO-(Ci-C4 alkylene)-NH-, -CO-(C1C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO-( C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 5; g is 0 or 1; D is a fraction of drug selected from: or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; where the wavy line indicates the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to (L); the Ab fraction comprising at least one antigen binding site is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof, and, more preferably, it is selected from Trastuzumab and the anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), (V) or (VI) , with respect to the fraction that comprises at least one antigen-binding site and is in the range of 3 to 5. (f) A drug conjugate according to the present invention of formula (IV): D-(X)b-(AA)w-(T)gO 19~ Ab LPQQCn / Lznz / Σΐ / ΥΙΛΙ (IV) where: R19 is C2-C5 alkylene w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): N H where R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, and the wavy lines indicate the point of covalent attachments to (X)b (the wavy line to the left) and to (T)g if any, and to the linker (the wavy line to the right); and X is a -COOCH2-phenylene-NH group; b is 1; T is an extending group of the formula -CO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]4-NH-; g is 0 or 1; or of formula (V) D—(X)b-(AA)w—(T)g EITHER -M-O-j-Ab A(V) where M is -methyl-cyclohexylene-; b is 1; w is 0; X is an extension group selected from -(CH2)3S- and -(CH2)3NHCO(CH2)2Sg is 0; or of formula (VI) (SAW) LPQQCn / Lznz / Σΐ / ΥΙΛΙ where Rw is -C2-C5 alkylene R30 is -C3 alkylene w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): (III) J where R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, and the wavy lines indicate the point of covalent attachments to (X)b (the wavy line to the left) to (T)g if any some, and the linker (the wavy line to the right); and X is a -COOCH2-phenylene-NH group; b is 1; T is an extending group of the formula -CO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]4-NH-; g is 0 or 1; D is a drug fraction selected from: or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; where the wavy line indicates the covalent binding site to (X)b¡ the Ab fraction comprising at least one antigen-binding site is Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti81 antibody CD5, an anti-CD13 antibody and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof, and, more preferably, is selected from Trastuzumab and the anti-CD13 antibody or a fragment antigen-binding thereof or an immunologically active part thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof; and n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), with respect to the fraction Ab comprising at least one antigen-binding site and is in the range of 3 to 5, and preferably 4. g) a drug-antibody conjugate according to the present invention, selected from the group consisting of: either LPQQCn / Lznz / Σΐ / ΥΙΛΙ s- HN— where n is from 2 to 6, more preferably 3, 4, or 5 and each y is independently selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD4 antibody, CD5, an anti-CD13 antibody and an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof, and, more preferably, is selected from Trastuzumab and the anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof. In one embodiment, the drug-antibody conjugates according to the present invention exclude: LPQQCn / Lznz / Σΐ / ΥΙΛΙ More preferably, the drug-antibody conjugate is selected from the group consisting of: where n is from 2 to 6, more preferably 3, 4, or 5 and is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, most preferably Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, s—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, LPQQCn / Lznz / Σΐ / ΥΙΛΙ 3— where n is from 2 to 6, more preferably 3, 4, or 5 and is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, more preferably is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, HN—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, swhere n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, and LPQQCn / Lznz / Σΐ / ΥΙΛΙ where n is from 2 to 6, more preferably 3, 4, or 5 and is selected from Trastuzumab and an anti-CD13 antibody or antigen-binding fragment thereof or an immunologically active part of the itself, more preferably it is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof. h) a drug-antibody conjugate according to the present invention, selected from the group consisting of: LPQQCn / Lznz / Σΐ / ΥΙΛΙ s- HN— where n is from 2 to 6, more preferably 3, 4, or 5 and each y is independently selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD4 antibody, CD5, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof, and, more preferably, is selected from Trastuzumab and an anti-CD13 antibody or fragment antigen-binding thereof or an immunologically active part thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof; either LPQQCn / Lznz / Σΐ / ΥΙΛΙ where η is from 2 to 6, more preferably 3, 4, or 5 and is an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof. More preferably, the drug-antibody conjugate is selected from the group consisting of: where n is from 2 to 6, more preferably 3, 4, or 5 and is an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof. S~ where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, LPQQCn / Lznz / Σΐ / ΥΙΛΙ where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, HN—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, HN—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, LPQQCn / Lznz / Σΐ / ΥΙΛΙ HN— where η is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, HN—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, HN—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, HN— where η is from 2 to 6, more preferably 3, 4, or 5 is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, LPQQCn / Lznz / Σΐ / ΥΙΛΙ HN—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, HN—where n is from 2 to 6, more preferably 3, 4, or 5 and is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof, With particular preference, the drug-antibody conjugate according to the present invention should be in isolated or purified form. Preferred compounds of formula D-(X)b-(AA)w-(T)g-Li or of formula D-(X)b-(AA)w-(T)g-H according to the present invention include: • a compound of the formula D-(X)b-(AA)w-(T)g-Li or of the formula D-(X)b-(AA)w-(T)g-H in which each D, X, AA, T, Li, b, g and w are as defined herein; but, furthermore, where if the compound is a compound of formula D-(X)b-(AA)w-(T)g-H, then b+w+g#0. • a compound of formula D-(X)b-(AA)w-(T)g-Li or of formula D-(X)b-(AA)w-(T)g-H according to the present invention, in the fact that: Li is a binder of formula: LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ where: the wavy line indicates the point of covalent attachment to (T)g if any, to (AA)W if any, to (X)b if any, or to D; R19 is selected from -C1-C12 alkylene-, -O-(C1-C12 alkylene), -C6-C12 arylene on one or more rings which may be optionally substituted with one or more substituents Rx, -C1-C12 alkylene-arylene CeC12 - where the arylene group is on one or more rings which may be optionally substituted with one or more Rx substituents, -C6-C12 arylene -C1-C12 alkylene - where the arylene group is on one or more rings which may be optionally substituted with one or more substituents Rx, -C5C12 heterocycle - where the heterocycle group can be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -Ci-Ci2 alkylene-(C5-C12 heterocycle)- where the heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one carbon atom. oxygen, nitrogen or sulfur on said one or more rings, said group is optionally substituted with one or more substituents Rx, -(Cs-Ci2 heterocycle)-C1-C12 alkylene where the heterocycle group may be a saturated or unsaturated group possessing one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -(OCH2CH2)r- and -CH2-(OCH2CH2)r- , where each of the aforementioned alkylene substituents, alone or together with another moiety on the carbon chain, may be optionally substituted with one or more Rx substituents; r is an integer from 1-6; and each D, Rx, X, AA, T, b, g and w is as defined herein; but where if the compound is a compound of formula D-(X)b-(AA)w-(T)g-H, then b+w+g^O. • a compound of formula D-(X)b-(AA)w-(T)g-Li or of formula D-(X)b-(AA)w-(T)g-H according to the present invention, wherein : L1 is a binder of the formula: EITHER LPQQCn / I 7Π7 / 3 / ΥΙΛΙ where: the wavy line indicates the point of covalent attachment to (T)g if any, to (AA)W if any, to (X)b if any, or to D; R19 is selected from -Ci-Ce alkylene-, -O-(Ci-Ce alkylene), -Ci-Cs alkylene-C6-C12 arylene where the arylene group is found on one or more rings which may be optionally substituted by one or more Rx substituents, and -C6-C12 arylene-Ci-Cs alkylene - where the arylene group is found on one or more rings that may be optionally substituted with one or more Rx substituents, where each of the above substituents, alone or attached to another moiety on the carbon chain, may be optionally substituted by one or more Rx substituents; (AA)w is of formula (II): H N (II) where the wavy lines indicate the point of covalent attachment to (X)b, if any, to D (the wavy line to the left) and to (T)g if any, to L1 or to a hydrogen atom ( the wavy line to the right); where R21 is selected, at each occurrence, from the group consisting of hydrogen, methyl, isopropyl, secbutyl, benzyl, indolylmethyl, -(CH2)3NHCONH2, -(CH2)4NH2, -(CH2)3NHC(=NH)NH2y -( CH2)4NHC(=NH)NH2, and w is an integer from 0 to 6; X is an extending group selected from the group consisting of where D is conjugated via an amine group (for example, where Z is -NH-): -COO-(C2-C4 alkylene)NH-, -COO-CH2-phenylene -NH, where the phenylene group may be substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms carbon, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and - COO-(C2-C4 alkylene)NHCO(Ci-C3 alkylene)S- or where D is conjugated via a hydroxy group (for example, where Z is -O-): -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, where the phenylene group may be substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms carbon, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups that have 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2 alkylene- C4)S-, and -CONH-(C2C4 alkylene)NHCO(Ci-C3 alkylene)S-; T is an extending group selected from -CO-(Ci-C4 alkylene)-NH-; -CO-(Ci-C4 alkylene)-[O(C2-C4 alkylene)]j-NH- and -COO-(Ci-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 10; LPQQCn / Lznz / Σΐ / ΥΙΛΙ b is 0 or 1; g is 0 or 1; where, if the compound is a compound of formula D-(X)b-(AA)w-(T)g-H, then b+w+g#0; and D is a drug fraction of formulas I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, and IGb; and is covalently linked through a hydroxy or amine group; or is a moiety of drug of formula (IHa) or formula (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, where: where the wavy lines of (IHa) and (IHb) indicate the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to L-i; Ri is -OH or -CN; R2 is a group -C(=O)Ra, where Rase is selected from hydrogen and substituted or unsubstituted Ci-Ce alkyl, where optional substituents are one or more Rx substituents; R3 is hydrogen or a -ORb group, where Rb is a substituted or unsubstituted Ci-Οθ alkyl group, where optional substituents are one or more Rx substituents. Yes-NH-u -O-; and Zes -NH-u-O-. • a compound of formula D-(X)b-(AA)w-(T)g-Li or of formula D-(X)b-(AA)w-(T)g-H according to the present invention, wherein : Li is a group of formula: 0V j—C—Rle-N~J J where: the wavy line indicates the point of covalent attachment to (T)g if any, to (AA)W if any, to (X)b if any, or to D; R19 is selected from -Ci-Ce alkylene phenylene-Ci-Ce alkylene - where the phenylene group may be optionally substituted with one or more substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having of 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, where each of the aforementioned alkylene substituents, alone or attached to another moiety on the carbon chain, may be optionally substituted with one or more Rx substituents selected from group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, aryl groups having 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups, and, preferably, there is a Ci-Ce alkylene group; w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): LPQQCn / Lznz / Σΐ / ΥΙΛΙ (III) where the wavy lines indicate the point of covalent attachment to X (the wavy line to the left) and to (T)g if any, to Li or a hydrogen atom (the wavy line to the left). the right); Rsz is selected from methyl, benzyl, isopropyl, sec-butyl, and indolylmethyl; R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2, and -(CH2)3NHC(=NH)NH2; X is an extension group selected from: where D is conjugated via an amine group (for example, where Z is -NH-): -COO-CH2-phenyleneNH-, -COO(CH2)3NHCOO-CH2-phenylene-NH, -COO-(CH2)3 )NH-, -COO(CH2)3-S-, and -COO-(CH2)3NHCO(CH2)2S-, O where D is conjugated via a hydroxy group (for example, where Z is -O-): - COO-CH2-phenyleneNH-, -CONH(CH2)3NHCOOCH2-phenylene-NH-, -CONH(CH2)3NH-, -CONH(CH2)3-S-, and CONH(CH2)3NHCO(CH2)2S- . where T is an extending group selected from -CO-(Ci-C4 alkylene)-NH-, -CO-(C1C4 alkylene)-[O-(C2-C4 alkylene)]¡-NH-, and -COO-( C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 5; b is 0 or 1; g is 0 or 1; where if the compound is a compound of formula D-(X)b-(AA)w-(T)g-H, then b+w+g#0; and D is a drug fraction of formulas I, IA, IB, IC, ID, IE, IF, IG, la, lAa, IBa, ICa, IDa, lEa, IFa, IGa, Ib, lAb, IBb, ICb, IDb, lEb, IFb, and IGb; and is covalently linked through a hydroxy or amine group; or is a moiety of drug of formula (IHa) or formula (IHb), or a pharmaceutically acceptable salt, ester, solvate, tautomer, or stereoisomer thereof: LPQQCn / Lznz / Σΐ / ΥΙΛΙ where the wavy lines in (IHa) and (IHb) indicate the point of covalent attachment; Ri is -CN or -OH; R2 is acetyl; R3 is hydrogen or methoxy, preferably hydrogen; Y is -NH-u-O-; and Z is -NH- or -O-. • a compound of formula D-(X)b-(AA)w-(T)g-Li or of formula D-(X)b-(AA)w-(T)g-H according to the present invention, in which: Li is a binder of formula: where: the wavy line indicates the point of covalent attachment to (T)g if any, to (AA)W if any, to (X)b if any, or to D; R19 is -C2-C6 alkylene-; w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): LPQQCn / Lznz / Σΐ / ΥΙΛΙ (III) R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, where the wavy lines indicate the point of covalent attachments to X (the wavy line to the left) and to (T)g if any, to L1 or to a carbon atom. hydrogen (the wavy line to the right); X is an extension group selected from -COO-CH2-phenylene-NH-, -COO(CH2)3NHCOO-CH2phenylene-NH, -COO-(CH2)3)NH-, -COO(CH2)3-S-, y-COO-(CH2)3NHCO-(CH2)2S-; where T is an extending group selected from -CO-(Ci-C4 alkylene)-NH-, -CO-(C1C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO-( C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 5; b is 0 or 1; g is 0 or 1; where if the compound is a compound of formula D-(X)b-(AA)w-(T)g-H, then b+w+g#0; and D is a drug fraction selected from: or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; where the wavy line indicates the point of covalent binding. • a compound of formula D-(X)b-(AA)w-(T)g-Li or of formula D-(X)b-(AA)w-(T)g-H according to the present invention, wherein : L1 is a group of formula: in which: the wavy line indicates the point of covalent attachment to (T)g if any, to (AA)W if any, to (X)b, if any or to D; R19 is a -C2-C5 alkylene-; w is 0 or 2, and where w is 2, then (AA)Wes of formula (III): LPQQCn / Lznz / Σΐ / ΥΙΛΙ (III) in which R22 is isopropyl, R23 is selected from methyl, and -(CH2)3NHCONH2, where the wavy lines indicate the point of covalent attachments to X (the wavy line to the left) and to (T)g if any, to L1 or to a hydrogen atom (the wavy line to the right); X is a group -COO-CH2-phenylene-NH-; T is a group -CO-(CH2)2-[O-(CH2)2]4-NH-; b is 0 or 1; g is 0 or 1; where if the compound is a compound of formula D-(X)b-(AA)w-(T)g-H, then b+w+g^O; and D is a drug fraction selected from: or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof; where the wavy line indicates the point of covalent binding. • a compound of formula D-X-(AA)w-(T)g-Li selected from: • a compound of formula D-X-(AA)w-(T)g-Li selected from: LPQQCn / Lznz / Σΐ / ΥΙΛΙ LPQQCn / I 7Π7 / 3 / ΥΙΛΙ The term "pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers" in the drug conjugates of the present invention refers to any salt, ester, solvate, hydrate or stereoisomeric form or any other compound which, upon administration to the patient , is capable of providing a compound as described herein, either directly or indirectly. However, it will be appreciated that salts which are not pharmaceutically acceptable also fall within the scope of the invention since they may be useful in the preparation of pharmaceutically acceptable salts. The preparation of salts, prodrugs and derivatives can be carried out by methods known in the state of the art. For example, pharmaceutically acceptable salts of compounds provided herein are synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts, for example, are prepared by the reaction of the 101 free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture of both. Generally, non-aqueous media are preferred, such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile. Examples of acid addition salts include mineral acid addition salts such as hydrochloride, hydrobromide, iohydrate, sulfate, nitrate, phosphate, and organic acid addition salts such as acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate. Examples of the alkali addition salts include inorganic salts such as sodium, potassium, calcium, and ammonium salts, and organic alkali salts such as ethylenediamine, ethanolamine, A / ,A / -dialkyleneethanolamine, triethanolamine and basic amino acids. The drug conjugates of the present invention may be in crystalline form, either as free compounds or as solvates (eg, hydrates) and both forms are intended to be within the scope of the present invention. Solvation methods are generally known in the art. Any compound that is a prodrug of the drug conjugate of the present invention is within the scope and spirit of the invention. The term "prodrug" is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. These derivatives should readily occur to those skilled in the art and include, for example, compounds in which a free hydroxy group is converted to an ester derivative. Many suitable prodrugs are well known to one skilled in the art and can be found, for example, in Burger "Medicinal Chemistry and Drug Discovery, 6aed. (Donald J. Abraham ed., 2001, Wiley) and "Design and Applications of Prodrugs" (H. Bundgaard ed., 1985, Harwood Academic Publishers), the contents of which are incorporated herein by reference. Regarding the compounds of the present invention, pharmacologically acceptable esters are not particularly limited and can be selected by a person having basic knowledge in the art. In the case of such esters, it is preferred that such esters can be cleaved by a biological process such as in vivo hydrolysis. The group constituting such esters (the group shown as R when its esters are expressed as -COOR) may be, for example, a C1-C4 alkoxy C1-C4 alkyl group such as methoxyethyl, 1-ethoxyethyl, 1- methyl-1-methoxyethyl, 1-(isopropoxy)ethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl or t-butoxymethyl; a C1-C4 alkoxy C1-C4 alkyl group, for example 2-methoxyethoxymethyl; an aryloxy Ce-CioC1-C4 alkyl group, for example, phenoxymethyl; a halogenated C1-C4 alkoxyC1-C4 alkyl group, for example 2,2,2-trichloroethoxymethyl or bis(2-chloroethoxy)methyl; a C1-C4 alkoxycarbonyl C1-C4 alkyl group, for example, methoxycarbonylmethyl; a C1-C4 cyanoalkyl group, for example, cyanomethyl or 2-cyanoethyl; a C1-C4 alkylthiomethyl group, for example methylthiomethyl or ethylthiomethyl; a Ce-Cío arylthiomethyl group, for example phenylthiomethyl or naphthylthiomethyl; a C1-C4 alkylsulfonyl C1-C4 lower alkyl, which may be optionally substituted by one or more halogen atoms, such as 2-methanesulfonylethyl or 2-trifluoromethanesulfonylethyl; a Ce-CioC1-C4 alkyl arylsulfonyl group, for example, 2-benzenesulfonylethyl or 2-toluenesulfonylethyl; a C1-C7 acyloxy C1-C4 aliphatic alkyl group, for LPQQCn / Lznz / Σΐ / ΥΙΛΙ 102 example, formyloxymethyl, acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl, valeryloxymethyl, isovaleryloxymethyl, hexanoyloxymethyl, 1-formyloxyethyl, 1-acetoxyethyl, 1-propionyloxyethyl, 1-butyryloxyethyl, -pivaloyloxyethyl, 1-valeryloxyethyl, 1-isovaleryloxyethyl, 1-hexanoyloxyethyl, 2-formyloxyethyl, 2-acetoxyethyl, LPQQCn / Lznz / Σΐ / ΥΙΛΙ 2-propionyloxyethyl, 2-butyryloxyethyl, 2-pivaloyloxyethyl, 2-valeryloxyethyl, 2-isovaleryloxyethyl, 2-hexanoyloxyethyl, 1-formyloxypropyl, 1-acetoxypropyl, 1-propionyloxypropyl, 1-butyryloxypropyl, 1-pivaloyloxypropyl, 1-valeryloxy propyl, 1- isovaleryloxypropyl, 1-hexanoyloxypropyl, 1-acetoxybutyl, 1-propionyloxybutyl, 1-butyryloxybutyl, 1-pivaloyloxybutyl, 1-acetoxypentyl, 1-propionyloxypentyl, 1-butyryloxypentyl, 1-pivaloyloxypentyl or 1-pivaloyloxyhexyl; a cycloalkylcarbonyloxy Cs-Ce C1-C4 alkyl group, such as cyclopentylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl, 1-cyclopentylcarbonyloxyethyl, 1-cyclohexylcarbonyloxyethyl, 1-cyclopentylcarbonyloxypropyl, 1-cyclohexylcarbonyloxypropyl, 1-cyclopentylcarbonyloxybutyl or 1-cyclohexylcarbonyloxybutyl; an arylcarbonyloxy Ce-CioC1-C4 alkyl group, for example, benzoyloxymethyl; a C1-C4 alkoxycarbonyloxy alkyl group, such as methoxycarbonyloxymethyl, 1-(methoxycarbonyloxy)ethyl, 1-(methoxycarbonyloxy)propyl, 1-(methoxycarbonyloxy)butyl, 1-(methoxycarbonyloxy)pentyl, 1-(methoxycarbonyloxy)hexyl, ethoxycarbonyloxymethyl, 1-(ethoxycarbonyloxy)ethyl, 1-(ethoxycarbonyloxy)propyl, 1-(ethoxycarbonyloxy)butyl, 1-(ethoxycarbonyloxy)pent¡l, 1-(ethoxycarbonyloxy¡)hex¡l, propoxycarbonyloxymethyl, 1-(propoxycarbonyloxy¡)ethyl, 1-(propoxycarbonyloxy¡)propyl, 1-(¡sopropoxycarbonyloxy)ethyl, 1-(butoxycarbonyloxy)ethyl, isobutoxycarbonyloxymethyl, 1-(¡sobutoxycarbonyloxy¡)but¡l, pentyloxycarbonyloxymethyl, hexyloxycarbonyloxymethyl, -(propoxycarbonyloxy)butyl, 1-(isopropoxycarbonyloxy)butyl, -(butoxycarbonyloxy)propyl, -(isobutoxycarbonyloxyjetyl, t-butoxycarbonyloxy methyl, -(pentyloxycarbonyloxyjetyl, isopropoxycarbonyloxymethyl, butoxycarbonyloxymethyl, -(butoxycarbonyloxy)butyl, 1-(¡sobutoxycarbonyloxy)propyl, 1-(t-butoxycarbon¡loxy)ethyl, 1-(pentyloxy¡carbon¡loxy)propyl, 1-(hexyloxy¡carbonyloxy¡)ethyl or 1-(hexyloxy¡carbonyloxy)propyl; a cycloalkyloxycarbonyloxy Cs-Ce 1-(cyclopentyloxycarbonyloxy)ethyl, cyclohexyloxycarbonyloxymethyl, 1-(cyclohexyloxycarbonyloxy)butyl group; C1-C4 alkyl, such as cyclopentyloxycarbonyloxymethyl, 1-(cyclopentyloxycarbon¡lox¡)propyl, 1-(cyclopentyloxycarbon¡lox¡)but¡lo, 1-(cyclohexyloxycarbonyloxy¡)ethyl, 1-(clohexyloxycarbon¡loxy)propyl or a group [5- (Ci-C4 alkyl)-2-oxo-1,3-dioxolen-4-yl]methyl such as (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl lo, (5-ethyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-propyl-2-oxo-1,3dioxolen-4-yl)methyl, (5-isopropyl-2- oxo-1,3-dioxolen-4-yl)methyl or (5-butyl-2-oxo-1,3-dioxolen-4-yl)methyl; a [5-(phenyl, which may be optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, or one or more halogen atoms)-2-oxo-1,3-dioxolen-4-yl]methyl group such as, for example, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl, [5-(4-methylphenyl)-2-oxo-1,3-dioxolen-4-yl]methyl, [5- (4-methoxyphenyl)-2-oxo-1,3-dioxolen-4-yl]methyl, [5(4-fluorophenyl)-2-oxo-1,3-dioxolen-4-yl]methyl or [ 5-(4-chlorophenyl)-2-oxo-1,3-dioxolen-4-yl]methyl; or a phthalidyl group, which may be optionally substituted by one or more C1-C4 alkyl or C1-C4 alkoxy groups, such as phthalidyl, dimethylphthalidyl or dimethoxyphthalidyl, and is preferably a pivaloyloxymethyl group, a phthalidyl group or a group (5-methyl-2-oxo-1,3-dioxolen-4-¡l)methyl, and, more preferably, a group (5meti Ι-2-οχο-1,3-dioxolen-4-i I )put it. Any compound mentioned herein is intended to represent said compound. 103 specific, as well as certain variations or forms. In particular, the compounds mentioned herein may have asymmetric centers and thus exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds mentioned herein, and their mixtures, are considered to be within the scope of the present invention. Thus, any given compound mentioned herein is to represent any of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Particularly, the conjugates of drugs of the formula [D-(X)b-(AA)w-(T)g-(L)]n-Ab and the compounds of the formula D-X-(AA)w-(T)g- Li or D-X-(AA)w-(T)g-H may include enantiomers according to their asymmetry or diastereoisomers. Also, stereoisomerism around the double bond is possible, so in some cases the molecule could exist as an (E)-isomer or (Z)-isomer. If the molecule contains multiple double bonds, each double bond will have its own stereoisomerism, which might be the same as or different from the stereoisomerism of the other double bonds in the molecule. Individual isomers and mixtures of isomers fall within the scope of the present invention. Also, the compounds mentioned herein can exist as geometric isomers (ie, cis and trans isomers), as tautomers, or as atropisomers. Specifically, the term "tautomer" refers to one of two or more structural isomers of a compound that exist in equilibrium and are readily converted from one isomeric form to another. Common tautomeric pairs are aminoimine, amide-imide, keto-enol, lactam-lactim, etc. Additionally, all compounds mentioned herein are to represent hydrates, solvates, and polymorphs, and mixtures thereof when such forms exist in the medium. Furthermore, the compounds mentioned herein can exist in isotopically labeled forms. All geometric isomers, tautomers, atropisomers, hydrates, solvates, polymorphs, and isotopically labeled forms of the compounds mentioned herein, and mixtures thereof, are considered to be within the scope of the present invention. Protected forms of the compounds disclosed herein are considered to be within the scope of the present invention. Suitable protecting groups are well known to those skilled in the art. A general review of protecting groups in organic chemistry is provided by Wuts, PGM, and Greene TW in Protecting Groups in Organic Synthesis, 4aEd. Wiley-Interscience, and by PJ Kocienski in Protecting Groups, 3rd Ed. Georg Tieme Verlag. These references provide sections on protecting groups for OH, amino, and SH groups. All such references are incorporated in their entirety herein by reference. Within the scope of the present invention, a protecting group is defined as the O-linked moiety that results from the protection of OH through the formation of a suitable protected OH group. Examples of protected OH groups include ethers, silyl ethers, esters, sulfonates, sulfenates and sulfinates, carbonates, and carbamates. In the case of ethers, the protecting group for OH can be selected from methyl, methoxymethyl, methylthiomethyl, (phenyldimethylsilylmethoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, [(3,4-dimethoxybenzyl)oxy]methyl, p-nitrobenzyloxymethyl, o-nitrobenzyloxymethyl, [( / 7)-1-(2-nitrophenyl)ethoxy]methyl, (4-methoxyphenoxy)methyl, guaiacolmethyl, [(p-phenylphenyl)oxy]methyl, t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2-cyanoethoxymethyl, bis(2-chloroethoxy¡)methyl, 2,2,2 LPQQCn / Lznz / Σΐ / ΥΙΛΙ 104 Trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, menthoxymethyl, O-bis(2-acetoxy-ethoxy)methyl, tetrahydropyranyl, fluorous tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxy-tetrahydrothiopyranyl, S, S -4-methoxytetrahydrothiopyranyl dioxide, 1-[(2-chloro-4-methyl)-phenyl]-4-methoxypiper¡d¡n-4-¡l, 1-(2-fluorophenyl)- 4-methoxypiperidin-4-yl, 1-(4-chlorophenyl)-4-methoxy¡p¡per¡n-4-yl, 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3, 3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 2- hydroxyethyl, 2-bromoethyl, 1 -[2-(trimethylsilyl)ethoxy]ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl , 1-methyl-1-phenoxyethyl, 2,2,2-trichloroethyl, 1,1-dianisil-2,2,2trichloroethyl, 1,1,1,3,3,3-hexafluoro-2 -phenylisopropyl, 1-(2-cyanoethoxy)ethyl, 2-trimethylsilylethyl, 2-(benzylthio)ethyl, 2-(phenylselenyl)ethyl, t-butyl, cyclohexyl, 1-methyl-T-cyclopropylmethyl, allyl, prenyl, cinnamyl, 2-phenylyl, propargyl, p-chlorophenyl, p-methoxyphenyl, p-nitrophenyl, 2,4-dinitrophenyl, 2,3,5,6-tetrafluoro-4(trifluoromethyl)phenyl, benzyl, p-methoxybenzyl, 3, 4-dimethoxybenzyl, 2,6-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, pentadienylnitrobenzyl, pentadienylnitroperonyl, halobenzyl, 2,6-dichlorobenzyl, 2,4-dichlorobenzyl, 2,6-difluorobenzyl, p-cyanobenzyl, fluorous benzyl, 4 -fluorousalkoxybenzyl, trimethylsilylxylyl, p-phenylbenzyl, 2-phenyl-2-propyl, p-acylaminobenzyl, p-azidobenzyl, 4-azido-3-chlorobenzyl, 2-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, p-(methylsulfinyl)benzyl, p- silethanolbenzyl, 4-acetoxybenzyl, 4-(2-trimethylsilyl)ethoxymethoxybenzyl, 2-naphthylmethyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, 2-quinolinylmethyl, 6-methoxy-2 -(4-methylphenyl)-4-quinolinemethyl, 1-pyrenylmethyl, diphenylmethyl, 4-methoxydiphenylmethyl, 4-phenyldiphenylmethyl, ρ,ρ'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, tris(4-tbutylphenyl)methyl, or- naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenyl-methyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxy)phenyldphenylmethyl, 4 ,4',4”-tr¡s(4,5-dichlorophthal¡m¡dophenyl)methyl, 4,4',4”-trls(levul¡no¡lox¡phenyl)methyl, 4 ,4',4”-tris(benzo¡lox¡phenyl)methyl, 4,4'-dimethoxy-3”-[A / (imidazol¡lmethyl)]trit¡lo, 4,4'-dimethox ¡-3”-[A / -(¡m¡dazolilet¡l)carbamo¡l]trit¡l, bis(4-methoxyphenyl)-1'-pyrenylmethyl, 4-(17-tetrabenzo[a, c,g, / ]fluoren¡lmethyl)-4,4”-dimethoxy¡tr¡l, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-phenylthioxantyl, 9-(9-phenyl- 10-oxo)anthryl, 1,3-benzodithiolan-2-yl, 4,5-bis(ethoxycarbonyl)-[1,3]-dioxolan-2-yl, S,S-benzisothiazolyl dioxide. In the case of silyl ethers, the protecting group for OH can be selected from trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, 2-norbornyldimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, di-f-butylmethylsilyl, bis(t-butyl)-1-pyrenylmethoxysilyl, tris(trimethylsilyl)silyl, (2-hydroxystyryl)dimethylsilyl, (2-hydroxystyryl)diisopropylsilyl, f-butylmethoxyphenylsilyl, f-butoxydiphenylsilyl , 1,1,3,3-tetraisopropyl-3-[2-(triphenylmethoxy)ethoxy]disiloxane-1-yl, and fluorous silyl. In the case of esters, the protecting group for OH together with the unprotected OH oxygen atom to which it is attached form an ester which can be selected from formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trichloroacetamidate, trifluoroacetate , methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, phenylacetate, diphenylacetate, 3-phenylpropionate, bisfluorinated chain-type propanolyl, 4-pentenoate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, 5[3-bis(4- methoxyphenyl)hydroxymethylphenoxy]levulinate, pivaloate, 1-adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate, 4-bromobenzoate, 2,5-difluorobenzoate, p-nitrobenzoate, 105 picolinate, nicotinate, 2-(azidomethyl)benzoate, 4-azidobutyrate, (2-azidomethyl)phenylacetate, 2-{[(t¡t¡ltio)ox¡]methyl}benzoate, 2-{[( 4-methoxytr¡t¡l¡o)oxy]methyl}benzoate, 2-{[methyl(trit¡t¡o)am¡no]methyl}benzoate, 2-{{[(4-methoxytrityl)th¡o]methylamino}methyl}benzoate, 2-(allyloxy)phen¡lacetate, 2-(prenyloxymethyl)benzoate, 6-(levulin¡lox¡methyl)-3-methoxy¡-2-n¡trobenzoate, 6-(levulin¡loxymethyl)-3-methoxy -4-n¡trobenzoate, 4-benzyloxybutyrate, 4-trialkylsilyloxy-butyrate, 4-acetox¡-2,2dimethylbutyrate, 2,2-dimethyl-4-pentenoate, 2-iodobenzoate, 4-nitro-4-methylpentanoate, or- (dibromomethyl)benzoate, 2-formylbenzenesulfonate, 4-(methylthio-methoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2-(chloroacetoxymethyl)benzoate, 2-[(2-chloroacetoxy)ethyl]benzoate, 2-[2-(benzyloxy)ethyl]benzoate, 2-[2-(4-methoxybenzyl-oxy)ethyl]benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4 -(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxycarbonyl)benzoate, a-naphthoate, nitrate, alkyl Λ / ,Λ / ,Λ / ',Λ / '-tetramethylphosphorodiamidate, and 2-chlorobenzoate. In the case of sulfonates, sulfenates, and sulfinates, the protecting group for OH together with the unprotected OH oxygen atom to which it is attached forms a sulfonate, sulfenate, or sulfinate which may be selected from sulfate, allylsulfonate, methanesulfonate, benzylsulfonate, tosylate and dimethylphosphinothioyl. In the case of carbonates, the protecting group for OH together with the unprotected OH oxygen atom to which it is attached form a carbonate which can be selected from methyl carbonate, methoxymethyl carbonate, 9-fluorenylmethyl carbonate, ethyl, bromoethyl carbonate, 2-(methylthiomethoxy)ethyl carbonate, 2,2,2-trichloroethyl carbonate, 1,1-dimethyl2,2,2-trichloroethyl carbonate, 2-(trimethyls¡ carbonate l¡l)ethyl, 2-[dimethyl(2-naphthylmethyl)silyl]ethyl carbonate, 2-(phenylsulfonyl)ethyl carbonate, 2-(triphenylphosphon¡o)ethyl carbonate, carbonate c / s-[4[[(methoxytrit¡l)sulfen¡l]ox¡]tetrahydrofuran-3-¡l]oxy¡, isobutyl carbonate, t-butyl carbonate, vinyl carbonate, allyl carbonate , cinnamyl carbonate, propargyl carbonate, p-chlorophenyl carbonate, p-nitrophenyl carbonate, 4-ethoxy-1-naphthyl carbonate, 6-bromo-7-hydroxycoumarin-4-ylmethyl carbonate, benzyl, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, anthraquinon-2-ylmethyl carbonate, 2-dansylethyl carbonate, 2-(4-nitrophenyl carbonate )ethyl, 2-(2,4-dinitrophenyl)ethyl carbonate, 2-(2-nitrophenyl)propyl carbonate, 2-(3,4-methylenedioxy-6-nitrophenyl)propyl carbonate, 2-Cyano-1-phenylethyl, 2-(2-pyridyl)amino-1-phenylethyl carbonate, 2-[ / X / -methyl-A / -(2-pyridyl)]amino-1-phenylethyl carbonate, phenacyl carbonate , 3',5'-dimethoxybenzoin carbonate, methyl dithiocarbonate, and S-benzyl thiocarbonate. And, in the case of carbamates, the protecting group for OH together with the unprotected OH oxygen atom to which it is attached forms a carbamate that can be selected from dimethyl thiocarbamate, A / -phenyl carbamate, and A carbamate. / -methyl-A / -(o-nitrophenyl). Within the scope of the present invention, an amino protecting group is defined as the A / linked moiety that results from the protection of the amino group through the formation of a suitable protected amino group. Examples of protected amino groups include carbamates, ureas, amides, heterocyclic systems, / V-alkylamines, A / -alkenylamines, AZ-alkynylamines, / V-arylamines, imines, enamines, 106 N-metal derivatives, N-N derivatives, N-P derivatives, N-Si derivatives, and N-S derivatives. In the case of carbamates, the protecting group for the amino group together with the amino group to which it is attached form a carbamate which can be selected from methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate, 2,6- di-t-butyl-9-fluorenylmethyl, 2,7-b¡s(trimethyls¡l¡l)fluorenylmethyl carbamate, 9-(2-sulfo)fluorenylmethyl carbamate, carbamate 9-(2,7dibromo)fluorenylmethyl, 17-tetrabenzo[a,c,g, / ]fluorenylmethyl carbamate, 2-chloro-3-indenylmethyl carbamate, benz[f]inden-3-ylmethyl carbamate, 1-, 1-dioxobenzo[í>]-thiophen-2-ylmethyl, 2-methylsulfonyl-3-phenyl-1-prop-2-enyl carbamate, 2,7-di-f-butyl-[9,( 10,10-dioxo-10,10,10,10tetrahydrothioxanth¡l)]methyl, 2,2,2-trichloroethyl carbamate, 2-trimethylsilylethyl carbamate, (2-phenyl-2- tnmethylsil¡l)ethyl, 2-phenylethyl carbamate, 2-chloroethyl carbamate, 1,1-dimethyl-2haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate, 1,1-carbamate dimethyl-2,2,2-trichloroethyl, 2-(2'-pyridyl)ethyl carbamate, 2-(4'-pyridyl)ethyl carbamate, 2,2-bis(4'-nitrophenyl) carbamate )ethyl, 2-[(2-nitrophenyl)dithio]-1-phenylethyl carbamate, 2-(A / , / \ / -dicyclohexylcarboxamido)ethyl carbamate, f-butyl carbamate, fluorous BOC carbamate, 1-adamantyl carbamate, 2-adamantyl carbamate, 1-(1-adamantyl)-1-methylethyl carbamate, 1-methyl-1-(4-biphenyl) carbamate l)ethyl, 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate, triisopropylsilyloxy carbamate, vinyl carbamate, allyl carbamate, prenyl carbamate, 1-isopropylallyl carbamate, cinnamyl, 4-nitrocinnamyl carbamate, 3-(3'pyridyl)prop-2-enyl carbamate, hexadienyl carbamate, propargyl carbamate, 1,4-but-2-ynyl biscarbamate, 8-yl carbamate quinolyl, N-hydroxyIpiperidinyl carbamate, alkyl dithiocarbamate, benzyl carbamate, 3,5-di-t-butylbenzyl carbamate, p-methoxybenzyl carbamate, p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-carbamate chlorobenzyl, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate, 4-trifluoromethylbenzyl carbamate, fluorous benzyl carbamate, 2-naphthylmethyl carbamate, 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 4-phenylacetoxybenzyl carbamate, carbamate 4-azidobenzyl, 4-azido-methoxybenzyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)-benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-( trifluoromethyl)-6-chromonylmethyl, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, 2-(4-nitrophenylsulfonyl)ethyl carbamate, 2-(4-nitrophenylsulfonyl)ethyl carbamate -(2,4dinitrophenylsulfonyl)ethyl, 2-(4-trifluoromethylphenylsulfonyl)ethyl carbamate, [2-(1,3dithianyl)]methyl carbamate, 2-phosphonioethyl carbamate, 2-[phenyl carbamate (methyl)sulfonio]ethyl, 1-methyl-1-(t-phenylphosphonium)ethyl carbamate, 1,1-dimethyl-2-cyanoethyl carbamate, 2-dansylethyl carbamate, 2- (4-nitrophenyl)ethyl, 4-methylthiophenyl carbamate, 2,4-dimethylthiophenyl carbamate, m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl) carbamate ethyl, α-methylnitroperonyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, 2-nitrophenylethyl carbamate, 6-nitroveratril carbamate, 4-methoxyphenacyl carbamate, 3',5'-dimethoxybenzoin carbamate, 9-xanthenylmethyl carbamate, A / -methyl- / V-(o-nitrophenyl) carbamate, t-amyl carbamate, 1-methylcyclobutyl, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, cyclobutyl carbamate, cyclopentyl carbamate, cyclohexyl carbamate, isobutyl carbamate, isobornyl carbamate, LPQQCn / Lznz / Σΐ / ΥΙΛΙ 107 Cyclopropylmethyl, p-decyloxybenzyl carbamate, diisopropylmethyl carbamate, 2,2-dimethoxy-carbonylvinyl carbamate, o-(A / , / V-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3- (A / ,A / dimethyl-carboxam¡do)propyl, butynyl carbamate, 1,1-dimethylpropynyl carbamate, 2-iodoethyl carbamate, 1-methyl-1 -(4'-pyr¡d¡ carbamate l)ethyl, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, p-(p-methoxyphenylazo)benzyl carbamate, p-(phenylazo)benzyl carbamate, 2,4-carbamate ,6-trimethylbenzyl, isonicotinyl carbamate, 4-(trimethyl-ammonium)benzyl carbamate, p-cyanobenzyl carbamate, d¡(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, dephenyl carbamate, 2-carbamate, 4,6-trit-butylphenyl, 1-methyl-1-phenylethyl carbamate, and S-benzyl thiocarbamate. In the case of ureas, the protecting groups for the amino group can be selected from phenothiazinyl-(10)-carbonyl, N'-ptoluenesulfonylaminocarbonyl, M-phenylaminothiocarbonyl, 4-hydroxyphenylaminocarbonyl, 3-hydroxytryptaminocarbonyl, and A / '-phenylaminothiocarbonyl. In the case of amides, the protecting group for the amino together with the amino group to which it is attached form an amide which can be selected from formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, pent-4-enamide , picolinamide, 3-pyridylcarboxamide, M-benzoylphenylalanilamide, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, 2,2-dimethyl-2-(o-n¡trophenyl)acetamide, o-nitrophenoxyacetamide, 3-(onitrophenyl)propanamide , 2-methyl-2-(o-nitrofenoxy¡)propanamide, 3-methyl-3-nitrobutanamide, o-nitrocinamide, o-nitrobenzamide, 3-(4-t-butyl-2,6-dinitrofen¡ l)-2,2-dimethylpropanamide, o-(benzoyloxime-t¡l)benzamide, 2-(acetoxymethyl)benzamide, 2-[(f-butyldiphenylsilox¡)methyl]benzamide, 3-(3',6' -dioxo-2',4',5'-trimethylcyclohexaT,4'-diene)-3,3-dimethylpropionamide, o-hydroxy-trans-cinnamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide , aceto-acetamide, 3-(p-hydroxyphenyl)propanamide, (Af-dithiobenzyloxycarbonylaminojacetamide, and AZ-acetylmethionine amide. In the case of heterocyclic systems, the protecting group for the amino group together with the amino group to which it is attached form a heterocyclic system which can be selected from 4,5-diphenyl-3-oxazolin-2-one, A / -phthal ¡mida, W-dichlorophthalimide, / V-tetrachlorophthalimide, A / -4-nitrophthalimide, Af-thiodiglycoloyl, A / -d¡t¡asuccinimida, N-2,3diphenylmaleimide, / V-2,3-dimethylmale¡m ¡da, A / -2,5-d¡methylpyrrola, / V-2,5-bis(tr¡¡soprop¡ls¡lox¡)p¡rrola, adduct Λ / -1,1,4,4 -tetramethyldisililazacyclopentane, Λ / -1,1,3,3-tetramethyl-1,3-disilaisoindolin, / V-diphenylsilyldiethylene, A / -5-substituted-1,3-dimethyl-1,3,5-triazacyclohexane- 2-one, A / -5-substituted-1,3-benzyl-1,3,5-triazacyclohexan-2one, 1-substituted 3,5-dinitro-4-pyridone, and 1,3,5-dioxazine. In the case of A / -alkyl, A / -alkenyl, AAalkynyl or / V-arylamines, the protecting group for the amino group can be selected from A / -methyl, M-t-butyl, M-allyl, A / -prenyl, A / -cinnamyl, / V-phenylallyl, M-propargyl, AZ-methoxymethOyl, A / -[2-(trimethyls¡l¡l)ethoxy]methyl, A / -3-acetoxypropyl, A / -cyanomethyl, A / -2-azanorbornenes, M-benzyl, A / -4-methoxybenzyl, N-2,4dimethoxybenzyl, A / -2-hydroxybenzyl, M-ferrocenylmethyl, A / -2,4-dinitrophenyl, o-methoxyphenyl, p-methoxyphenyl , A / -9-phenylfluorenyl, ΛΖ-fluorenyl, A / -2-picolylamine N'-oxide, A / -7-methoxycomar-4-ylmethyl, A / -diphenylmethyl, A / -bis(4-methoxyphenyl)methyl , A / -5-dibenzosuberyl, AZ-triphenylmethyl, A / -(4-methylphenyl)diphenylmethyl, and / V-(4-methoxyphenyl)diphenylmethyl. In the case of imines, the protecting group for the amino group can be selected from A / -1,1-dimethylthiomethylene, A / -benzylidene, A / -p-methoxybenzylidene, M-diphenylmethylene, A / -[2 -p¡r¡dyl)mesit¡l]methylene, Ν-(Ν\ / V-dimethylaminomethylene), / V-í / V. / V-dibenzylaminomethylene), N-(N-tbutylaminomethylene), / V, / V -isopropyldene, / V-p-nitrobenzylidene, / V-salicylidene, Λί-5-chlorosalicylidene, LPQQCn / Lznz / Σΐ / ΥΙΛΙ 108 A / -(5-chloro-2-hydroxyphenyl)phenylmethylene, M-cyclohexylidene, and A / -f-butylidene. In the case of enamines, the protecting group for the amino group can be selected from A / -(5,5-dimethyl-3-oxo-1-cyclohexenyl), A / -2,7-dichloro-9-fluorenylmethylene, A / -1-(4,4-dimethyl-2,6-dioxoc¡clohex¡l¡dene)ethyl, A / -(1,3-dimethyl-2,4,6-( 1 H,3H, 5H)tnoxopyr¡m¡n-5-¡l¡dene)-methyl, A / -4,4,4-trifluoro-3-oxo-1-butenyl, and A / - (1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3yl). In the case of N-metal derivatives, the protecting group for the amino group can be selected from N-borane, A / -diphenylborinic ester, A / -diethylborinic ester, A / -9-borabicyclononane, A / -di ester fluoroborinic, and 3,5-bis(trifluoromethyl)feniboronic acid; and also includes A / -phenyl(pentacarbonylchromo)carbenyl, A / -phenyl(pentacarbonyl-tungsten)carbenyl, A / -methyl(pentacarbonylchromo)carbenyl, A / -methyl(pentacarbonyltungsten)carbenyl, AZ-copper chelate, / V-zinc chelate, and an 18crown-6- derivative. In the case of N-N derivatives, the protecting group for the amino group together with the amino group to which it is attached form an N-N derivative which can be selected from / V-nitroamino, AZ-nitrosoamino, amine oxide, azide, derivative triazene, and N-trimethylsiliImethyl-ZV-benzylhydrazine. In the case of N-P derivatives, the protected group for the amino group with the amino group to which it is attached forms an N-P derivative which can be selected from diphenylphosphinamide, dimethylthiophosphinamide, diphenylthiophosphinamide, dialkylphosphoramidate, dibenzylphosphoramidate, diphenylphosphoramidate, and iminotriphenylphosphorane. In the case of N-S1 derivatives, the protecting group for NH2 can be selected from f-butyldiphenylsilyl and triphenylsilyl. In the case of N-S derivatives, the protected amino group can be selected from N-sulfenyl or N-sulfonyl derivatives. The N-sulfenyl derivatives can be selected from benzenesulfenamide, 2-nitrobenzenesulfenamide, 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, 1-(2,2,2-trifluoro-1,1-diphenyl )ethylsulfenamide, and M-3-nitro2-pyridinesulfenamide. The N-sulfonyl derivatives can be selected from methanesulfonamide, trifluoromethanesulfonamide, í-butylsulfonamide, benzylsulfonamide, 2-(trimethylsylyl)ethanesulfonamide, p-toluenesulfonamide, benzenesulfonamide, o-anisylsulfonamide, 2-nitrobenzenesulfonamide, 4-nitrobenzenesulfonamide , 2,4-dinitrobenzenesulfonamide, 2-naphthalenesulfonamide, 4-(4',8'dimethoxynaphthylmethyljbenzenesulfonamide, 2-(4-methylphenyl)-6-methox¡-4-methylsulfonamide, 9-anthracenesulfonamide, pyridine-2-sulfonamide, benzothiazole-2-sulfonamide, phenacylsulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide, 2,4,6-trimethoxybenzenesulfonamide, 2,6-dimethyl-4-methoxybenzenesulfonamide, pentamethylbenzenesulfonamide, 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide, 4-methoxybenzenesulfonamide, 2,4,6-trimethylbenzenesulfonamide, 2,6-dimethoxy-4-methylbenzenesulfonamide, 3-methoxy-4-f-butylbenzenesulfonamide , and 2,2,5,7,8-pentamethylchroman-6-sulfonamide. Within the scope of the present invention, a protecting group for SH is defined as the fraction bound to S that results from the protection of the SH group through the formation of a suitable protected SH group. Examples of such protected SH groups include thioethers, disulfides, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates. In the case of thioethers, the protecting group for SH can be selected from S-alkyl, S-benzyl, S-p-methoxybenzyl, S-o-hydroxybenzyl, S-p-hydroxybenzyl, S-oacetoxybenzyl, S-p-acetoxybenzyl, S-p-nitrobenzyl, S-o- nitrobenzyl, S-2,4,6-trimethylbenzyl, S-2,4,6trimethoxybenzyl, S-4-picolyl, S-2-picolyl-A / -oxide, S-2-quinolinylmethyl, S-9-anthrylmethyl , S-9-fluorenylmethyl, S-xanthenyl, S-ferrocenylmethyl, S-diphenylmethyl, S-bis(4-methoxyphenyl)methyl, S-5-dibenzosuberyl, LPQQCn / Lznz / Σΐ / ΥΙΛΙ 109 S-triphenylmethyl, 4-methoxytrityl, S-diphenyl-4-pyridylmethyl, S-phenyl, S-2,4-dinitrophenyl, S-2-quinolyl, S-f-butyl, S-1-adamantyl, S-methoxymethyl, S- isobutoxymethyl, S-benzyloxymethyl, S-1-ethoxyethyl, S-2-tetrahydropyranyl, S-benzylthiomethyl, S-phenylthiomethyl, S-acetamidomethyl (Acm), S-trimethylacetamidomethyl, S-benzamidomethyl, S-allyloxycarbonylaminomethyl, S-A / -[2 ,3,5,6-tetrafluoro-4-(A / '-p¡peridino)-phenyl- / \ / -allylox¡carbon¡lam¡nomethyl, S-phthalimidomethyl, S-phenylacetamidomethyl, S-acetylmethyl , S-carboxymethyl, S-cyanomethyl, S-(2-nitro-1phenyl)ethyl, S-2-(2,4-dinitrophenyl)ethyl, S-2-(4'-pyridyl)ethyl, S-2 -cyanoethyl, S-2-(trimethylsil¡l)ethyl, S-2,2bis(carboethoxy)ethyl, S-(1-m-nitrophenyl-2-benzoyl)ethyl, S-2-phenylsulfonylethyl, S-1 -(4-methylphenylsulfonyl)-2methylprop-2-yl, and S-p-hydroxyphenacyl. In the case of disulfides, the protected SH group can be selected from S-ethyl disulfide, S-t-butyl disulfide, S-2-nitrophenyl disulfide, S-2,4-dinitrophenyl disulfide, S-2- phenylazophenyl, S-2-carboxyphenyl disulfide, and S-3-nitro-2-pyridyl disulfide. In the case of silyl thioethers, the protecting group for SH can be selected from the list of groups provided above for OH protection with silyl ethers. In the case of thioesters, the protecting group for SH can be selected from S-acetyl, S-benzoyl, S-2-methoxyisobutyryl, S-trifluoroacetyl, S-A / -[[pbiphenylyl)-isopropyloxy]carbonyl]-A / -methyl-Y-aminothiobutyrate, and S-A / -(t-butoxycarbonyl)-A / -methyl-Y-aminothiobutyrate. In the case of thiocarbonate, the protecting group for SH can be selected from S-2,2,2-trichloroethoxycarbonyl, S-t-butoxycarbonyl, S-benzyloxycarbonyl, S-p-methoxybenzyloxycarbonyl, and S-fluorenylmethylcarbonyl. In the case of thiocarbamate, the protected SH group can be selected from S-(Netylcarbamate) and S-( / V-methoxymethylcarbamate). The mention of these groups should not be construed as a limitation of the scope of the invention since they were mentioned as a mere illustration of protecting groups for the OH, amino and SH groups, and other groups possessing such a function may be known to those skilled in the art. in the art and such groups are to be understood as also encompassed by the present invention. For the purpose of providing a more concise description, some of the quantitative expressions provided herein are not qualified with the term "approximately". It is understood that, whether the term approximately is used explicitly or not, each amount stated herein is to refer to the actual value given, as well as to the approximation to such value given that could reasonably be inferred based on the basis of common knowledge in the art, including equivalents and approximations due to experimental and / or measurement conditions for said given value. “Antibody-drug conjugates (ADC)” represent an approach aimed at delivering a cytotoxic molecule to a cancer cell (see, for example, international patent applications WO-A-2004 / 010957, WO-A-2006 / 060533 and WO-A-2007 / 024536). These compounds are generally referred to as drug, toxin, and radionuclide conjugates. Killing of tumor cells occurs by binding the drug conjugate to a tumor cell and releasing and / or activating the cytotoxic activity of the drug moiety. The selectivity provided by drug conjugates minimizes toxicity to normal cells, thereby improving patient tolerance of the drug. Three examples of such drug-antibody conjugates that have received marketing approval are: Gemtuzumab ozogamicin for acute myelogenous leukemia, LPQQCn / I 7Π7 / 3 / ΥΙΛΙ 110 Brentuximab vedotin for relapsed and refractory Hodgkin lymphoma and anaplastic large cell lymphoma, and ado-Trastuzumab emtansine for breast cancer, especially HER2+. The effectiveness of cancer chemotherapy drugs generally depends on differences in growth rates, biochemical pathways, and physiologic characteristics between cancerous and normal tissues. Consequently, most standard chemotherapies are relatively nonspecific and have dose-limited toxicities that contribute to suboptimal therapeutic effects. One approach to selectively target malignant cells and not healthy tissues is to use specific monoclonal antibodies (mAbs) that recognize tumor-associated antigens expressed on the surface of tumor cells [Meyer, D.L. and Senter, P.D. (2003) Recent advances in antibody drug conjugates for cancer therapy, Annu. Rep. Med. Chem., 38, 229-237; Chari, R.V. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs, Acc. Chem. Res. 41, 98-107, Over 30 agents related to type G immunoglobulins ( IgG) have been approved in the last 25 years, mainly for cancers and inflammatory diseases. An alternative strategy consists of resorting to the chemical conjugation of small antineoplastic molecules to mAbs, used both as vehicles (increased half-life) and as targeting agents (selectivity). Considerable effort has been directed toward the use of monoclonal antibodies (mAbs) for targeted drug delivery due to their high selectivities for tumor-associated antigens, favorable pharmacokinetics, and relatively low intrinsic toxicities. mAb-drug conjugates (ADCs) are formed by covalently linking anticancer drugs to mAbs, generally through a conditionally stable linker system. By binding cell surface antigens, the mAbs used for most ADCs are actively transported to lysosomes or other intracellular compartments, where enzymes, low pH, or reducing agents facilitate drug release. However, there are currently limited ADCs in development. Antigens must have high tumor cell selectivity to limit toxicity and off-target effects. A plethora of tumor-associated antigens was investigated in preclinical models and in clinical trials including antigens overexpressed on B cells (eg, CD20, CD22, CD40, CD79), T cells (CD25, CD30), carcinoma cells (HER2, EGFR, EpCAM, EphB2, PSMA), endothelial (endoglin) or stromal (fibroblast-activated protein) cells, to name a few [Teicher BA. Antibody-drug conjugate targets, Curr Cancer Drug Targets 9(8):982-1004, 2009]. An important property for ADC targets is their ability to be internalized. This may be an intrinsic feature of the antigen itself, or it may be induced by binding of the antibody to its antigen. Indeed, the internalization of the ADC is crucial to reduce the toxicity associated with an extracellular delivery of the drug payload. With respect to conjugated small molecules and in contrast to the vast diversity of LPQQCn / Lznz / Σΐ / ΥΙΛΙ 111 putative antigen targets, a limited number of families of cytotoxic drugs used as payloads in ADCs are currently under active investigation in clinical trials: calicheamicin (Pfizer), duocarmycins (Synthon), pyrrolobenzodiazepines (Spirogen), irinotecan (Immunomedics) , maytansinoids (DM1 and DM4; ImmunoGen + Genentech / Roche, Sanofi-Aventis, Biogen Idee, Centocor / Johnson & Johnson, Millennium / Takeda), and auristatins (MMAE and MMAF; Seattle Genetics+ Genentech / Roche, Medlmmune / AstraZeneca, Bayer- Schering, Celldex, Progenies, Genmab). Calicheamicin, duocarmycins, and pyrrolobenzodiazepines are DNA minor groove linkers, irinotecan is a topoisomerase I inhibitor, while maytansinoids and auristatins are tubulin depolymerizing agents. Interestingly, a representative of three of these cytotoxic-derived ADCs made it to the final stages of clinical trials. Trastuzumab emtansine (T-DM1), trastuzumab linked to a maytansinoid hemisynthetic drug via a stable linker (FDA approval dated February 22, 2013 for advanced HER2-positive breast cancer); Inotuzumab ozogamicin (CMC-544), a humanized anti-CD22 mAb (G5 / 44, IgG4) conjugated to a calicheamicin with an acid (acetylphenoxybutanoic) labile linker (B-cell non-Hodgkin lantern); Brentuximab vedotin, a humanized anti-CD30 mAb linked to a monomethylauristatin E (MMAE), via a maleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate linker (FDA approval dated August 19, 2011 for anaplastic large cell lymphoma and Hodgkin's lymphoma). The binders represent the key component of ADC structures. Several classes of second-generation binders have been investigated, including acid-labile hydrazone (lysosome) binders (eg, gemtuzumab and inotuzumab ozogamicin); disulfide-based binders (reducing intracellular environment); non-cleavable thioether binders (catabolic degradation in lysosomes) (eg, trastuzumab emtansine); peptide binders (eg citrulline-valine) (lysosomal proteases such as cathepsin B) (eg brentuximab vedotin): see eg WO-A-2004 / 010957, WO-A-2006 / 060533 and WO-A-2007 / 024536. Purification of drug-antibody conjugates by size exclusion chromatography (TSC) has also been described [see, for example, Liu et aL, Proc. nati. Acad. Sci. USA, 93: 8618-8623 (1996), and Chari et al., Cancer Research, 52: 127-131 (1992)]. Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2 / neu receptor. Its main use is to treat certain breast cancers. HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from the outside of the cell (molecules called EGF) to the inside of the cell, turning genes on and off. HER proteins stimulate cell proliferation. In some cancers, notably certain types of breast cancer, HER2 is overexpressed, causing cancer cells to reproduce uncontrollably. The HER2 gene is amplified in 20-30% of early-stage breast cancers, causing it to overexpress epidermal growth factor (EGF) receptors on the cell membrane. In some types of cancer, HER2 can signal without growth factors reaching the receptor and binding to the receptor, so its effect on the cell is constitutive; however, trastuzumab is not LPQQCn / Lznz / Σΐ / ΥΙΛΙ 112 cash in this case. The HER2 pathway promotes cell growth and division when it functions normally; however, when overexpressed, cell growth is accelerated beyond its normal limits. In some types of cancer, the pathway is exploited to promote rapid cell growth and proliferation, and thus tumor formation. In cancer cells, the HER2 protein can be expressed up to 100 times more than in normal cells (2 million versus 20,000 per cell). This overexpression leads to strong and constant proliferative signaling and hence tumor formation. HER2 overexpression also causes checkpoint inactivation, thus leading to further increases in proliferation. In the compounds of the present invention, Ab is a moiety comprising at least one antigen binding site. In one embodiment, Ab can be any suitable agent that is capable of binding to a target cell, preferably an animal cell, and more preferably a human cell. Examples of such agents include lymphokines, hormones, growth factors, and nutrient transport molecules (eg, transferrin). In another example, Ab can be an aptamer, and can include a nucleic acid or peptide aptamer. When Ab is a moiety comprising at least one antigen binding site, the moiety is preferably an antigen binding peptide or polypeptide. In a preferred embodiment, the moiety is an antigen-binding antibody or fragment thereof. The term "antibody" in the drug conjugates of the present invention refers to any immunoglobulin, preferably a full length immunoglobulin. Preferably, the term encompasses monoclonal antibodies, polyclonal antibodies, multispecific antibodies, such as bispecific antibodies, and antibody fragments thereof, provided they exhibit the desired biological activity. The antibodies may be derived from any species, but are preferably of rodent, eg, rat or mouse, rabbit, or human origin. Alternatively, the antibodies, preferably monoclonal antibodies, can be humanized, chimeric, or antibody fragments thereof. The term "chimeric antibodies" can also include primatized antibodies that contain variable domain antigen-binding sequences derived from a non-human primate (eg, old world monkey, ape, etc.) and human constant region sequences. Immunoglobulins can also be of any type (eg, IgG, IgE, IgM, IgD, and IgA), class (eg, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule. The term "monoclonal antibody" refers to a substantially homogeneous population of antibody molecules (ie, the individual antibodies comprising the population are identical except for naturally occurring mutations that may be present in minor amounts), produced by a single clone of B lineage cells, often hybridoma. Importantly, each monoclonal has the same antigenic specificity; that is, it is directed against a single determinant on the antigen. The production of monoclonal antibodies can be carried out by methods known in the art. LPQQCn / I 7Π7 / 3 / ΥΙΛΙ 113 technique. However, as an example, monoclonal antibodies can be made by the hybridoma method (Kohler et al (1975) Nature 256:495), the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4: 72), or the EBV hybridoma technique (Colé et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Alternatively, the monoclonal antibody can be produced using recombinant DNA methods (see US 4816567) or isolated from phage antibody libraries using the techniques described in Clackson et al (1991) Nature, 352:624. -628; Marks et al. (1991) J. Mol. BioL, 222:581-597. Polyclonal antibodies are antibodies directed against different determinants (epitopes). This heterogeneous population of antibody can be derived from the sera of immunized animals by various procedures well known in the art. The term bispecific antibody refers to an artificial antibody made up of two different monoclonal antibodies. They can be designed to either bind two adjacent epitopes on a single antigen, thereby increasing both avidity and specificity, or to bind two different antigens for numerous applications, but particularly for NK cell recruitment. for its acronym in English) and T cytotoxic or for the retargeting of toxins, radionuclides or cytotoxic drugs for the treatment of cancer (Holliger and Hudson, Nature Biotechnology, 2005, 23(9), 1126-1136). The bispecific antibody may have a hybrid immunoglobulin heavy chain with a first binding specificity in one group, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other group. This asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, such as the presence of an immunoglobulin light chain in only one half of the bispecific molecule for an easy way of separation (WO 94 / 04690; Suresh et al. al., Methods in Enzymology, 1986, 121:210, Rodrigues et al., 1993, J. of Immunology 151:6954-6961, Carter et al., 1992, Bio / Technology 10:163-167, Carter et al. , 1995, J. of Hematotherapy 4:463-470, Merchant et al., 1998, Nature Biotechnology 16:677-681. Methods for preparing hybrid or bispecific antibodies are known in the art. In one method, bispecific antibodies can be produced by fusing two hybridomas into a single quadroma by chemical crosslinking or genetic fusion of two different Fab or scFv modules (Holliger and Hudson, Nature Biotechnology, 2005, 23(9), 1126-1136). . The term "chimeric antibody" refers to an antibody in which different parts are derived from different animal species. For example, a chimeric antibody can derive the variable region from a mouse and the constant region from a human. By contrast, a humanized antibody is predominantly from a human, although it does contain non-human parts. Specifically, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from hypervariable regions of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate, possessing the desired specificity, affinity, and ability. In some cases, residues in the framework region (RM) of the human immunoglobulin are replaced by corresponding non-human residues. Likewise, the LPQQCn / I 7Π7 / 3 / ΥΙΛΙ 114 humanized antibodies may comprise residues not found in the recipient antibody or donor antibody. These modifications are made to further refine the performance of the antibody. In general, the humanized antibody will comprise substantially all of at least one and usually two variable domains in which all or nearly all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or nearly all of the RMs are those of a human immunoglobulin sequence. The humanized antibody, optionally, will also comprise at least a portion of an immunoglobulin (Fe) constant region, generally that of a human immunoglobulin. Recombinant antibodies, such as chimeric and humanized monoclonal antibodies, can be produced by recombinant DNA techniques known in the art. Fully human antibodies can be produced using transgenic mice that are unable to express endogenous immunoglobulin heavy and light chain genes, but can express human heavy and light chain genes. Transgenic mice are immunized in the normal manner with a selected antigen. Monoclonal antibodies directed against the antigen can be obtained by conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice are rearranged during B cell differentiation and subsequently undergo class switching and somatic mutation. Thus, with the use of such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For a review of this technology for producing human antibodies, see Lonberg and Huszar (1995, Int. Rev. Immunol. 13:65-93). For a detailed explanation of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, for example, US Patent Nos. 5,625,126; 5633425; 5569825; 5661016; 5545806; each of which is incorporated herein in its entirety by reference. Other human antibodies are commercially available, for example, from Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA). The term "antigen-binding fragment" in the drug conjugates of the present invention refers to a portion of a full-length antibody wherein such antigen-binding antibody fragments retain the antigen-binding function of a full-length antibody. corresponding complete. The antigen-binding fragment may comprise a part of a variable region of an antibody, said part comprising at least one, two, preferably three CDRs selected from CDR1, CDR2 and CDR3. The antigen-binding fragment may also comprise a part of an immunoglobulin heavy and light chain. Examples of antibody fragments include Fab, Fab', F(abj2, scFv, di-scFv, sdAb, and BÍTE (bispecific T-cell linkers), Fv fragments including nanobodies, diabodies, diabody-Fc fusions, tnabodies, and , tetrabodies; minibodies; linear antibodies; fragments produced by an expression library of Fabs, anti-idiotypic (antiId) antibodies, CDRs (complementarity determining region), and epitope-binding fragments of any of the above that bind immunospecifically to a target antigen such as cancer cell antigens, viral antigens or microbial antigens, molecules of LPQQCn / I 7Π7 / 3 / ΥΙΛΙ 115 single domain or single chain antibodies including heavy chain antibodies only, eg, camelid VHH and shark V-NAR domains; and multispecific antibodies formed from antibody fragments. For comparative purposes, a full-length antibody, referred to as an antibody, is an antibody comprising VL and VH domains, as well as complete heavy and light chain constant domains. The antibody may also have one or more effector functions, which refers to the biological activities attributable to the Fe region (a native sequence Fe region or amino acid sequence variant Fe region designed according to state of the art methods). to alter receptor binding) of an antibody. Examples of antibody effector functions include Clq binding; complement-dependent cytotoxicity; Fe receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down-regulation of cell surface receptors (eg, B-cell receptors; BCRs), etc. The antibody can also be a functionally active fragment (also referred to herein as an immunologically active part), derivative or analog of an antibody that immunospecifically binds to a target antigen, such as a cancer cell antigen, a viral antigen , or a microbial antigen or other antibodies bound to tumor cells. In this regard, "functionally active" means that the fragment, derivative, or analog is capable of producing anti-idiotype antibodies that recognize the same antigen as the antibody from which the fragment, derivative, or analog is derived recognized the fragment, derivative, or analog. Specifically, in an exemplary embodiment, the idiotype antigenicity of the immunoglobulin molecule can be enhanced by deletion of CDR and framework sequences that are C-terminal to the CDR sequence that specifically recognizes the antigen. For the purpose of determining which CDR sequences bind to antigen, synthetic peptides containing CDR sequences can be used in antigen binding assays by any binding assay method known in the art (for example, the antigen binding assay). BIA core), see, eg, Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md; Kabat E et al., 1980, J. of Immunology 125(3):961-969). The term "antibody" can also include an antibody fusion protein or a functionally active fragment thereof, eg, to which the antibody is fused by means of a covalent bond (eg, a peptide bond), either in the N-terminus or at the C-terminus with an amino acid sequence from another protein (or to a part thereof, such as a part of at least 10, 20 or 50 amino acids of the protein) that is not the antibody. The antibody or its fragment can be covalently linked to the other protein at the N-terminus of the constant domain. Also, the antibody or antigen-binding fragments of the present invention may include analogues and derivatives of antibodies or antigen-binding fragments thereof that are modified, such as by covalent attachment of any type of molecule with the proviso that such covalent attachment allows the antibody to retain its antigen-binding immunospecificity. Examples of modifications include glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by LPQQCn / Lznz / Σΐ / ΥΙΛΙ 116 known blocking / protecting groups, proteolytic cleavage, binding to a cellular antibody unit or to another protein, etc. Any of a number of chemical modifications can be carried out by known techniques including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis, in the presence of tunicamycin, etc. Additionally, the analogue or derivative may contain one or more unnatural amino acids. Antibodies or antigen-binding fragments of the present invention may also have modifications (eg, substitutions, deletions, or additions) in the Fc domain of the antibody. Specifically, the modifications may be in the Fe hinge region and result in increased binding for the FcRn receptor (WO 97 / 34631). In one embodiment, the antibody in the drug conjugate of the present invention can be any antigen-binding antibody or fragment thereof, preferably a monoclonal antibody that is useful in the treatment of a disease, preferably cancer. The cancer can be breast cancer, colorectal cancer, endometrial cancer, kidney cancer, melanoma, leukemias, lung cancer, multiple myeloma, lymphomas (for example, Hodgkin's disease or non-Hodgkin's lymphoma), solid tumors such as sarcomas and carcinomas, melanoma, mesothelioma, osteosarcoma, ovarian cancer, and kidney cancer. In a preferred embodiment, the cancer is lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer. In a more preferred embodiment, the cancer is colorectal cancer, breast cancer, leukemia, lymphoma, and ovarian cancer. Antibodies that may be useful in the treatment of cancer include, but are not limited to, antibodies against the following antigens: CA125 (ovarian), CA15-3 (carcinomas), CA19-9 (carcinomas), L6 (carcinomas), Lewis Y (carcinomas), Lewis X (carcinomas), alpha fetoprotein (carcinomas), CA 242 (colorectal), placental alkaline phosphatase (carcinomas), prostate-specific antigen (prostate), prosthetic acid phosphatase (prostate), epidermal growth factor ( carcinomas), for example, EGF receptor 2 protein (breast cancer), MAGE-I (carcinomas), MAGE-2 (carcinomas), MAGE-3 (carcinomas), MAGE-4 (carcinomas), antitransferrin receptor (carcinomas ), p97 (melanoma), MUCI-KLH (breast cancer), CEA (colorectal), gplOO (melanoma), MARTI (melanoma), PSA (prostate), IL-2 receptor (T-cell leukemia and lymphomas), CD20 (non-Hodgkin lymphoma), CD52 (leukemia), CD33 (leukemia), CD22 (lymphoma), human chorionic gonadotropin (carcinoma), CD38 (multiple myeloma), CD40 (lymphoma), mucin (carcinomas), P21 (carcinomas) , MPG (melanoma), and Neu oncogenic product (carcinomas). Some specific useful antibodies include, but are not limited to, BR96 mAb (Trail, P.A., et al Science (1993) 261,212-215), BR64 (Trail, PA, et al Cancer Research (1997) 57, 100-105, mAbs against CD40 antigen, such as S2C6 mAb (Francisco, J.A., et al Cancer Res. (2000) 60:3225-3231), mAbs against CD70 antigen, such as 1F6 mAb, and mAbs against CD30 antigen, such as AGIO (Bowen, M.A., et al (1993) J. Immunol., 151:5896-5906; Wahl et al., 2002 Cancer Res. 62(13):3736-3742) Many other internalizing antibodies that bind to tumor-associated antigens and have been reviewed can be used (Franke, A.E., et al Cancer Biother Radiopharm. (2000) 15:459-476; Murray, J.L., (2000) Semin Oncol , 27:64-70; Breitling, F., and Dubel, S., LPQQCn / Lznz / Σΐ / ΥΙΛΙ 117 Recombinant Antibodies, John Wiley, and Sons, New York, 1998). The present invention encompasses the treatment of cancers associated with these antibodies. Other tumor associated antigens include, but are not limited to, BMPR1B, E16, STEAP1, STEAP2, 0772P. MPF, Nap¡3b, Sema5b, PSCA hlg, ETBR, MSG783, TrpM4, CRYPTO, CD21, CD79b, FcRH2, HER2, NCA, MDP, IL20Ra, Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD79A, CXCR5 , HLA-DOB, P2X5, CD72, LY64, FCRH1, IRTA2 and TENB2. In an alternative embodiment, the antibody in the drug conjugate of the present invention may be an antigen-binding antibody or fragment thereof, preferably a monoclonal antibody, that immunospecifically binds to a viral antigen, a microbial antigen, or an antigen of a cell that produces autoimmune antibodies associated with an autoimmune disease. Viral antigen can include, but is not limited to, any viral peptide, polypeptide, or protein, such as, for example, HIV gpl20, HIV nef, RSV F-glycoprotein, influenza neuraminidase, influenza hemagglutinin, HTLV tax, glycoprotein herpes simplex virus (eg, Gb, Ge, Gd, and Ge) and hepatitis B surface antigen that is capable of eliciting an immune response. Microbial antigen can include, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (eg, a bacterial, fungal, pathogenic protozoal, or yeast polypeptide including, eg, LPS and capsular polysaccharide) that is capable of producing an immune response. In another embodiment, the antibody or antigen-binding fragment binds to an epitope that is present on a cell, such as a tumor cell. Preferably, when the cell is a tumor cell, the tumor cell epitope is not present on non-tumor cells, or is present at a lower concentration or in a different spherical configuration from that of the tumor cells. In one embodiment, the antibody or its antigen-binding fragment binds to an epitope present in the context of one of the following antigens: CA125, CA15-3, CA19-9 L6, Lewis Y, Lewis X, alpha fetoprotein, CA 242, placenta alkaline phosphatase, prostate-specific antigen, prosthetic acid phosphatase, epidermal growth factor, eg, EGF receptor 2 protein, MAGE-I, MAGE-2, MAGE-3, MAGE-4, receptor anti-transferrin, p97, MUCI-KLH, CEA, gplOO, MARTI, PSA, IL-2 receptor, CD20, CD52, CD33, CD22, human chorionic gonadotropin, CD38, CD40, mucin, P21, MPG, Neu oncogenic product, BMPR1B, E16, STEAP1, STEAP2, 0772P. MPF, Napi3b, Sema5b, PSCA hlg, ETBR, MSG783, TrpM4, CRYPTO, CD21, CD79b, FcRH2, HER2, NCA, MDP, IL20Ra, Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD79A, CXCR5, HLA -DOB, P2X5, CD72, LY64, FCRH1, IRTA2, TENB2, a viral antigen (such as any viral peptide, polypeptide or protein, such as HIV gpl20, HIV nef, RSV F glycoprotein, influenza virus neuraminidase, influenza virus hemagglutinin, HTLV tax, herpes simplex virus glycoprotein (eg, Gb, Ge, Gd, and Ge), and hepatitis B surface antigen) that is capable of eliciting an immune response ), microbial antigen (any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (for example, a bacterial, fungal, pathogenic protozoal, or yeast polypeptide, which LPQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ 118 includes, for example, a capsular polysaccharide (LPS) that is capable of producing an immune response) or an antigen from a cell that produces autoimmune antibodies associated with an autoimmune disease. In one embodiment, when the antigen is ErBB2 (also known as ERBB2, CD340, or HER2; such terms can be used interchangeably), the antibody or its antigen-binding fragment can bind to one or more of the following epitopes: ARHC L (SEQ ID NO: 1), QNGS (SEQ ID NO: 2) and PPFCVARC PSG (SEQ ID NO: 3). These epitopes correspond to positions 557-561,570-573 and 593603, respectively of the human HER2 polypeptide sequence (Access: NM_004448, Version: NM 004448.3). In another embodiment, the antibody can be any antibody known for the treatment or prevention of a viral or microbial infection; that is, an infectious disease. Examples of such antibodies include, but are not limited to, PRO542 (Progenies) which is a CD4 fusion antibody useful for the treatment of HIV infection; OsTAVIR (Protein Design Labs, Inc., CA) which is a human antibody useful for the treatment of hepatitis B virus; PROTOVIR. (Protein Design Labs, Inc., CA) which is a humanized lgG1 antibody useful for the treatment of cytomegalovirus (CMV); and anti-LPS antibodies. Other antibodies useful in the treatment of infectious diseases include, but are not limited to, antibodies against the antigens of pathogenic bacterial strains (Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria gonorrheae, Neisseria meningitidis, Corynebacterium diphtheriae, Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Hemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenas, Klebsiella rhinoscleromotis, Staphilococcus aureus, Vibrio cholerae, Escherichia coli, Pseudomonas aeruginosa, Campylobacter (Vibrio) fetus, Aeromonas hydrophila, Bacillus cereus, Edwardsiella tarda, Yersinia enterocolitica, Y ersinia pestis, Yersinia pseudotuberculosis, Shigella dysenteriae , Shigella flexneri, Shigella sonnei, Salmonella typhimurium, Treponema pallidum, Treponema pertenue, Treponema carateneum, Borrelia vincentii, Borrelia burgdorferi, Leptospira icterohernorrhagiae, Mycobacterium tuberculosis, Pneumocystis carinii, Francisella tularensis, Brucella abortus, Brucella suis, Brucella me litensis, Mycoplasma spp., Rickettsia prowazeki, Rickettsia tsutsugumushi, Chlamydia spp.); pathogenic fungi (Coccidioides immitis, Aspergillus fumigatus, Candida albicans, Blastomyces dermatitidis, Cryptococcus neoformans, Histoplasma capsulatum); protozoa (Entomoeba histolytica, Toxoplasma gondii, Trichomonas tenas, Trichomonas hominis, Trichomonas vaginalis, Tryoanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania brazíliensis, Pneumocystis pneumonia, Plasmodium vivax, Plas modium falciparum, Plasmodium malaria); o Helminths (Enterobius vermicularis, Trichuris trichiura, Ascaris lumbricoides, Trichinella spiralis, Strongiloides stercoralis, Schistosoma japonicum, Schistosoma mansoni, Schistosoma haematobium, and hookworms). Other antibodies useful for the treatment of viral diseases include, but are not limited to, antibodies against antigens of pathogenic viruses, including, by way of example and not limited to: Poxviridae, Herpesviridae, Herpes Simplex Virus 1, Herpes Simplex Virus 2, Adenoviridae, LPQQCn / Lznz / Σΐ / ΥΙΛΙ 119 Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza virus, parainfluenza virus, mumps, measles, respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, virus Hepatitis E, non-A / non-B hepatitis virus, Rhinoviridae, Coronaviridae, Rotoviridae, and human immunodeficiency virus. In an alternative embodiment, the antibody in the drug conjugate of the present invention can also be any antibody known for the treatment of prevention of autoimmune disorders, such as, but not limited to, Th2 cell-related disorders (eg, atopic dermatitis, atopic asthma, rhinoconjunctivitis, allergic rhinitis, Omenn syndrome, systemic sclerosis, and graft-versus-host disease); Th1 cell-related disorders (eg, rheumatoid arthritis, multiple sclerosis, psoriasis, Sjorgren's syndrome, Hashimoto's thyroiditis, Grave's disease, primary biliary cirrhosis, Wegener's granulomatosis, and tuberculosis); disorders related to activated B lymphocytes (eg, systemic lupus erythematosus, Goodpasture syndrome, rheumatoid arthritis, and type I diabetes); and chronic active hepatitis, Addison's disease, allergic alveolitis, allergic reaction, allergic rhinitis, Alport's syndrome, Anaphylaxis, ankylosing spondylitis, antiphospholipid syndrome, Arthritis, Ascariasis, Aspergillosis, atopic allergy, atropic dermatitis, atropic rhinitis, Behcet's disease, Bird-Fancier lung, bronchial asthma, Caplan syndrome, cardiomyopathy, celiac disease, Chagas disease, chronic glomerulonephritis, Cogan syndrome, cold agglutinin disease, congenital rubella infection, CREST syndrome, Crohn's disease, cryoglobulinemia, syndrome Cushing's, dermatomyositis, discoid lupus, Dresser's syndrome, Eaton-Lambert syndrome, Echovirus infection, encephalomyelitis, endocrine ophthalmopathy, Epstein-Barr virus infection, horse strain, erythematosis, Evan's syndrome, Felty's syndrome, fibromyalgia, Fuch's cyclitis, gastric atrophy, gastrointestinal allergy, giant cell arteritis, glomerulonephritis, Goodpasture syndrome, graft-versus-host disease, Graves' disease, Guillain-Barre's disease, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, adrenal atrophy idiopathic, idiopathic pulmonary fibritis, IgA nephropathy, inflammatory bowel diseases, insulin-dependent diabetes mellitus, juvenile arthritis, juvenile diabetes mellitus (Type I), Lambert-Eaton syndrome, laminitis, lichen planus, lupoid hepatitis, lupus lymphopenia, Meniere's disease, mixed connective tissue disease, multiple sclerosis, Myasthenia Gravis, pernicious anemia, polyglandular syndromes, presenile dementia, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, recurrent abortion, Reiter's syndrome, rheumatic fever , rheumatoid arthritis, Sampter's syndrome, schistosomiasis, Schmidt's syndrome, scleroderma, Shulman's syndrome, Sjorgen's syndrome, Stiff-Man's syndrome, sympathetic ophthalmia, systemic lupus erythematosus, Takayasu's arteritis, temporal arteritis, thyroiditis, thrombocytopenia, thyrotoxicosis, toxic epidermal necrolysis, type B insulin resistance, type I Diabetes Mellitus, ulcerative colitis, uveitis, vitiligo, Waldenstrom's macroglobulinemia and Wegener's granulomatosis. Antibodies immunospecific for an antigen on a cell that is responsible for the production of autoimmune antibodies can be obtained by any method known to those skilled in the art, such as chemical synthesis or recombinant expression techniques. The LPQQCn / Lznz / Σΐ / ΥΙΛΙ Examples of autoimmune antibodies include, but are not limited to, antinuclear antibodies; Antids DNA; anti-ss DNA, anticardiolipin antibody IgM, IgG; antiphospholipid antibody IgM, IgG; anti-SM antibody; antimitochondrial antibody; thyroid antibody; microsomal antibody; thyroglobulin antibody; Anti SCL-70; Anti-Jo; anti-U1RNP; Anti-La / SSB; Anti-SSA; anti-SSB; antiperitoneal cell antibody; antihistones; anti-RNP; C-ANCA; PANCA; anticentromere; antifibrillarin, and anti-GBM antibody. In another embodiment, the antibody to the drug conjugate of the present invention can be an antibody that binds to both a receptor and a complex of receptors expressed on an activated lymphocyte, such as one associated with autoimmune disease. The receptor or receptor complex may comprise a member of the immunoglobulin gene superfamily, a member of the TNF receptor superfamily, an integrin, an interleukin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein , a lectin, or a complement control protein. Non-limiting examples of suitable members of the immunoglobulin superfamily are CD2, CD3, CD4, CD5, CD8, CD13, CD19, CD22, CD28, CD79, CD90, CD152 / CTLA-4, PD-I, and ICOS. Non-limiting examples of suitable members of the TNF receptor superfamily are CD27, CD40, CD95 / Fas, CD134 / 0X40, CD137 / 4-1BB, TNF-RI, TNFR-2, RANK, TACI, BOMA, osteoprotegerin, Apo2 / TRAEL-RI, TRAIL-R2, TRAIL-R3, TRABL-R4, and APO-3. Non-limiting examples of suitable integrins are CDI la, CDIIb, CDIIc, CD18, CD29, CD41, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD103, and CD104. Non-limiting examples of suitable lectins are type C, type S and type I lectin. An antibody that binds to a molecular target or antigen of interest, for example, the ErbB2 antigen, is an antibody capable of binding to that antigen with sufficient affinity such that the antibody is useful in targeting a cell that expresses the antigen. When the antibody is an antibody that binds ErbB2, it will generally preferentially bind ErbB2 as opposed to other ErbB receptors, and may be an antibody that does not significantly cross-react with other proteins such as EGFR. , ErbB3 or ErbB4. In such embodiments, the degree of antibody binding to these non-ErbB2 proteins (eg, cell surface binding to an endogenous receptor) will be less than 10% as determined by an ErbB2-activated cell sorting assay. fluorescence (FACS) or radioimmunoprecipitation (RIA). Sometimes the anti-ErbB2 antibody will not significantly cross-react with the rat neu protein, eg, as described by Schecter et al., Nature 312:513-516 (1984) and by Drebin et al. , in Nature 312:545-548 (1984). In another embodiment, the antibody of the drug conjugate or target of the present invention can be selected from an antibody or target mentioned in the following table. These antibodies are immunospecific for a target antigen or can be obtained commercially or produced by any method known in the art, such as recombinant expression techniques. LPQQCn / I 7Π7 / 3 / ΥΙΛΙ 121 Table 1: Therapeutic monoclonal antibodies Name Trade name Target 3F8 Ganglioside GD2 8H9 B7-H3 Abagovomab CA-125 (mimic) Abciximab ReoPro CD41 7E3 Abituzumab CD51 Abrilumab Integrin α4β7 Actoxumab Clostridium difficile Adalimumab Humira TNF-a Adecatumumab EpCAM Atidortoxumab Sta toxin alfa phylococcus aureus Aducanumab Beta-amyloid Afasevikumab IL17Ae IL17F Afutuzumab CD20 Alemtuzumab Campath, Lemtrada CD52 Alirocumab Praluent PCSK9 Altumomab Hybri-ceaker CEA Amatuximab Mesothelin Andecaliximab gelatinase B Anetumab MSLN Anifrolumab interferon α / β receptor Anrukinzumab IL-13 Apolizumab HLA-DR β chain Aprutumab FGFR2 Ascri nvacumab Kinase 1 activin receptor type Aselizumab L-selectin (CD62L) Atezolizumab Tecentriq PD-L1 Atidortoxumab Staphylococcus aureus alpha toxin Atinumab RTN4 Atorolimumab Rhesus factor Avelumab Bavencio PD-L1 Azintuxizumab CD319 Bapineuzumab amyloid beta Basiliximab Simulect CD25 (IL-2 receptor a-chain) Bavitu ximab phosphatidylserine BCD-100 PD-1 Bectumomab LymphoScan CD22 Begelomab DPP4 Belantamab BCMA Belimumab Benlysta BAFF Bemarituzumab FGFR2 Benralizumab Fasenra CD125 Berlimatoxumab Bicomponent leukocidin from Staphylococcus aureus Bersanlimab ICAM-1 Bertilimumab CCL11 (eotaxin-1) Besilesomab Scintimun An CEA-related tigen Bevacizumab Avastin VEGF-A Bezlotoxumab Zinplava Clostridium difficile Blinatomumab Blincyto CD19, CD3 Bimagrumab ACVR2B Bimekizumab IL 17Ae IL17F LPQQCn / Lznz / Σΐ / ΥΙΛΙ 122 Name Trade name Purpose Birtamimab Serum amyloid protein A Bivatuzumab CD44 v6 BIW009 C1s Bleselumab CD40 Blontuvetmab Blontress CD20 Blosozumab SOST Bococizumab Proteinase 1 regulated by neural apoptosis Brazikumab IL23 Brentuximab Adcentris CD30 (TNFRSF8) Briakinumab IL-12, IL-23 Brodalumab Siliz IL-17 Brontictuzumab Notch 1 Burosumab Crysvita FGF 23 Cabiralizumab CSF1R Camidanlumab CD25 Camrelizumab Programmed cell death 1 Canakinumab llaris IL-1 Cantuzumab MUC-1 Capromab Prostascint Prosthetic carcinoma cells Carlumab MCP-1 Carotuximab endoglin Catumaxomab Removab EpCAM, CD3 CC49 TAG-72 cBR 96 Lewis Y antigen Cedelizumab CD4 Cemiplimab PCDC1 Cergutuzumab IL2 Cetrelimab Programmed cell death 1 Cetuximab Erbitux EGFR Cibisatamab CEACAM5 Cixutumumab IGF-1 receptor (CD221) Clazakizumab IL6 Clenoliximab CD4 Clivatuzumab hPAM4-Cide MUC1 Codrituzumab glipan 3 Cofetuzumab PT K7 Coltuximab CD19 Conatumumab TRAIL-R2 Concizumab TFPI Cosfroviximab ZMapp Glycoprotein of the Ebola virus CR6261 Influenza A hemagglutitin Crenezumab 1-40-3-amyloid Crizanlizumab Selectin P Crotedumab GCGR Cusatuzumab CD70 Dacetuzumab CD40 Daclizumab Zenapax CD25 (IL-2 receptor a chain) Dalotuzumab IGF-1 receptor (CD221) Dapirolizumab pe goal CD154 ( CD40L) Daratumumab Darzalex CD38 Dectrekumab IL-13 I CQOCO / 1 7Π7 / 3 / ΥΙΛΙ 123 Name Trade Name Target Demcizumab DLL4 Denintuzumab CD19 Denosumab Prolia RANKL Depatuxizumab EGFR Derlotuximab Story Complex Detumomab B-cell lymphoma Dezamizumab Serum Amyloid P Component Dinutuximab Unituxin Ganglioside GD2 Diridavumab Hemagglutinin Domagrozumab GDF-8 Drozi tumab DR5 Duligotuzumab ERBB3 (HER3) Dupilumab Dupixent IL4 Durvalumab Imfinzi PD -L1 Dusigitumab ILGF2 Ecromeximab Ganglioside GD3 Eculizumab Soliris C5 Edobacomab endotoxin Edrecolomab Panorex EpCAM Efalizumab Raptiva LFA-1 (CD11a) Eldelumab Interferon-gamma-induced protein Elezanumab RGMA Elgemtumab ERBB3 (HER3) Elotuzumab Empliciti SLAMF7 Elsilimomab IL-6 Emactuzumab CSF1R Emapalumab Gamifant Interferon gamma Emibetuzumab HHGFR Emicizumab Hemlibra F9, F10 activated Enapotamab AXL Enavatuzumab Receptor TWEAK Enfortumab nectin 4 Enlimomab pegol ICAM-1 (CD54) Enoblituzumab CD276 Enokizumab IL9 Enoticumab DLL4 Ensituximab 5AC Epitumomab episialin Epratuzumab CD22 Eptinezumab Calcitonin gene-related peptide Erenumab Aimovig CGRP Ertumaxomab Rexomun HER2 / neu, CD3 Etaracizumab Abegrin integrin ανβ3 Etigilimab TIGIT Etrolizumab integrin β? Evinacumab Angiopoietin 3 Evolocumab Repatha PCSK9 Exbivirumab Hepatitis B surface antigen Fanolesomab NeutroSpec CD15 Faralimomab Interferon receptor Faricimab VEGF-A and Ang-2 I ΓΟΟΟΩ / 1 7Π7 / 3 / ΥΙΛΙ 124 Name Trade name Purpose Farletuzumab Folate receptor 1 Fasinumab HNGF FBTA05 Lymphomun CD20 Felvizumab Respiratory syncytial virus Fezakinumab IL-22 Fibatuzumab Ephrin A3 receptor Ficlatuzumab HGF Figitumumab IGF-1 (CD221) receptor Firivumab Influenza virus hemagglutinin A Flanvotumab TYRP1 (glycoprotein 75) Fletikumab IL-20 Fontolizumab HuZAF IFN-y Foralumab CD3 epsilon Foravirumab Rabies virus glycoprotein Fremanezumab Calcitonin gene-related alpha peptide Fresolimumab TGF-β Frunevetmab NGF Fulranumab NGF Futuximab EGFR Galcanezumab calcitonin Galiximab CD80 Ganitumab Recipient 1 (CD221) Gantenerumab amyloid beta Gatipotuzumab MUC1 Gavilimomab CD147 (basigin) Gedivumab Hemagglutinin HA Gemtuzumab Mylotarg CD33 Gevokizumab IL-Ιβ Gilvetmab PCDC1 Gimsilumab CSF2 Girentuximab Rencarex Carbonic anhydrase 9 (CA-IX) Glembatumumab GPNMB Golimumab Simponi TNF- a Gomiliximab CD23 (IgE receptor) Gosuranemab Tau protein Guselkumab T remfya IL23 lanalumab BAFF-R Ibalizumab Trogarzo CD4 Ibritumomab Zevalin CD20 Icrucumab VEGFR-1 Idarucizumab Praxbind dabigatran Ifabotuzumab EPHA3 lladatuzumab CD97B IMAB362 CLDN18.2 Imalumab MIF Imaprelimab MCAM Imciromab Myos cint Cardiac myosin Imgatuzumab EGFR Inclacumab P-selectin Indatuximab SDC1 indusatumab GUCY2C I ÍOOCH / 1 7Π7 / 3 / ΥΙΛΙ 125 Name Trade name Purpose inebilizumab CD19 Infliximab Remicade TNF-a Inolimomab CD25 (IL-2 receptor a chain) Inotuzumab Besponsa CD22 Intetumumab CD51 Ipilimumab Yervoy CD152 lomab-B CD45 Iratumumab CD30 (TNFRSF8) Isatuximab CD38 Iscalimab CD40 Istiratumab IGF1R, CD221 Itolizumab Alzumab CD6 Ixekizumab Taltz IL-17A Keliximab CD4 Labetuzumab CEA-Cide CEA Lacnotuzumab CSF1, MCSF Ladiratuzumab LIV-1 Lanadelumab kallkrein Landogrozumab GDF-8 Laprituximab EGFR Larcaviximab Ebola virus glycoprotein Lebrikizumab IL-13 Lemalesomab N CA-90 (Granulocyte Antigen) Lendalizumab C5 Lenvervimab Hepatitis B surface antigen Lenzilumab CSF2 Lerdelimumab TGF beta 2 Leronlimab CCR5 Lesofavumab Hemagglutinin HA Lexatumumab TRAIL-R2 Libivirumab Hepatitis B surface antigen Lifastuzumab Sodium-phosphate cotransporter Ligelizumab IGHE Lilotomab CD37 Lintuzumab CD33 Li rilumab KIR2D Lodelcizumab PCSK9 Lokivetmab Cytopoint Canis lupus familiaris IL31 Loncastuximab CD19 Losatuxizumab EGFR, ERBB1 HER1 Lorvotuzumab CD56 Lucatumumab CD40 Lulizumab pegol CD28 Lumiliximab CD23 (Receptor) Lumretuzumab ERBB3 (HER3) Lupartumab LYPD3 Lutikizumab Interleukin 1 alpha MABpl Xilonix IL1A Mapatumumab TRAIL-R1 Margetuximab HER2 Marstacimab TFPI LFQQCn / ί7Π7 / 3 / ΥΙΛΙ 126 Name Trade name Target Maslimomab T-cell receptor Mavrilimumab Matuzumab receptor a-chain EGFR Mepolizumab Bosatria IL-5 Metelimumab TGF beta 1 Milatuzumab CD74 Minretumomab TAG-72 Mirikizumab IL23A Mirvetuximab Folate receptor alpha Mitumomab Ganglioside GD3 Modotuximab Extra domain EGFR cell III Mogamulizumab Poteligeo CCR4 Monalizumab NKG2A Morolimumab Factor Rhesis Mosunetuzumab CD3E, MS4A1, CD20 Motavizumab Numax Respiratory syncytial virus Moxetumomab CD22 Muromonab-CD3 Orthoclone OKT3 CD3 Namilumab CSF2 Naratuximab CD37 Narnatumab RON Natalizumab Tysabri integrin 04 Navic ixizumab DLL4 Navivumab Hemagglutinin A of Influenza A virus Naxitamab C-Met Nebacumab endotoxin Necitumumab Portrazza EGFR Nemolizumab IL31RA Nerelimomab TNF-a Nesvacumab angiopoietin 2 Netakimab Interleukin 17A Nimotuzumab Theracim, Theraloc EGFR Nirsevimab RSVFR Nivolumab Opdivo PD-1 Obiltoxaximab Anthim Anthrax from Bacillus anthracis Obinutu zumab Gazyva CD20 Ocaratuzumab CD20 Ocrelizumab Ocrevus CD20 Odulimomab LFA-1 (CD11a) Ofatumumab Arzerra CD20 Olaratumab Lartruvo PDGF-R a Oleclumab 5'-nucleotidase Olendalizumab Complement C5a Olokizumab IL6 Omalizumab Xolair IgE Fe Region WHO721 MASP-2 Onartuzumab human dispersal factor receptor kinase Ontuxizumab TEM1 Onvatilimab VSIR Opicinumab LINGO-1 Oregovomab Ova Rex CA-125 I CQOCO / 1 7Π7 / 3 / ΥΙΛΙ 127 Name Trade name Purpose Orticumab oxLDL Otelixizumab CD3 Otilimab GMCSF Otlertuzumab CD37 Oxelumab OX-40 Ozanezumab NOGO-A Ozoralizumab TNF-a Pagibaximab Acid Palivizumab Synagis, Abbosynagis Respiratory syncytial virus F protein Pamrevlumab CTGF Panitumumab Vectibix EGFR Pankomab Tumor-specific MUC1 glycosylation Panobacumab Pseudomonas aeruginosa Parsatuzumab EGFL7 Pascolizumab IL-4 Pasotuxizumab Folate hydrolase Pateclizumab LTA Patritumab ERBB3(HER3) Pembrolizumab Keytruda PD1 Pemtumomab Theragyn MUC1 Perakizumab IL17A Pertuzumab Omnitarg HER2 / neu Pidilizumab PD-1 Pinatuzumab CD22 Pin tumomab Adenocarcinoma antigen Placulumab Human TNF Plozalizumab CCR2 Pogalizumab Member 4 of the TNFR superfamily Polatuzumab CD79B Ponezumab human beta-amyloid Porgaviximab Zaire Ebola virus glycoprotein Prasinezumab NACP Prezalizumab ICOSL Priliximab CD4 Pritoxaximab E. coli Shiga toxin type 1 Pritumumab vimentin PRO 140 CCR5 Quilizumab IGHE Racotumomab Vaxira Ganglioside NGNA Ra dretumab fibronectin extradomain B Rafivirumab Glycoprotein from rabies virus Ralpancizumab Proteinase 1 regulated by neural apoptosis Ramucirumab Cyramza VEGFR2 Ranevetmab NGF Ravagalimab CD40 Ravulizumab C5 Raxibacumab Protective antigen, anthrax toxin Refanezumab myelin-associated glycoprotein Regavirumab Cytomegalovirus B glycoprotein Relatlimab LAG3 Remtolum ab Interleukin 17 alpha, TNF LFQQCn / ί7Π7 / 3 / ΥΙΛΙ 128 Name Trade name Purpose Reslizumab Cinqair IL-5 Rilotumumab HGF Rinucumab Platelet-derived growth factor receptor beta Risankizumab IL23A Rituximab MabThera, Rituxan CD20 Rivabazumab pegol Pseudomonas aeruginosa type III secretion system Robatumumab IGF-1 (CD221) receptor Rmab RabiS glycoprotein Rabies virus G Roledumab RHD Romilkimab Interleukin 13 Romosozumab Evenity sclerostin Rontalizumab IFN-a Rosmantuzumab Spondin 3 root plate specific Rovalpituzumab DLL3 Rovelizumab LeukArrest CD11, CD18 Rozanolixizumab FCGRT Ruplizumab Antova CD154 (CD40L) SA 237 IL-6R Sacituzumab TROP-2 Samalizumab CD200 Samrotamab LRRC15 Sapelizumab IL6R Sarilumab Kevzara IL6 Satralizumab IL6 receptor Satumomab TAG-72 Secukinumab Cosentyx IL-17A Selicrelumab CD40 Seribantumab ERBB3 (HER3) Setoxaximab Shiga toxin type 2 from E. cabbage! Setrusumab SOST Sevirumab Cytomegalovirus Sibrotuzumab FAP SGN-CD19A CD19 SHP647 Mucosal addressin cell adhesion molecule Sifalimumab IFN-a Siltuximab Sylvant IL-6 Simtuzumab LOXL2 Sintilimab PD-1 Siplizumab CD2 Sirtratumab SLITRK6 Sirukumab IL-6 Sofitu zumab CA-125 Solanezumab beta amyloid Sonepcizumab sphingosine-1 -phosphate Sontuzumab episialin Spartalizumab PDCD1, CD279 Stamulumab myostatin Suptavumab RSVFR Sutimlimab C1S Suvizumab HIV-1 Suvratoxumab Staphylococcus aureus alpha toxin LPQQCn / ί7Π7 / 3 / ΥΙΛΙ 129 Name Trade name Target Tabalumab BAFF Tacatuzumab AFP-Cide Alpha Fetoprotein Talacotuzumab CD123 Talizumab igE Tamtuvetmab Tactress CD52 Tanezumab NGF Taplitumomab CD19 Tarextumab Notch Receptor Tavolimab CD134 Tefibazumab Aurexis Clumping Factor A Telisotuzumab HGFR Tenatumoma b tenascin C Teneliximab CD40 Teplizumab CD3 Tepoditamab Lectin 2 associated with dendritic cells Teprotumumab IGF-1 receptor (CD221) Tesidolumab C5 Tetulomab CD37 Tezepelumab TSLP Tibulizumab BAFF Tildrakizumab llumya IL23 Tigatuzumab TRAIL-R2 Timigutuzumab HER2 Timolumab AOC3 Tiragotumab TIGIT Tislelizumab PCDC1, CD279 Tisotumab Factor III coagulation Tocilizumab Actemra, RoActemra IL-6 receptor Tomuzotuximab EGFR, HER1 Toralizumab CD154 (CD40L) Tosatoxumab Staphylococcus aureus Tositumomab Bexxar CD20 Tovetumab CD140a Tralokinumab IL-13 Trastuzumab Herceptin HER2 / neu TRBS07 Ektomab Ganglioside GD2 Tregalizumab CD4 Tremelimumab CTLA-4 Trevogrumab Factor 8 growth differentiation Tucotuzumab EpCAM Tuvirumab Hepatitis B virus Ublituximab MS4A1 Ulocuplumab CXCR4 (CD184) Urelumab 4-1BB (CD137) Urtoxazumab Escherichia coli Ustekinumab Stelara IL-12, IL-23 Utomilumab 4-1 BB (CD137) Vadastuximab CD33 Vanalimab CD40 Vandortuzumab STEAP1 Vantictumab Receptor protein frizzled LFQQCn / ί7Π7 / 3 / ΥΙΛΙ 130 Name Trade name Purpose Vanucizumab angiopoietin 2 Vapaliximab AOC3 (VAP-1) Varisacumab VEGF-A Varlilumab CD27 Vatelizumab ITGA2 (CD49b) Vedolizumab Entyvío integrin Ο4β? Veltuzumab CD20 Vepalimomab AOC3 (VAP-1) Vesencumab NRP1 Visilizumab Nuvion CD3 Volociximab integrin αδβι Vonlerolizumab CD134 Vopratelimab ICOS Vorsetuzumab CD70 Votumumab HumaSPECT Vunakizumab CTAA16.88 antigen Interleukin 17 alpha Xentuzuma b IGF1, IGF2 XMAB-5574 CD19 Zalutumumab HuMax-EGFr EGFR Zanolimumab HuMax- CD4 CD4 Zatuximab HER1 Zenocutuzumab ERBB3, HER3 Ziralimumab CD147 (basigin) Zolbetuximab CLDN18 Zolimomab CD5 LPQQCn / I 7Π7 / 3 / ΥΙΛΙ In addition to those mentioned above, the antibody of the drug-antibody conjugate of the present invention may be Vitaxin, which is a humanized antibody for the treatment of sarcomas; Smart IDIO which is a humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphomas; Oncolym which is a radiolabeled murine anti-HLA-DrIO antibody for the treatment of non-Hodgkin lymphoma; and Allomune, which is a humanized anti-CD2 mAb for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma. The antibody of the drug conjugate of the present invention can also be any antibody fragment known for the treatment of any disease, preferably cancer. Again, such antibody fragments are immunospecific for a target antigen and are commercially available or produced by any method known in the art, eg, recombinant expression techniques. Examples of such available antibodies include any of the following table. Table 2: Therapeutic monoclonal antibody fragments Fragment type / format Name Trade name Target Fab / chimeric abciximab Reo Pro CD41 (integrin alpha-I Ib) Fab / humanized abrezekimab Interleukin 13 F(abj2 / mouse Afelimomab TNF-a F(ab')2 / humanized Alacizumab pegol VEGFR2 Fab / mouse Anatumomab TAG-72 131 Fragment type / format Name Trade name Target Fab / sheep CroFab Snake Venom Fab / sheep DigiFab Digoxin Fab / sheep Digibind Digoxin Fab' / mouse arcitumomab CEA-scan CEA Fab' / mouse bectumomab LymphoScan CD22 Fab' / mouse biciromab FibriScint fibrin II , BiTE beta chain / mouse Blinatumomab Blincyto CD19 scFv / humanized brolucizumab VEGFA sdAb / humanized caplacizumab Cablivi VWF Fab' / PEGylated humanized certolizumab pegol Cimzia TNF-a Fab / humanized citatuzumab EpCAM F(ab')2 / dorlimomab mouse Unknown scFv / humanized chimeric duvortuxizumab CD19, CD3E scFv / human efungumab Mycograb Hsp90 F(ab')2 / human erlizumab ITGB2 (CD18) Di-scFy flotetuzumab IL-3 receptor scFv / human gancotamab unknown F(ab')2 / mouse igovomab lndimacis-125 CA -125 Fab / humanized lampalizumab CFD scFv / humanized letolizumab TRAP Fab / mouse nacolomab Antigen C242 Fab / mouse naptumomab 5T4 Fab / mouse nofetumomab unknown scFv / humanized oportuzumab Vicinium EpCAM Fab / humanized ranibizumab Lucentis VEGF-A BiTE / mouse Solitomab EpCAM Fab' / mouse sulesomab LeukoScan NCA-90 (Granulocyte Antigen) Fab Tadocizumab integrin aiibps Fab / mouse Telimomab unknown scFv / humanized Vobarilizumab IL6R Fab / humanized Thromboview D-dimer Fab / PEGylated humanized CDP791 VEGF Fab / bispecific humanized MDX-H210 Her2 / Neu & CD64 (yFcR1) scFv / humanized Pexelizumab Complement C5 (ScFv)4 fused to mouse streptavidin CC49 Pancarcinoma antigen TAG-72 ScFv fused to human β-lactamase SGN-17 P97 antigen ScFv fused to human PEG F5 scFv-PEG Immunoliposome Her2 Diabody (Vh-Vl)2 human C6.5K-A Her2 / Neu Diabody (Vh-Vl)2 human L19 L19-YIFN fibronectin EDB domain I CQOCO / 1 7Π7 / 3 / ΥΙΛΙ 132 Fragment Type / Format Name Trade Name Target Diabody (Vl-Vh)2 Human T84.66 CEA Minibody (scFv-Ch3)2 Murine-Human Chimera (Minibody) T84.66 CEA Minibody Murine-Human Chimera (Minibody) 10H8 Her2 Dimer from ScFv Fe (ScFv)2-FC murine-human chimera (minibody) T84.66 bispecific CEA scFv (Vl-Vh-Vh-Vl) mouse r28M CD28 and MAP bispecific scFv (Vl-Vh-Vh-Vl) unknown origin BITE MT103 CD19yCD3 bispecific scFv (Vl-Vh-Vh-Vl) unknown origin BÍTE Ep-CAM and CD3 Bispecific tandem diabody (VH-VL-VH -VL) (mouse) Tandab CD19yCD3 Fusion hHV-p-lactamase camelid Nanobody CEA Dab / human dAb Anti-TNFa TNFa hhV / camelid Nanobody TNFa hhV / camelid Nanobody Von Willebrand Factor Fab fragment, antigen binding (one group) F(ab')2 fragment, antigen binding, includes hinge region (both groups) Fab' fragment, antigen binding, includes hinge region (one group) scFv single chain variable fragment di-scFv single chain variable fragment, dimeric. (Holliger & Hudson, Nature Biotechnology, 2005, 23(9), 1126-1136). In a preferred embodiment, the antibody in the drug conjugates of the present invention is directed to a cell surface antigen. In other preferred embodiments, the antibody in the drug conjugates of the present invention can bind to a receptor encoded by the ErbB gene. The antibody can specifically bind to an ErbB receptor selected from EGFR, HER2, HER3, and HER4. Preferably, the antibody in the drug conjugate can specifically bind to the extracellular domain of the HER2 receptor and inhibit the growth of tumor cells that overexpress the HER2 receptor. The drug conjugate antibody can be a monoclonal antibody, eg, a murine monoclonal antibody, a chimeric antibody, or a humanized antibody. Preferably, the antibody LPQQCn / Lznz / Σΐ / ΥΙΛΙ 133 humanized can be huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 or huMAb4D5-8 (Trastuzumab), particularly preferably Trastuzumab. The antibody can also be an antibody fragment, eg a Fab fragment. Other preferred antibodies include: (i) anti-CD4 antibodies. The drug conjugate antibody can be a monoclonal antibody, eg, a murine monoclonal antibody, a chimeric antibody, a humanized antibody; (ii) anti-CD5 antibodies. The drug conjugate antibody can be a monoclonal antibody, eg, a murine monoclonal antibody, a chimeric antibody, a humanized antibody; (iii) anti-CD13 antibodies. The drug conjugate antibody can be a monoclonal antibody, eg, a murine monoclonal antibody, a chimeric antibody, a humanized antibody; (iv) anti-CD20 antibodies. The drug conjugate antibody can be a monoclonal antibody, eg, a murine monoclonal antibody, a chimeric antibody, a humanized antibody. Preferably, the humanized antibody is Rituximab or an antibody fragment thereof, eg, a Fab fragment; and (v) anti-CD30 antibodies. The drug conjugate antibody can be a monoclonal antibody, eg, a murine monoclonal antibody, a chimeric antibody, a humanized antibody. Preferably, the humanized antibody is Brentuximab vedotin or an antibody fragment thereof. In one embodiment of the invention, the antibody-drug conjugate may demonstrate one or more of the following: (i) increased cytotoxicity (or a decrease in cell survival), (ii) increased cytostatic activity (cytostasis), (¡ ii) increased binding affinity for the target antigen or epitope, (iv) increased internalization of the conjugate, (v) reduced side effects in the patient, and / or (vi) improved toxicity profile. This increase may be related to a drug-antibody conjugate known in the art that binds to the same epitope or antigen or to a different epitope or antigen. Processes for the preparation of drug-antibody conjugates The drug-antibody conjugates of the present invention can be prepared according to techniques well known in the art. Processes for conjugating fractions comprising at least one antigen-binding site antibody or as, for example, antibodies, to a number of different drugs using different processes were previously described and exemplified, for example, in WO-A -2004 / 010957, WO-A-2006 / 060533 and WO-A-2007 / 024536, the contents of which are incorporated herein by reference. These comprise the use of a linking group that derives the drug, toxin or radionuclide in such a way that it can bind to the moiety, such as an antibody. Binding to a moiety, such as an antibody, is generally by one of three routes: via free thiol groups on cysteines after reduction LÓQQCn / ίΖΠΖ / ΣΙ / ΥΙΛΙ 134 partial disulfide groups on the antibody; by free amino groups in Physines in the antibody; and by free hydroxyl groups on serines and / or threonines on the antibody. The binding method varies depending on the binding site in the fraction, eg, an antibody. Purification of drug-antibody conjugates by size exclusion chromatography (TSC) has also been described [see, eg, Llu et al., Proc. nati. Acad. Set (USA), 93: 8618-8623 (1996), and Chañ et al., Cancer Research, 52: 127-131 (1992)]. In accordance with what was previously observed, the payloads of the drugs of the drug conjugates of the present invention are derivatives of ecteinascidin disclosed or that fall within the scope of the international patent application for invention number PCT / EP2018 / 060868, the content of which is incorporated herein by reference. These compounds are synthesized according to the processes described in the present application. As noted above, there is provided a process for the preparation of a drug conjugate according to the present invention comprising conjugating an Ab moiety comprising at least one antigen binding site and a drug D of formula (IH), (IHa) or (IHb), Ab and D which are as defined herein. An example of a process for the preparation of a drug conjugate of the present invention comprises the preparation of the antibody-drug conjugates of formula (G) or (G j of the present invention in the following manner: LPQQCn / I 7Π7 / 3 / ΥΙΛΙ (Gj said process comprises the following steps: (i) reacting a drug (D-H) of formula (IH)-H: 135 LPQQCn / Lznz / Σΐ / ΥΙΛΙ where the substituents in the definitions of (IH)-H are as defined above for the (DJ to provide a compound of formula (F) or (Fj, respectively: 136 (ii) partial reduction of one or more disulfide bonds in the antibody to be conjugated to provide a reduced Ab-SH antibody possessing free thiol groups: reduction of disulfide bonds LPQQCn / I 7Π7 / 3 / ΥΙΛΙ Ab-SH (II) reaction of the partially reduced Ab-SH antibody possessing free thiol groups with the compound of formula (F) or (Fj produced in step (i) to provide the desired drug-antibody conjugate of formula (G) or (Gj, respectively: (Gj In another preferred embodiment of this process, the antibody is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, and an anti-CD 30 antibody, or a fragment thereof. antigen-binding itself or an immunologically active part thereof, or is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, and most preferably is Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof. Likewise, the partial reduction of this monoclonal antibody is carried out with the use of trls[2-carbox¡ethyl]phosphino hydrochloride (TCEP). Another example of a process for the preparation of a drug conjugate of the present invention comprises the preparation of drug-antibody conjugates of formula (W) or (Wj of the present invention in the following manner: 137 LPQQCn / Lznz / Σΐ / ΥΙΛΙ said process comprises the following steps: (i) reacting the antibody with 2-iminothiolane hydrochloride (Traut's reagent) to provide a thiol-activated antibody: (ii) Reacting the thiol-activated antibody with the compound of formula (F) or (Fj, to provide the desired drug-antibody conjugate of formula (W) or (Wj, respectively. (Wj. In another preferred embodiment of this process, the antibody is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, and an anti-CD30 antibody, or a fragment thereof. antigen-binding or an immunologically active part thereof, or is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, and most preferably is Trastuzumab or an antigen-binding fragment antigen-binding part thereof or an immunologically active portion thereof. Another example of a process for the preparation of a drug-antibody conjugate of the present invention comprises the preparation of drug-antibody conjugates of formula (O) or (P) as follows: 138 S(CH2)1-3CONH(CH2)1.6OCO-D(O) LPQQCn / Lznz / Σΐ / ΥΙΛΙ S(CH2)i-3-OCO-D (P) said process comprises the following steps: (i) either: (a) reacting a drug (D-H) of formula (IH)-H: R3 where the substituents in the definitions of (IH)-H are as defined above, with a compound of formula X2-C(O)-Xi where Xi and X2 are leaving groups to provide a compound of formula (B): D^X·, (B) and the point of union of the moiety -(C=O)Xi is the free -NH2 group of the compound of formula D-H, (b) reacting said drug (D-H) of formula (IH) -H as defined above with 4-nitro-phenylchloroformate to provide a compound of formula (J): NO2 D. and the point of attachment of the (4-nitrophenyl)-O-CO- group is the same as that of the Xi(CO) moiety in 139(a) above; (i) either: (c) reacting the compound of formula (B) produced in step (i) with a hydroxy compound of formula HO-(CH2)i-6NHProtNH and removing the ProtNH group from the coupled compound to provide a compound of formula (C): EITHER D^O—(CH2)i-6-nh2 LPQQCn / I 7Π7 / 3 / ΥΙΛΙ (C) and subsequently reacting the resulting compound of formula (C) with a compound of formula Me-S-S-(CH2)i-3-CO2H to give a compound of formula (K ): O O ιι Λ / s\SMe(K) (d) reacting the compound (J) produced in step (i) with a compound of formula HO-(CH2)i-3SProtSH and removing the ProtSH group from the coupled compound to provide a compound of formula (L): DO(CH2)i-3-S-S-(CH2)i-3-O^D (L) (iii) React (K) or (L) produced in step (ii) with dithiothreitol under reducing disulfide conditions to provide compounds of formulas (M) and (N), respectively: 0 or A A nAdO(CH2)i-6NHXCH2)i-3-SH O(CH2)i-3-SH (Μ) (N) (iv) React the antibody to be conjugated with succin¡n¡mid¡l- 4-(A / maleimidomethyl)c¡clohexane-1-carboxylate to derivate said antibody in one or more lysine groups with a succinimidyl-4-(A / -maleimidomethyl)cyclohexane-1 group -carbonite: (v) reacting the antibody derivative produced in step (iv) with (Μ) or (N) produced in step (iii) to provide the desired antibody-drug conjugate of formula (O) or (P): 140 S(CH2)i-3CONH(CH2)1.6OCO-D(O) LPQQCn / I 7Π7 / 3 / ΥΙΛΙ (P) The compound of formula X2-C(O)-Xi is preferably 1,Τ-carbonyldiimidazole. Similarly, the hydroxy compound reacted with the compound of formula (B) is preferably HO-(CH2)24-NHProtNH, and more preferably HO-(CH2)3-NHProtNH. In a preferred embodiment of the present invention, the compound reacted with the compound of formula (C) to provide the compound of formula (K) is 3-(methyldisulfanyl)propanoic acid. In another preferred embodiment, the compound HO-(CH2)i-3SProtSH which is reacted with a compound of formula (J) to provide a compound of formula (L) is HO-(CH2)3SProtSH. When binding to the drug-binding moiety occurs via free thiol groups on cysteines after partial reduction of disulfide groups in the moiety comprising at least one antigen-binding site, such as a monoclonal antibody, partial reduction is generally first conducted by dissolving to a suitable concentration and buffering the solution before partial reduction of the disulfide bonds by addition of a suitable reducing agent such as tris[2- carboxyethyl]phosphino (TCEP) or dithiothreitol (DTT). By choosing suitable ratios of the fraction to be reduced, such as monoclonal antibody and reducing agent, reaction conditions and reduction time, it is possible to obtain a desired free thiol-fraction ratio, e.g. example, four free thiol groups per monoclonal antibody. The partially reduced fraction, such as the partially reduced monoclonal antibody possessing the free thiol groups, prepared as described above, is then reacted with drug-binding compounds of the invention of formula D-(X)b- (AA)w-(T)gLi (where the Li group in said compound is a maleimide group that is free to react with thiol groups). The resulting drug-antibody conjugates are purified by any suitable means known in the art, eg, by size exclusion chromatography (STC) [see, eg, Liu et al., Proc. nati. Acad. Sel. USA, 93: 8618-8623 (1996), and Chari et al., Cancer Research, 52: 127-131 (1992)]. In a preferred embodiment of the present invention, the monoclonal antibody partially 141 reduced is Trastuzumab or an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof, preferably Trastuzumab or an antigen-binding fragment thereof or an immunologically active part thereof; or preferably, an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof. In an alternative embodiment of the invention, the lysines in the fraction comprising at least one antigen-binding site, such as a monoclonal antibody, may first be reacted with succinimidyl-4-(A / -maleimidomethyl)cyclohexane- 1-carboxylat. A free amino group on an antibody can react with the N-hydroxysuccinimide ester to provide a maleimide-activated antibody: LPQQCn / Lznz / Σΐ / ΥΙΛΙ maleimide activated antibody SVK ( The maleimide-activated antibody can then be reacted with a compound of formula D-(X)b-(AA)w-(T)g-H possessing a reactive thiol moiety. In an alternative embodiment of the invention, the lysines in the fraction comprising at least one antigen-binding site, such as a monoclonal antibody, may first be reacted with 2-iminothiolane hydrochloride (Traut's reagent). A free amino group on an antibody can react with the imidic thiolactone to provide a thiol-activated antibody. N' / OI' thiol-activated antibody A specific example of processes for the preparation of drug-antibody conjugates of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab of the present invention by means of conjugation of free thiol groups on cysteines after a partial reduction of disulfide groups in the antibody is shown in Figure 1. Another specific example of the processes for the preparation of the drug-antibody conjugates of the formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab of the present invention by conjugation with groups free amino acids in lysines after antibody reaction with Traut's reagent is shown in 142 Figure 2. Compositions comprising the drug-antibody conjugate of the invention and their uses Also provided is a pharmaceutical composition containing a drug conjugate according to the present invention and a pharmaceutically acceptable carrier. Examples of administration forms of a drug conjugate having the general formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab of the present invention include, in without limitation, the oral, topical, parenteral, sublingual, rectal, vaginal, ocular, and intranasal routes. Parenteral administration includes subcutaneous, intravenous, intramuscular injections, intrasternal injection or infusion techniques. Preferably, the compositions are administered parenterally. Pharmaceutical compositions of the invention may be formulated such that a drug conjugate of the present invention may be bioavailable upon administration of the composition to an animal, preferably a human. The compositions may take the form of one or more dosage units, where, for example, a tablet may be a single dosage unit, and a container of a drug-antibody conjugate of the present invention in aerosolized form may contain a plurality of dose units. The pharmaceutically acceptable carrier or vehicle may be in particulate form, such that the compositions are, for example, in tablet or powder form. Vehicles can be liquid, with the compositions, for example, in the form of an oral syrup or injectable liquid. In addition, the vehicles can be gaseous, so as to provide an aerosol composition useful, for example, in administration by inhalation. The term "vehicle" refers to a diluent, adjuvant, or excipient, with which a drug-antibody conjugate of the present invention is administered. These pharmaceutical carriers can be liquid, eg, water, and oils, including those of animal, vegetable, synthetic, or petroleum origin, eg, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Vehicles can be saline, acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. In one embodiment, when administered to an animal, the drug-antibody conjugates of the present invention or pharmaceutically acceptable compositions and vehicles are sterile. Water is a preferred vehicle when the antibody-drug conjugates of the present invention are administered intravenously. Saline solutions and aqueous solutions of dextrose and glycerol can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, skim milk. dried, glycerol, propylene, glycol, water, ethanol and the like. The compositions herein, if desired, may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. When intended for oral administration, the composition is preferably in solid or liquid form, when gel, suspension, semi-solid, or semi-liquid forms are included within the forms considered herein as solid or liquid. 143 As a solid composition for oral administration, the composition may be formulated in the form of a powder, a granule, a tablet, a pill, a capsule, a chewing gum, a wafer or the like. Such a solid composition generally contains one or more inert diluents. In addition, one or more of the following may be present: binders such as carboxymethyl cellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch, and the like; lubricants such as magnesium stearate; slip agents such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate, or orange flavoring; and a coloring agent. When the composition is in the form of a capsule (eg a gelatin capsule), it may contain, in addition to materials of the type mentioned above, a liquid carrier such as polyethylene glycol, cyclodextrin or a fatty oil. The composition may be in the form of a liquid, for example an elixir, syrup, solution, emulsion or suspension. The liquid may be useful for oral administration or for administration by injection. When intended for oral administration, a composition may comprise one or more of a sweetening agent, preservatives, dye / color, and a flavor enhancer. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer, and an isotonic agent may also be included. The preferred route of administration is parenteral administration including, but not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, intranasal, intracerebral, intraventricular, intrathecal, intravaginal, or transdermal administration. The preferred mode of administration is left to the discretion of the practitioner and will depend, in part, on the site of the medical condition (such as the site of the cancer). In a more preferred embodiment, these antibody-drug conjugates of the present invention are administered intravenously. Liquid compositions of the invention, whether in the form of solutions, suspensions, or the like, may also include one or more of the following: sterile diluents, such as water for injection, saline, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic monoglycerides or diglycerides, polyethylene glycols, glycerin, or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; and tonicity adjusting agents such as sodium chloride or dextrose. A parenteral composition may be contained in an ampoule, a disposable syringe, or a multidose flask made of glass, plastic, or other material. Physiological saline is a preferred adjuvant. The amount of the drug conjugate of the present invention that is effective in treating a particular disorder or condition will depend on the nature of the disorder or condition and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can be used to help identify optimal dose ranges. The precise dose to be used in the LPQQCn / Lznz / Σΐ / ΥΙΛΙ 144 compositions will also depend on the route of administration, and the severity of the disease or disorder and should be decided according to the criteria of the professional or the circumstances of each patient. The compositions comprise an effective amount of a drug conjugate of the present invention so as to obtain a suitable dose. The correct dose of the compounds will vary depending on the particular formulation, the mode of application, and their particular site, host, and disease being treated, eg, cancer, and if so, the type of tumor. Other factors such as age, body weight, sex, diet, timing of administration, excretion rate, host status, drug combinations, reaction sensitivities, and severity of disease will be taken into account. Administration can be carried out continuously or periodically within the maximum tolerated dose. The drug conjugate of the present invention or compositions may be administered by any convenient route, eg, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings. In specific embodiments, it may be desirable to administer one or more drug conjugates of the present invention or compositions locally to the area in need of treatment. In one embodiment, administration may be by direct injection into the site (or previous site) of a cancer, tumor, or neoplastic or preneoplastic tissue. In another embodiment, administration can be effected by direct injection at the site (or previous site) of a manifestation of an autoimmune disease. Pulmonary administration may also be employed, for example, with the use of an inhaler or nebulizer and formulation with an atomizing agent, or by infusion into a synthetic or fluorocarbon pulmonary surfactant. In certain embodiments, the drug-antibody conjugate of the present invention or compositions can be formulated as a suppository, with traditional binders and carriers such as triglycerides. The compositions herein may take the form of solutions, suspensions, emulsions, tablets, pills, capsules, liquid-containing capsules, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other suitable form of use. . Other examples of suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences by E.W. Martin. The pharmaceutical compositions can be prepared by a methodology well known in the state of the pharmaceutical art. For example, a composition to be administered by injection can be prepared by combining a drug conjugate of the present invention with water so as to form a solution. A surfactant may be added to facilitate the formation of a homogeneous solution or suspension. We have found that the drug conjugates and compositions of the present invention are particularly effective in the treatment of cancer. Thus, in accordance with what has been described above, the present invention provides a method of treating a patient in need thereof, notably a human, afflicted with cancer comprising administering to the afflicted person a therapeutically effective amount of a drug conjugate or LPQQCn / Lznz / Σΐ / ΥΙΛΙ 145 a composition of the present invention. The present invention provides a drug conjugate according to the present invention for use in the treatment of cancer, and, more preferably, a cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia , multiple myeloma, lymphoma, gastric and ovarian cancer. The most preferred cancer is breast cancer. The drug conjugates and compositions of the present invention are useful for inhibiting the growth of a tumor cell or cancer cell, or for treating cancer in an animal. The drug conjugates and compositions of the present invention can be used accordingly in various situations for the treatment of animal cancers. Conjugates of the invention containing a drug binding moiety comprising at least one antigen binding site can be used to deliver a drug or drug unit to a tumor cell or cancer cell. Without being limited by theory, in one embodiment, the fraction containing at least one antigen-binding site of a drug conjugate of the present invention binds to or associates with a cancer cell or tumor cell-associated antigen and the conjugate The drug of the present invention can be taken into a tumor cell or cancer cell through receptor-mediated endocytosis. The antigen may be bound to a tumor cell or cancer cell or may be an extracellular matrix protein associated with the tumor cell or cancer cell. Once inside the cell, one or more specific sequences within the binding unit are hydrolytically cleaved by one or more tumor cell- or cancer cell-associated proteases or hydrolases, resulting in the release of a drug or binding compound. drug. The released drug or drug-binding compound is then free to migrate into the cell and induce cytotoxic activities. In an alternative embodiment, the drug or drug unit is cleaved from the drug conjugate of the present invention outside the tumor cell or cancer cell, and the drug or drug-binding compound subsequently enters the cell. In one embodiment, the moiety comprising at least one antigen binding site binds to the tumor cell or cancer cell. In another embodiment, the moiety comprising at least one antigen-binding site binds to a tumor cell or cancer cell antigen found on the surface of the tumor cell or cancer cell. In yet another embodiment, the moiety comprising at least one antigen-binding site binds to a tumor cell or cancer cell antigen that is an extracellular matrix protein associated with the tumor cell or cancer cell. The specificity of the fraction comprising at least one antigen-binding site for a particular tumor cell or cancer cell may be important in determining which tumors or cancers are most effectively treated. For example, the drug conjugates of the present invention possessing a Trastuzumab unit may be useful for treating antigen-positive carcinomas including leukemias, lung cancer, colon cancer, lymphomas (eg, Hodgkin's disease, non-Hodgkin's lymphoma) , solid tumors such as sarcomas and carcinomas, multiple myeloma, kidney cancer, and melanoma. The cancer can preferably be lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma LPQQCn / Lznz / Σΐ / ΥΙΛΙ 146 or ovarian cancer. For example, the drug conjugates of the present invention possessing a Rituximab unit may be useful for treating CD-20-expressing tumors, such as hematologic cancers including leukemias and lymphomas. For example, the drug conjugates of the present invention possessing an anti-CD4 antibody unit may be useful for treating CD-4-expressing tumors, such as hematologic cancers including lymphomas. For example, the drug conjugates of the present invention possessing an anti-CD5 antibody unit may be useful for treating CD-5-expressing tumors, such as hematologic cancers including leukemias and lymphomas. For example, the drug conjugates of the present invention possessing an anti-CD13 antibody unit may be useful for treating CD-13-expressing tumors, such as hematologic cancers including leukemias and lymphomas. Other particular...

Claims

1. A drug conjugate comprising a drug moiety covalently linked to the drug conjugate moiety, wherein the drug conjugate has the formula [D-(X)b-(AA)w-(T)g-(L)-]nAb, wherein: D is a drug moiety having the following formula (I) or one of its pharmaceutically acceptable salts, esters, solvates, tautomers, or stereoisomers, LPQQCn / Lznz / SA / YILI, H° H. wherein: D is covalently linked by means of a hydroxyl or amine group to (X)b, if any, or to (AA)W, if any, or to (T)g, if any, or to (L); Y is -NH- or -O-; R1 is -OH or -CN; R2 is a -C(=O)Ra group; R3 is hydrogen or an -ORb group; R4 is selected from -CH2OH and -CH2NH2; Ra is selected from hydrogen, substituted or unsubstituted Ci-Ci2 alkyl, substituted or unsubstituted C2-Ci2 alkenyl, and substituted or unsubstituted C2-Ci2 alkynyl;Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; X and T are extension groups that may be the same or different; each AA is independently an amino acid unit; L is a linking group; w is an integer from 0 to 12; b is an integer from 0 or 1; g is an integer from 0 or 1; Ab is a moiety comprising at least one antigen-binding site; yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the moiety comprising at least one antigen-binding site and is in the range of 1 to 20; wherein the drug moiety D is conjugated via position R4. 247; 2. The drug conjugate according to claim 1, wherein D is selected from formula l1 or l1b, or from one of its pharmaceutically acceptable salts or esters: LPQQCn / LZnZ / q / YIAI where: R1 is -NH-OO-; R2 is -OH or -CN; R2 is a -C(=O) Ra group; R3 is hydrogen or an -ORt group; R4 is selected from -CH2OH and -CH2NH2; Ra is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; and Rb is selected from substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl.

3. The drug conjugate according to any of claims 1 to 2, wherein R4 is -CH2O-.

4. The drug conjugate according to claim 1 or claim 2, wherein R4 is -CH2NH.

5. The drug conjugate according to claim 1, wherein D is a compound of formula: 248 LPQQCn / Lznz / SA / YILI or one of its pharmaceutically acceptable salts or esters; wherein the wavy line indicates the point of covalent bonding to (X)b, if any, or to (AA)W, if any, or to (T)g, if any, or (L); preferably of formula: 249 LPQQCn / L7n7 / 3 / YIAI 250 LPQQCn / LZnZ / q / YIAI or one of its pharmaceutically acceptable salts or esters; preferably of formula: 251 or one of its pharmaceutically acceptable salts or esters.

6. The drug conjugate according to claim 1, wherein D is a compound of formula: 252 LPQQCn / LZnZ / q / YIAI AcO Me. Λ or one of its pharmaceutically acceptable salts or esters; wherein the wavy line indicates the point of covalent bonding to (X)b, if any, or to (AA)W, if any, or to (T)g, if any, or (L).

7. The drug conjugate according to claim 1, wherein D is a compound of formula: or one of its pharmaceutically acceptable salts or esters; wherein the wavy line indicates the point of covalent bonding to (X)b, if any, or to (AA)W, if any, or to (T)g, if any, or (L).

8. The drug conjugate according to claim 1, wherein D is a compound of formula: OMe or one of its pharmaceutically acceptable salts or esters; wherein the wavy line indicates the point of covalent bonding to (X)b, if any, or to (AA)W, if any, or to (T)g, if any, or (L).

9. The drug conjugate according to claim 1, wherein D is a compound of formula: or one of its pharmaceutically acceptable salts or esters; wherein the wavy line indicates the point of covalent bonding to (X)b, if any, or to (AA)W, if any, or to (T)g, if any, or (L).

10. The drug conjugate according to claim 1, wherein D is a compound of formula: OMe HO,.. ...X ,Me or one of its pharmaceutically acceptable salts or esters; wherein the wavy line indicates the point of covalent bonding to (X)b, if any, or to (AA)W, if any, or to (T)g, if any, or (L).

11. A drug conjugate comprising a drug moiety covalently bonded to the drug conjugate moiety, wherein the drug conjugate has the formula [D-(X)b-(AA)w-(T)g-(L)-]nAb wherein: D is a drug moiety having the following formula (IH) or one of its pharmaceutically acceptable salts, esters, solvates, tautomers, or stereoisomers: 254 r3 (IH) LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: the wavy line indicates the point of covalent bonding to (X)b if any, to (AA)W if any, to (T)g if any, or to (L); each Y and Z is independently selected from -NH- and -O-; Ri is -OH or -CN; R2 is a -C(=O)Ra group; R3 is hydrogen or an -ORb group; Ra is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl, wherein the optional substituents are one or more Rx substituents; and Rb is selected from substituted or unsubstituted C1-C12 alkyl,substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl, wherein the optional substituents are one or more Rx substituents; The Rx substituents are selected from the group consisting of C1-C12 alkyl groups that may be optionally substituted with at least one Ry group, C2-C12 alkenyl groups that may be optionally substituted with at least one Ry group, C2-C12 alkynyl groups that may be optionally substituted with at least one Ry group, halogen atoms, oxo groups, thio groups, cyano groups, nitro groups, ORy, OCORy, OCOORy, CORy, COORy, OCONRyRz, CONRyRz, S(O)Ry, SO2Ry, P(O)(Ry)ORz, NRyRz, NRyCORz, NRyC(=O)NRyRz, NRyC(=NRy)NRyRz, aryl groups having 6 to 18 carbon atoms in one or more rings that may be optionally substituted with one or more substituents that may be the same or different ones selected from the group consisting of Ry, ORy, OCORy, OCOORy, NRyRz, NRyCORz, and NRyC(=NRy)NRyRz,aralkyl groups comprising an alkyl group having 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, aralkyloxy groups comprising an alkoxy group having 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, and a 5- to 14-membered heterocyclic group, saturated or unsaturated, having one or more rings and at least one oxygen, nitrogen, or sulfur atom in said one or more rings, the heterocyclic group being optionally substituted with one or more Ry substituents, and wherein there are more than 255 of an optional substituent in any given group, and the optional Ry substituents may be the same or different; each Ry and Rz is independently selected from the group consisting of hydrogen, C1-C12 alkyl groups, C1-C12 alkyl groups being substituted with at least one halogen atom,aralkyl groups comprising a C1-C12 alkyl group substituted with an aryl group having 6 to 18 carbon atoms in one or more rings and heterocycloalkyl groups comprising a C1-C12 alkyl group substituted with a 5- to 14-membered heterocyclic group, saturated or unsaturated, having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings; X and T are extension groups which may be the same or different; each AA is independently an amino acid unit; L is a linking group; w is an integer ranging from 0 to 12; b is an integer of 0 or 1; g is an integer of 0 or 1; Ab is a moiety comprising at least one antigen-binding site; yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] with respect to the fraction comprising at least one antigen-binding site and is in the range of 1 to 20.

12. A drug conjugate according to claim 11, or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, wherein D is a drug fraction selected from formulas (IHa) and (IHb): LPQQCn / Lznz / SA / YILI R3 ^3 (IHa) (IHb) wherein the wavy lines, R1, R2, R3, Y, and Z are as defined for formula (IH).

13. The drug conjugate according to any of claims 1 to 4, or 11 to 12, where Y is -NH-.

14. The drug conjugate according to any of claims 1 to 4, or 11 to 12, where Y is -O-.

15. The drug conjugate according to any of claims 1 to 4, or 11 to 14, wherein R1 is -OH.

16. The drug conjugate according to any of claims 1 to 4, or 11 to 14, 256 where Ri is -CN.

17. The drug conjugate according to any of claims 1 to 4, or 11 to 16, wherein R2 is a -C(=O)Ra group wherein Ra is a substituted or unsubstituted Ci-Ce alkyl; preferably wherein Ra is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl, and substituted or unsubstituted tert-butyl.

18. The drug conjugate according to claim 17, wherein R2 is acetyl.

19. The drug conjugate according to any of claims 1 to 4, or 11 to 18, wherein R3 is hydrogen or -ORb where Rb is substituted or unsubstituted Ci-Ce alkyl; preferably wherein Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl.

20. The drug conjugate according to claim 19 wherein R3 is hydrogen.

21. The drug conjugate according to claim 19 wherein Ra is -ORb where Rb is substituted or unsubstituted Ci-Ce alkyl; preferably wherein Rb is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, substituted or unsubstituted sec-butyl and substituted or unsubstituted tert-butyl.

22. The drug conjugate according to claim 21 wherein R3 is methoxy.

23. The drug conjugate according to any of claims 1 to 22, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodine, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, ptoluenesulfonate, sodium, potassium, calcium, ammonium, ethylenediamine, ethanolamine, A / ,A / -dialkyleneethanolamine, triethanolamine, and basic amino acids.

24. A drug conjugate according to any of the preceding claims, wherein L is a linking group selected from the group consisting of: LPQQCn / Lznz / Σΐ / YΥΙΛΙ 257 LPQQCn / LZnZ / q / YIAI 0 0,, O uo ^_¿_Rig-Ó-NN=^ , Ud-R19-NN=^ . <5—R^g—M—Y—| ' OHSOH OOO , Uδ-R19-N—ΰ-OH2, μΰ-Rig-Ó— ' OO Ud-R19-s—' ^-¿-r19-on=^ where: the wavy lines indicate the point of covalent bonds to an Ab (the wavy line to the right) and (T)g if there is one, to (AA)W if there is one, to (X)b if there is one, or to D (the wavy line to the left); R19 is selected from C1-C12 alkylene, C3-C8 carbocycle, O-(C1-C12 alkylene), Ce-Cis arylene in one or more rings that may be optionally substituted with one or more Rx substituents, C1-C12 alkylene - Ce-Cis arylene - where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents,-arylene Ce-C-is- C1-C12 alkylene - where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents, -C1-C12 alkylene-(C3-Cs carbocycle)-, -(C3-C8 carbocycle)-C1-C12 alkylene -C5-C14 heterocycle - where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -C1-C12 alkylene -(CsC14 carbocycle)- where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents,- C1-C12 alkylene -(C5C14 heterocycle)- where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -(C5C14 heterocycle-C5C14 alkylene- where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -(OCH2CH2)r- and -CH2-(OCH2CH2)r , where each of the above-mentioned alkylene substituents, alone or attached to another moiety 258 in the carbon chain, may be optionally substituted with one or more Rx substituents; R30 is a Ci-Ce alkylene group M is selected from the group consisting -Ci-Ce-alkylene, -Ci-Cb-alkylene -(C3-Cs carbocycle)-, (CH2CH2O)s-,-alkylene Ci-Ce -(carbocycle C3-C8)-CON(H or alkyl Ci-Cej-alkylene Ci-Ce -, phenylene which may be optionally substituted with one or more substituents Rx, phenylene-alkylene Ci-Cb - where the phenylene moiety may be optionally substituted with one or more substituents Rx and -alkylene Ci-Cb -CON(H or alkyl Ci-Csjalkylene Ci-Ce -; Q is selected from the group consisting of -N(H or alkylene Ci-C6)phenylene- and -N(H or alkyl Ci-Ce)(CH2)s; r is an integer ranging from 1 to 10; ys is an integer ranging from 1 to 10.

25. A drug conjugate according to any one of claims 1 to 24, wherein L is a bonding group selected from the group consisting of: LPQQCn / Lznz / SA / YILI where: the wavy lines indicate the point of covalent bonding to an Ab (the wavy line to the right) and (T)g if any, to (AA)W if any, or to (X)b (the wavy line to the left); R19 is selected from C1-C12 -alkylene, -O-(C1-C12)alkylene, C6-C12 -arylene in one or more rings that may be optionally substituted with one or more Rx substituents, C1-C12 -alkylene CaC12 - where the aryl group is located in one or more rings that may be optionally substituted with one or more Rx substituents, Cb-Ci2 -arylene Ci-Ci2 - where the aryl group is located in one or more rings that may be optionally substituted with one or more Rx substituents,-C5-C12 heterocycle- where said heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -C1-C12 alkylene -(CsCi2 heterocycle)- where said heterocycle group can be a saturated or unsaturated group having one or more rings comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -(C5-Ci2 heterocycle)-C1Ci2 alkylene- where said heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -(OCH2CH2)r- and -CH2-(OCH2CH2)r-,wherein each of the aforementioned alkylene substituents, alone or attached to another moiety in the carbon chain, may be optionally substituted with one or more substituents Rx; R3o is a Ci-Cb M -alkylene group selected from the group consisting of Ci-Ce -alkylene, Ci-Cb -(C3-Cs carbocycle) -alkylene and phenylene that may be optionally substituted with one or more substituents Rx; yr is an integer ranging from 1-6.

26. A drug conjugate according to any one of claims 1 to 25, LPQQCn / LZnZ / q / YIAI selected from formulations (IV),(V) and (VI): (VI) where: X and T are extension groups that may be the same or different; each AA is independently an amino acid unit; w is an integer ranging from 0 to 12; b is an integer of 0 or 1; g is an integer of 0 or 1; D is a drug fraction; Ab is a fraction comprising at least one antigen-binding site; n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-j where L is as defined in formula (IV), (V) or (VI) with respect to the fraction comprising at least one antigen-binding site and is in the range of 1 to 20; Ría is selected from -alkylene Ci-Cs -, -©-(alkylene Ci-Cs), -alkylene Ci-Cs -arylene Ce-C-iz where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents, and -arylene Cs-Ci2 -alkylene Ci-Cs - where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents,where each of the aforementioned alkylene substituents, alone or attached to another moiety in the carbon chain, may optionally be substituted by one or more Rx substituents; R30 is a C2-C4 -alkylene group; and M is selected from the group consisting of C1-C3 -alkylene - and C1-C3 -alkylene -(C5-C7 carbocycle)-.

27. A drug conjugate according to claim 26 selected from formulas (IV), (V) and (VI): 260 LPQQCn / LZnZ / q / YIAI (VI) where: X and T are extension groups which may be the same or different; each AA is independently an amino acid unit; w is an integer ranging from 0 to 12; b is an integer of 0 or 1; g is an integer of 0 or 1; D is a drug fraction; Ab is a fraction comprising at least one antigen-binding site; n is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-j where L is as defined in (IV), (V) or (VI) with respect to the fraction comprising at least one antigen-binding site and is in the range of 1 to 20;R19 is selected from Ci-Ce-alkylene, Ci-Ce-phenylene-alkylene, where the phenylene group may be optionally substituted with one or more Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups, where each of the above-mentioned alkylene substituents, alone or attached to another moiety in the carbon chain, may be optionally substituted with one or more Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, aryl groups having 6 to 12 carbon atoms, halogen atoms, nitro groups, and cyano groups, and, preferably, contains a Ci-Ce alkylene group; R30 is a C2-C4 alkylene group; and M is a C1-C3 alkylene (C5-C7 carbocycle).

28. A drug conjugate according to any of claims 1 to 27, wherein (AA)W is of formula (II): 261 LPQQCn / Lznz / SA / YILI (II) wherein the wavy lines indicate the point of covalent bonding to (X)b if any, or to the drug fraction (wavy line to the left) and (T)g if any, or to the linker (wavy line to the right); and R21 is selected, in each case, from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, CH2CH2CONH2, -CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, (CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, (CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl, yw is an integer ranging from 0 to 12.

29. A drug conjugate according to claim 28, wherein (AA)W is of formula (II), wherein: R2i is selected, in each case, from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, -(CH2)3NHCONH2, -(CH2)4NH2, -(CH2)3NHC(=NH)NH2 and -(CH2)4NHC(=NH)NH2; and w is an integer ranging from 0 to 6.

30. A drug conjugate according to any one of claims 1 to 28, wherein w is 0 or 2, and wherein w is 2, then (AA)W is of formula (III): 262 ο η R22 AW (III) wherein: the wavy lines indicate the point of covalent bonding to (X)b if any, to the drug moiety (wavy line to the left) and (T)g if any, or to the linker (wavy line to the right); R22 is selected from methyl, benzyl, isopropyl, sec-butyl and indolylmethyl; and R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2 and -(CH2)3NHC(=NH)NH2.

31. A drug conjugate according to any one of claims 1 to 30, wherein X is an extension group selected from: where D is covalently attached via an amine group (for example, where Z is -NH-): -COO-(Ci-Ce alkylene)NH-; -COO-CH2-(phenylene which may be optionally substituted with one or more Rx substituents)-NH-; -COO-(Ci-C6 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one or more RX substituents)-NH-; -COCH2NH-COCH2-NH-; -COCH2NH-; -COO-(Ci-Ce alkylene)S-; -COO-(C6-alkylene)NHCO(C6-alkylene); and where D is covalently bonded by means of a hydroxyl group (for example, where Z is -O-): -CONH-(C6-alkylene)NH-; -COO-CH2-(phenylene which may be optionally substituted with one or more Rx substituents)-NH-; -CONH-(C6-alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one or more RX substituents)-NH-; -COCH2NH-COCH2-NH-; -COCH2NH-;-CONH-(C6-C6 alkylene)S-; -CONH-(C6-C6 alkylene)NHCO(C6-C6 alkylene)S-; yb is 0 or 1, preferably 1.; 32. A drug conjugate according to any one of claims 1 to 31, wherein X is an extension group selected from the group consisting of: where D is covalently attached by means of an amine group (e.g., where Z LPQQCn / LZnZ / q / YIAI 263 is -NH-): -COO-(C2-C4 alkylene)NH-; -COO-CHz-phenylene-NH-, wherein said phenylene group may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups; -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-; -COCH2NH-COCH2-NH-; -COO-(C2-C4 alkylene)S-;-COO-(C2-C4 alkylene)NHCO(C2-C4 alkylene); or where D is covalently bonded via a hydroxyl group (e.g., where Z is -O-): -CONH-(C2-C4 alkylene)NH-; -COO-CH2-phenylene-NH-, wherein said phenylene group may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups; -CONH-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and groups cyano)-NH-; -COCH2NH-COCH2-NH-; -CONH-(C2-C4 alkylene)S-; -CONH-(C2-C4 alkylene)NHCO(C3-C2 alkylene)S-; and b is 0 or 1, preferably 1.; 33. A drug conjugate according to claim 32, wherein X is an extension group selected from the group consisting of: where D is covalently linked by means of an amine group (e.g., where Z is -NH-): -COO-CH2-phenylene-NH-COO(CH2)3NHCOOCH2-phenylene-NH-; -COO(CH2)3NH-; -COO(CH2)3-S-; -COO(CH2)3NHCO(CH2)2S-; or where D is covalently linked by means of a hydroxy group (e.g., where Z is LPQQCn / Lznz / Σΐ / ΥΙΛΙ 264 -0-): -COO-CH2-phenylene-NH-CONH(CH2)3NHCOOCH2-phenylene-NH-; -CONH(CH2)3NH-; -CONH(CH2)3-S-; -CONH(CH2)3NHCO(CH2)2S-; and b is 0 or 1, preferably 1.

34. A drug conjugate according to any one of claims 1 to 33, wherein T is an extension group selected from the group consisting of -CO-(C6-alkylene)-NH-, -CO(C6-alkylene)-[O-(C2-C6-alkylene)]i-NH-, -COO-(C6-alkylene)-[O-(C2-C6-alkylene)]j-NH-; wherein j is an integer from 1 to 25, and g is 0 or 1.

35. A drug conjugate according to claim 34, wherein T is an extension group selected from the group consisting of -CO-(C4-alkylene)NH-, -CO-(C4-alkylene)-[O(C2-C4 alkylene)]j-NH-, -COO-(C4-alkylene)-[O-(C2-C4 alkylene)]j-NH-, wherein j is an integer from 1 to 10; and g is 0 or 1.

36. A drug conjugate according to claim 35, wherein T is an extension group selected from the group consisting of -CO-(C4-alkylene)NH-, -CO-(C4-alkylene)-[O(C2-C4-alkylene)]i-NH-, -COO-(C4-alkylene)-[O-(C2-C4-alkylene)]j-NH-; wherein j is an integer from 1 to 5; and g is 0 or 1.

37. A drug conjugate according to any one of claims 11 to 36, wherein D is a drug fraction of formula (IHa) or formula (IHb) or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, wherein: Ri is CN or OH; R2 is C(=O)Ra, wherein Ra is selected from hydrogen and substituted or unsubstituted Ci-Ce alkyl, wherein the optional substituents are one or more Rx substituents; Rs is hydrogen or an -ORb group where Rb is a substituted or unsubstituted Ci-Ce alkyl group, wherein the optimum substituents are one or more Rx substituents, Yes -NH- or -O-; and Z is -NH- or -O-.

38. A drug conjugate according to claim 37, wherein D is a drug fraction of formula (IHa) or formula (IHb) or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, wherein: Ri is CN or OOH; R2 is acetyl; R3 is hydrogen or methoxy, more preferably hydrogen; Y is -NH- or -O-; and Z is -NH- or -O-.

39. A drug conjugate according to claim 37 or 38, wherein D is a drug fraction of formula (IHa) or formula (IHb), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers, or stereoisomers, wherein: Ri is CN; R2 is acetyl; Rs is hydrogen; Y is -NH- or -O-; and Z is -NH-.

40. A drug conjugate according to any of claims 1, 3, 4, 11 or 13 to 39, wherein D is selected from: or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, wherein the wavy line indicates the covalent bonding point to (X)b if any, to (AA)W if any, to (T)g if any, or to (L).

41. A drug conjugate according to any of claims 1 to 4 or 11 to 40, wherein D is one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers, wherein the wavy line indicates the covalent bonding point a(X)b if any, a(AA)W if any, a(T)g if any, or a(L).

42. A drug conjugate according to any of claims 1 to 41, wherein the Ab moiety comprising at least one antigen-binding site is an antigen-binding peptide.

43. A drug conjugate according to claim 42, wherein the Ab moiety comprising at least one antigen-binding site is an antibody, a single-domain antibody, or an antigen-binding fragment thereof. 266 44. A drug conjugate according to claim 42 or 43, wherein the Ab fraction comprising at least one antigen-binding site is a monoclonal antibody, polyclonal antibody, or bispecific antibody, and wherein the antibody or an antigen-binding fragment thereof is derived from any species, preferably a human, mouse, or rabbit.

45. A drug conjugate according to claim 43 or 44, wherein the antibody or its antigen-binding fragment is selected from the group consisting of a human antibody, an antigen-binding fragment of a human antibody, a humanized antibody, an antigen-binding fragment thereof of a humanized antibody, a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a glycosylated antibody, and a glycosylated antigen-binding fragment.

46. ​​A drug conjugate according to any of claims 43 to 45, wherein the antibody or its antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, an F(ab j2) fragment, and an Fv fragment.

47. A drug conjugate according to any of claims 43 to 46, wherein the antibody or its antigen-binding fragment is a monoclonal antibody that binds immunospecifically to cancer cell antigens, viral antigens, antigens of cells producing autoimmune antibodies associated with an autoimmune disease, microbial antigens, and, preferably, a monoclonal antibody that binds immunospecifically to cancer cell antigens.

48. A drug conjugate of any one of claims 1 to 47, wherein the Ab moiety comprising at least one antigen-binding site is an antibody selected from the group consisting of Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Basivelumab, Besivelumab, Besivacimab Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Coltuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Indabrituximab, Indabrituximab Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Lifastuzumab, Lorvotuzumab, Milatuzumab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olafatumab, Olafatumab Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Pinatuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Sofituzumab, Vadastuximab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody,an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof.

49. A drug conjugate of claim 48, wherein the Ab moiety comprising at least one antigen binding site is an antibody selected from the group consisting of Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiximab, Belivazumab, Blinciatumab Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Indutuzumab Ipilimumab, Labetuzumab, Ladiratuzumab, LPQQCn / Lznz / Σΐ / ΥΙΛΙ 267 Laprituximab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Ofatumumab, Olavizumab, Ovilizumab Panitumumab, Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Vadastuximab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, a CD13 antibody, an antibody 30,or a fragment thereof that binds to an antigen or an immunologically active part thereof.

50. A drug conjugate according to claim 48, wherein the Ab moiety comprising at least one antigen binding site is an antibody selected from the group consisting of Abciximab, Alemtuzumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denosumab, Dinutuximab, Durvalumab, Elotuzumab, Gemtuzumab, Ibritumomab, Inotuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuximab, Trastuzumab, an antibody anti-CD4, an antibody anti-CD5, an antibody anti-CD13, an anti-CD30 antibody, or an antigen-binding fragment thereof, or an immunologically active part thereof, most preferably Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody,an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment thereof or an immunologically active portion thereof, preferably Trastuzumab, and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof, more preferably Trastuzumab, or an antigen-binding fragment thereof or an immunologically active portion thereof.

51. A drug conjugate according to any one of claims 11 or 12, wherein: L is a bonding group selected from the group consisting of: LPQQCn / LZnZ / q / YIAI where: the wavy lines indicate the point of covalent bonding to an Ab (the wavy line to the right) or (T)g if any, or (AA)W if any, or (X)b if any, or D (the wavy line to the left); R19 is selected from C1-C12 alkylene, -O-(C1-C12 alkylene), C6-C12 arylene in one or more rings that may be optionally substituted with one or more Rx substituents, C1-C12 alkylene - CeC12 arylene - where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents, C6-C12 arylene - C1-C12 alkylene - where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents,-CsC12 heterocycle- where said heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group 268 is optionally substituted with one or more Rx substituents, -C1-C12 alkylene-(C5-C12 heterocycle) where said heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group is optionally substituted with one or more Rx substituents, -(C5-C12 heterocycle)-C1-C12 alkylene where said heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group is optionally substituted with one or more Rx substituents, -(OCH2CH2)r- and -CH2-(OCH2CH2)r-,where each of the alkylene substituents mentioned above, alone or attached to another moiety in the carbon chain, may be optionally substituted by one or more Rx substituents; R30 is a Ci-Ce - alkylene group; M is selected from the group consisting of O-Oβ - alkylene, Ci-Ce - (C3-Cs carbocycle) - alkylene and phenylene which may be optionally substituted with one or more Rx substituents; r is an integer ranging from 1-6; (AA)w is of formula (II): (ll) where the wavy lines indicate the point of covalent bonding to (X)b if any, or to the drug moiety (wavy line to the left) and (T)g if any, or to the bonding agent (wavy line to the right); R21 is selected, in each case, from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, CH2CH2CONH2, -CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3,-(CH2)3NHCHO, (CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, (CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl, 269 w is an integer ranging from 0 to 12; where X is an extension group selected from: where Z is -NH-: -COO-(C6-alkylene)NH-, -COO-CH2-(phenylene which may be optionally substituted with one or more RX substituents)-NH-, -COO-(C6-alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one or more RX substituents)-NH-, -COCH2NH-COCH2-NH-, -COCH2NH-, -COO-(C6-alkylene)S- -COO-(C6-alkylene)NHCO(C6-alkylene)S-; or where Z is -O-: -CONH-(alkylene Ci-CsjNH-, -COO-CH2-(phenylene which may be optionally substituted with one or more RX substituents)-NH-, -CONH-(alkylene Ci-C6)NH-COO-CH2-(phenylene which may be optionally substituted with one or more RX substituents)-NH-, -COCH2NH-COCH2-NH-, COCH2NH-, -CONH-(alkylene Ci-CejS-,-CONH-(C1-C6 alkylene)NHCO(C1-C6 alkylene); b is 0 or 1, preferably 1; wherein T is an extension group selected from -CO-(C1-C6 alkylene)-NH-, -CO-(C1-C6 alkylene)-[O-(C2-C6 alkylene)]j-NH-, and -COO-(C1-C6 alkylene)-[O-(C2-C6 alkylene)]j-NH-, where j is an integer from 1 to 25; g is 0 or 1; D is a pharmaceutically acceptable drug fraction of formula (IH), formula (IHa), or formula (IHb), or one of its salts, esters, solvates, tautomers, or stereoisomers, wherein: R1 is CNoOH; R2 is C(=O)Ra, where Ra is selected from hydrogen and substituted or unsubstituted C1-C6 alkyl, where the optional substituents are one or plus RX substituents; R3 is hydrogen or an -ORb group, where Rb is a substituted or unsubstituted C1-C6 alkyl group,where the optional substituents are one or more Rx substituents; Yes-NH-uO-; Z is -NH- or -O-; the Ab fraction comprising at least one antigen-binding site is an antibody or an antigen-binding fragment thereof and is selected from the group consisting of a human antibody, an antigen-binding fragment of a human antibody, a humanized antibody, an antigen-binding fragment of a humanized antibody, a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a glycosylated antibody, and a glycosylated antigen-binding fragment; yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] to the Ab fraction comprising at least one antigen-binding site and is in the range of 1 to 12.

52. A drug conjugate according to any one of claim 11 or 12, selected from formulations (IV), (V), and (VI): (IV) (V) (VI) wherein: R19 is selected from C6-C12 -alkylene, -O-(C6-C12 -alkylene), C6-C12 -alkylene, C6-C12 -alkylene, wherein the arylene group is located on one or more rings that may be optionally substituted with one or more Rx substituents, and wherein each of the above-mentioned alkylene substituents, alone or attached to another moiety in the carbon chain, may be optionally substituted with one or more Rx substituents; R30 is a C2-C4 -alkylene group; M is selected from the group consisting of -C1-C3 alkylene - and -C1-C3 alkylene -(C5-C7 carbocycle)-;(AA)w is of formula (II) where: the wavy lines indicate the point of covalent bonding to (X)b if any, or to the drug fraction (wavy line to the left) and to (T)g if any, or to the bonding agent (wavy line to the right); R21 is selected, in each case, from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, 271 benzyl, indolylmethyl, -(CH2)3NHCONH2, -(CH2)4NH2, -(CH2)3NHC(=NH)NH2 and -(CH2)4NHC(=NH)NH2; w is an integer from 0 to 6;X is an extension group selected from the group consisting of where Z is -NH-: -COO-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, wherein said phenylene group may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -COCH2NH-COCH2-NH-, COO-(alkylene C2-C4)S-, and -COO-(C2-C4 alkylene)NHCO(C3-C3 alkylene)S-;or where Z is -O-: -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, wherein said phenylene group may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO-CH2(phenylene which may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -COCH2NH-COCH2-NH, -CONH-(C2-C4 alkylene)S-, and -CONH-(alkylene C2-C4)NHCO(Ci-C3 alkylene)S-; b is 0 or 1, preferably 1;where T is an extension group selected from -CO-(C1-C4 alkylene)-NH-, -CO-(C1C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO-(C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 10; g is 0 or 1; D is a drug fraction of formula (IH), formula (IHa) or formula (IHb), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers where: R1 is CN or oOH; R2 is acetyl; R3 is hydrogen or methoxy, more preferably hydrogen; Y is -NH- or -O-; Z is -NH- or -O-;the Ab fraction comprising at least one antigen-binding site is an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment is a monoclonal antibody that binds immunospecifically to cancer cell antigens, viral antigens, antigens of cells producing autoimmune antibodies associated with an autoimmune disease, microbial antigens, and preferably a monoclonal antibody that binds immunospecifically to cancer cell antigens; yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] where L is as defined in formulas (IV), LPQQCn / Lznz / SA / YILI 272 (V) or (VI) to the Ab fraction comprising at least one antigen-binding site and is in the range of 3 to 8.

53. A drug conjugate according to any one of claim 11 or 12, selected from formulas (IV), (V) and (VI): LPQQCn / Lznz / SA / YILI OO (iv) (V) or -Ab n (VI) wherein: R19 is selected from -alkylene Ci-Ce -phenylene-alkylene Ci-Ce - wherein the phenylene group may be optionally substituted with one or more Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, wherein each of the above-mentioned alkylene substituents alone or attached to another moiety in the carbon chain may be optionally substituted with one or more Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups that have 1 to 6 carbon atoms, aryl groups that have 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups,and preferably Riges is a Ci-Ce alkylene group; Rao is a C2-C4 -alkylene group; M is a C1-C3 -(C5-C7)-alkylene group; w is 0 or 2, and where w is 2, then (AA)W is of formula (III): (Hl) where the wavy lines indicate the point of covalent bonding to (X)b if any, or to the drug moiety (wavy line to the left) and (T)g if any, or to the bonding agent (wavy line to the right); R22 is selected from methyl, benzyl, isopropyl, sec-butyl and indolylmethyl; R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2 and -(CH2)3NHC(=NH)NH2; 273 X is an extension group selected from the group consisting of -COO-(C2-C4 alkylene)NH-, COO-CH2-phenylene-NH-, wherein said phenylene group may be optionally substituted by one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups,-COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted by one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups or cyano groups)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO-(C2C4 alkylene)NHCO(C3-C3 alkylene)S-; b is 0 or 1, preferably 1; where T is an extension group selected from -CO-(C4-alkylene)-NH-, -CO-(C4-alkylene)-[O-(C2-C4-alkylene)]j-NH-, and -COO-(C4-alkylene)-[O-(C2-C4-alkylene)]j-NH-, where j is an integer from 1 to 5; g is 0 or 1; D is a drug fraction of formula (IHa) or formula (IHb), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers, or stereoisomers,where: Ri is CN; R2 is acetyl: R3 is hydrogen; Yes-NH-uO-; Zes-NH-; the Ab fraction comprising at least one antigen-binding site is a monoclonal antibody selected from the group consisting of Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Coltuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, Labetuzumab Laprituximab, Lifastuzumab, Lorvotuzumab, Milatuzumab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Perzuzumab, Pintuzumab Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Sofituzumab, Vadastuximab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody,an anti-CD13 antibody an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active part thereof; preferably Abciximab, Alemtuzumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denosumab, Dinutuximab, Durvaluzumab, Elozumab, Gembritumab, Ituzumab, Inotuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuzumab, Trastuzumab, and Tratuzumab anti-CD4, an LPQQCn / Lznz / Σΐ / ΥΙΛΙ 274 anti-CD5 antibody, an anti-CD13 antibody an anti-CD 30 antibody, or an antigen-binding fragment thereof or an immunologically active moiety thereof, preferably Brentuximab, Genotuzumab, Gemtumumab, Itumab Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody,an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment thereof or an immunologically active portion thereof, preferably Trastuzumab, and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof, more preferably Trastuzumab, or an antigen-binding fragment thereof or an immunologically active portion thereof; yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-] where L is as defined in formulas (IV), (V) or (VI) with respect to the Ab fraction comprising at least one antigen-binding site and is in the range of 3 to 5.

54. A drug conjugate of claim 53, the Ab moiety comprising at least one antigen binding site is an antibody selected from the group consisting of Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiliximab, Bevaliciatomumab, Blinciatumumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Indutuzumab Ipilimumab, Labetuzumab, Ladiratuzumab, Laprituximab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Petuzumab, Peratuzumab, Polatuzumab Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Vadastuximab, Vorsetuzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody and an anti-CD 30 antibody,or a fragment thereof that binds to an antigen or an immunologically active part thereof.

55. A drug conjugate according to claim 53, wherein the Ab moiety comprising at least one antigen binding site is an antibody selected from the group consisting of Abciximab, Alemtuzumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatomumab, Brentuximab, Catumaxomab, Cetuximab, Daclizumab, Daratumumab, Denosumab, Dinutuximab, Durvalumab, Elotuzumab, Gemtuzumab, Ibritumomab, Inotuzumab, Ipilimumab, Labetuzumab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ramucirumab, Rovalpituzumab, Siltuximab, Trastuzumab, an antibody anti-CD4, an antibody anti-CD5, an antibody anti-CD13, an anti-CD30 antibody, or an antigen-binding fragment thereof, or an immunologically active part thereof, most preferably Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody,an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof, preferably Trastuzumab, and an anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof, more preferably Trastuzumab, or an antigen-binding fragment or an immunologically active portion thereof. LPQQCn / Lznz / SA / YILI 275, 56. A drug conjugate according to claim 11, selected from formulas (IV), (V) and (VI): LPQQCn / LZnZ / q / YIAI (VI) wherein: R19 is a C2-C6 -alkylene; R30 is a C2-C4 -alkylene; M is a C1-C3 -(C5-C7)-alkylene; w is 0 or 2, and wherein w is 2, then (AA)W is of formula (III): (ni) wherein R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, wherein the wavy lines indicate the point of covalent bonding to (X)b if any, or to the drug moiety (wavy line to the left) and (T)g if any, or to the linker (wavy line to the right);X is an extension group selected from the group consisting of -COO-(C2-C4 alkylene)NH-, COO-CH2-phenylene-NH-, wherein said phenylene group may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene that may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO-(C2C4 alkylene)NHCO(C3-C3 alkylene)S; b is 0 or 1, preferably 1;where T is an extension group selected from -CO-(C1-C4 alkylene)-NH-, -CO-(C1C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO-(C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 5; g is 0 or 1; D is a drug fraction selected from: LPQQCn / LZnZ / q / YIAI or one of its pharmaceutically acceptable salts, esters, solvates, tautomers, or stereoisomers; where wavy lines indicate the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to the linker; The Ab fraction comprising at least one antigen-binding site is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof;yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formulas (IV), (V) or (VI), with respect to the Ab fraction comprising at least one antigen-binding site and is in the range of 3 to 5.; 57. A drug conjugate according to claim 56, wherein the Ab moiety comprising at least one antigen-binding site is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof.

58. A drug conjugate according to claim 56, wherein the Ab fraction comprising at least one antigen-binding site is Trastuzumab or an antigen-binding fragment thereof or an immunologically active portion thereof.

59. A drug conjugate according to any one of claims 11 or 12, selected from formulas (IV), (V), and (VI): 277 LPQQCn / LZnZ / q / YIAI (VI) wherein: R19 is -C2-C6 alkylene-; R30 is -C2-C4 alkylene-; M is -C1-C3 alkylene-(C5-C7 carbocycle-); w is 0 or 2, and wherein w is 2, then (AA)W is of formula (III): (Hl) wherein R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, and the wavy lines indicate the point of covalent bonding to (X)b if any, or the drug fraction (wavy line to the left) and (T)g if any, or to the linker (wavy line to the right);X is an extension group selected from the group consisting of -COO-(C2-C4 alkylene)NH-, COO-CH2-phenylene-NH-, wherein said phenylene group may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene that may be optionally substituted with one to four substituents Rx selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO-(C2C4 alkylene)NHCO(C3-alkylene)S-; b is 0 or 1, preferably 1;where T is an extension group selected from -CO-(C1-C4 alkylene)-NH-, -CO-(C1-C4 alkylene)-[O-(C2-C4 alkylene)]i-NH-, and -COO-(C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 5; g is 0 or 1; D is a drug fraction selected from: 278 LPQQCn / Lznz / SA / YILI or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers; where wavy lines indicate the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to the linker; The Ab fraction comprising at least one antigen-binding site is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof;yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formulas (IV), (V) or (VI), with respect to the fraction comprising at least one antigen-binding site and is in the range of 3 to 5.; 60. A drug conjugate according to claim 59, wherein the Ab moiety comprising at least one antigen-binding site is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof.

61. A drug conjugate according to claim 59, wherein the Ab fraction comprising at least one antigen-binding site is Trastuzumab or an antigen-binding fragment thereof or an immunologically active portion thereof.

62. A drug conjugate according to any one of claims 1 to 4, or 11 to 49, of formula (IV): D-(X)b-(AA)w-(T)g- (IV) wherein: R19 is a C2-C5 alkylene; w is 0 or 2, and where w is 2, then (AA)W is of formula (III): 279 (lll) LPQQCn / Lznz / SA / YILI wherein R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, and the wavy lines indicate the point of covalent bonding to (X)b if any, or to the drug moiety (wavy line to the left) and to (T)g if any, or to the bonding agent (wavy line to the right); X is a -COOCH2-phenylene-NH- group; b is 1; T is an extension group of formula -CO-(C4-alkylene)-[O-(C2-C4 alkylene)]4-NH-; g is 0 or 1; or of formula (V) D—(X)b-(AA)w—(T)g OO -M-óX Ab (V) where M is -methylcyclohexylene-; b is 1; w is 0; X is an extension group selected from -(CH2)3S- and -(CH2)3NHCO(CH2)2Sg is 0; or of formula (VI) (VI) where Rw is -C2-Cs alkylene -; R30 is -C3 alkylene -;w is 0 or 2, and where w is 2, then (AA)W is of formula (lll): (lll) where R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, and the wavy lines 280 indicate the point of covalent bonding to (X)b if any, or to the drug moiety (wavy line to the left) and (T)g if any, or to the bonding agent (wavy line to the right); and X is a -COOCH2-phenylene-NH group; b is 1; T is an extension group of formula -CO-(C4-alkylene)-[O-(C2-C4 alkylene)]4-NH-; g is 0 or 1; D is a drug fraction selected from: LPQQCn / Lznz / SA / YILI or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers; wherein the wavy line indicates the point of covalent bonding to (X)b if any, to (AA)W if any, to (T)g if any, or to the bonding agent;the Ab fraction comprising at least one antigen-binding site is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof; yn is the ratio of the group [D-(X)b-(AA)w-(T)g-(L)-], where L is as defined in formula (IV), with respect to the fraction comprising at least one antigen-binding site and is in the range of 3 to 5, and preferably 4.

63. A drug conjugate according to claim 62, wherein the Ab moiety comprising at least one antigen-binding site is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof.

64. A drug conjugate according to claim 62, wherein the Ab fraction comprising at least one antigen-binding site is Trastuzumab or an antigen-binding fragment thereof or an immunologically active portion thereof.

65. A drug-antibody conjugate according to claim 1, selected from the group consisting of: 281 η I CQOCH / 1 7P7 / 3 / YILI 282 LPQQCn / LZnZ / q / YIAI where n is from 2 to 6, more preferably 3, 4, or 5, and each y is independently selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment thereof or an immunologically active portion thereof, and, more preferably, is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof, particularly Trastuzumab or an antigen-binding fragment thereof or an immunologically active portion thereof of the same.

66. A drug conjugate according to claim 65, wherein the Ab moiety comprising at least one antigen-binding site is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof.

67. A drug conjugate according to claim 65, wherein the Ab fraction comprising at least one antigen-binding site is selected from Trastuzumab or an antigen-binding fragment thereof or an immunologically active portion thereof.

68. A drug conjugate according to claim 1, selected from the group consisting of: 283 LPQQCn / Lznz / SA / YILI 284 I CQOCO / 1 7P7 / 3 / YILI 285 S-HN— wherein n is from 2 to 6, more preferably 3, 4, or 5, and each y is independently selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment thereof or an immunologically active portion thereof, and, more preferably, is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof, particularly Trastuzumab or an antigen-binding fragment thereof an antigen or an immunologically active part thereof;or a drug conjugate of formula LPQQCn / LZnZ / q / YIAI 3— where n is from 2 to 6, most preferably 3, 4, or 5 and is an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active part thereof.; 69. A drug conjugate according to claim 68, wherein the Ab moiety comprising at least one antigen-binding site is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof.

70. A drug conjugate according to claim 68, wherein the Ab fraction comprising at least one antigen-binding site is selected from Trastuzumab or an antigen-binding fragment thereof or an immunologically active portion thereof.

71. A drug-antibody conjugate according to any of claims 1 to 70 in isolated or purified form.

72. A compound of formula D-(X)b-(AA)w-(T)g-Li, wherein: Li is a bonding agent selected from the group of formulas consisting of: 286 OO O ¿5—R19-N~3 d-R19-Ó-NH-NH2 Oo ^_¿_r19-NH-NH2, ^-¿-r19-n=c=o , oo ^_¿_Rig—N=C=S - Ó-R19-N-Ó-CH2-G, Oo o Ó-R19-Ó-J Ó-R19-SS o ^_<5-r19-o-nh2 wherein each of the wavy lines indicates the point of covalent bonding to (T)g if any, to (AA)W if any, to (X)b if any or to D; G is selected from halo, -O-mesyl and -O-tosyl; J is selected from halo, hydroxy, - / V-succinimidoxy, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR2o; R19 is selected from C1-C12-alkylene, C3-C8-carbocycle, -O-(C1-C12-alkylene), Ce-Cis-arylene in one or more rings that may be optionally substituted with one or more Rx substituents, C1-C12-alkylene, Ce-Cie-arylene where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents,-arylene C1-C12 -alkylene C1-C12 - where the arylene group is located in one or more rings that may be optionally substituted with one or more Rx substituents, -alkylene C1-C12 -(carbocycle C3-Cs)-, -(carbocycle C3-C8)-alkylene C1-C12 -, C5-C14 heterocycle - where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -alkylene C1-C12 (heterocycle Cs-Cu)- where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx substituents, -(heterocycle C5Cuj-alkylene C1-C12 -,where said heterocycle group can be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen, or sulfur atom in said one or more rings, said group being optionally substituted with one or more Rx, -(OCH2CH2)r-, and CH2-(OCH2CH2)r- substituents, where each of the aforementioned alkylene substituents, alone or attached to another segment in the carbon chain, can be optionally substituted with one or more Rx substituents; R2o is a Ci-Ci2 alkyl or aryl group having from 6 to 18 carbon atoms in one or more aromatic rings, said aryl groups being optionally substituted with one or more Rx substituents; r is an integer ranging from 1 to 10; b is an integer of 0 or 1; g is an integer from 0 or 1; w is an integer ranging from 0 to 12; each of D, Rx, X, T, and AA is as defined in any one of claims 1 to 71.

73. A compound of formula D-(X)b-(AA)w-(T)g-Li according to claim 72, wherein: Li is a bonding agent of formula: LPQQCn / LZnZ / q / YIAI where: the wavy line indicates the point of covalent bonding to (T)g if any, to (AA)W if any, to (X)b if any, or to D; R19 is selected from C1-C12 -O-(Ci-Ci2 alkylene), Ce-Ci2 -arylene in one or more rings that may be optionally substituted with one or more substituents Rx, C1-C12 -arylene CeC12 - where the arylene group is located in one or more rings that may be optionally substituted with one or more substituents Rx, Ce-Ci2 -arylene Ci-Ci2 - where the arylene group is located in one or more rings that may be optionally substituted with one or more substituents Rx, C5-C12 -heterocycle - where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen atom,nitrogen or sulfur in said one or more rings, said group is optionally substituted with one or more substituents Rx, -Ci-Ci2 alkylene -(CsCi2 heterocycle)- where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -(C5-Ci2 heterocycle)-C1-C12 alkylene where said heterocycle group may be a saturated or unsaturated group having one or more rings and comprising at least one oxygen, nitrogen or sulfur atom in said one or more rings, said group is optionally substituted with one or more substituents Rx, -(OCH2CH2)r- and -CH2-(OCH2CH2)r-, where each of the aforementioned alkylene substituents, alone or attached to another moiety in the carbon chain,may be optionally substituted with one or more Rx substituents; r is an integer ranging from 1-6; b is an integer of 0 or 1; g is an integer of 0 or 1; w is an integer ranging from 0 to 12; each of D, Rx, X, AA, and T is as defined in any one of claims 1 to 71.

74. A compound of formula D-(X)b-(AA)w-(T)g-Li according to claim 72, wherein: L1 is a bonding agent of formula: 288 LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: the wavy line indicates the point of covalent bonding to (T)g if any, to (AA)W if any, to (X)b if any, or to D; R19 is selected from -C6-C12 alkylene -, -O-(C6-C12 alkylene), -C6-C12 alkylene -C6-C12 alkylene - where the arylene group is located on one or more rings that may be optionally substituted with one or more Rx substituents,where each of the above-mentioned alkylene substituents alone or attached to another moiety in the carbon chain may be optionally substituted with one or more Rx substituents; (AA)w is of formula (II): (H) where the wavy lines indicate the point of covalent bonding to (X)b if any, or to D (the wavy line to the left) or to (T)g if any, to L1 to a hydrogen atom (the wavy line to the right); where R21 is selected, in each case, from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, -(CH2)3NHCONH2, -(CH2)4NH2, -(CH2)3NHC(=NH)NH2 and -(CH2)4NHC(=NH)NH2, and w is an integer from 0 to 6; X is an extension group selected from the group consisting of where D is conjugated by an amine group (e.g., where Z is -NH-): -COO-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH,where said phenylene group may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -COO-(C2-C4 alkylene)NH-COO-CH2-(phenylene that may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -COO-(C2-C4 alkylene)S-, and -COO(C2-C4 alkylene)-NHCO(C3-C3 alkylene)S-, or where D is conjugated by a hydroxy group (e.g., where Z is -O-): -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-,where said phenylene group may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO-CH2-(phenylene which may be optionally substituted with one to four Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkylene)S-, and CONH-(C2-C4 alkylene)NHCO(C1-C2 alkylene)S-; T is an extension group selected from -CO-(C4-alkylene)-NH-; -CO-(C4-alkylene)-[O(C2-C4 alkylene)]j-NH- and -COO-(C4-alkylene)-[O-(C2-C4 alkylene)]j-NH-,where j is an integer from 1 to 10; b is 0 or 1; g is 0 or 1; D is a drug fraction of formula (la) or formula (Ib), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers: LPQQCn / Lznz / SA / YILI or D is a drug fraction of formula (IHa) or formula (IHb), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers R3 R3 (IHa) (IHb) where the wavy lines of (IHa) and (IHb) indicate the point of covalent bonding to (X)b if any, to (AA)W if any, to (T)g if any, or to Li; R1 is -OH or -CN; R2 is a -C(=O)Ra group, where Ra is selected from hydrogen and substituted or unsubstituted C1-C6 alkyl, where the optimum substituents are one or more Rx substituents; 290 R3 is hydrogen or a -ORb group where Rb is a substituted or unsubstituted Ci-Ce alkyl group, where the optional substituents are one or more Rx substituents; Yes-NH-uO-; R4 (if present) is -CH2OH,or -CH2NH2; and Z (if present) is -NH- or -O-., 75. A compound of formula D-(X)b-(AA)w-(T)g-Li according to claim 72, wherein: L1 is a group of formula: O where: the wavy line indicates the point of covalent bonding to (T)g if any, to (AA)W if any, to (X)b if any or to D;R19 is selected from Ci-Ce-alkylene, Ci-Ce-phenylene-alkylene, where the phenylene group may be optionally substituted with one or more Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, halogen atoms, nitro groups, and cyano groups, where each of the above-mentioned alkylene substituents, alone or attached to another moiety in the carbon chain, may be optionally substituted with one or more Rx substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, aryl groups having 6 to 12 carbon atoms, halogen atoms, nitro groups, and cyano groups, and, preferably, contains a Ci-Ce alkylene group;w is 0 or 2, and where w is 2, then (AA)W is of formula (III): θ u R22 'W (III) J where the wavy lines indicate the point of covalent bonds to (X)b if any, or D (the wavy line to the left) and (T)g if any, to L1 or to a hydrogen atom (the wavy line to the right); R22 is selected from methyl, benzyl, isopropyl, sec-butyl and indolylmethyl; R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2 and -(CH2)3NHC(=NH)NH2; X is an extension group selected from where D is conjugated by an amine group (e.g., where Z is -NH-): -COO-CH2-phenyleneNH, -COO(CH2)3)NHCOO-CH2-phenylene-NH, -COO-(CH2)3NH-, -COO(CH2)3-S-, and -COO-(CH2)3NHCO(CH2)2S-; or where D is conjugated by a hydroxy group (e.g., where Z is -O-): -COO-CH2-phenylene 291 NH-, -CONH(CH2)3NHCOOCH2-phenylene-NH-, -CONH(CH2)3NH-, -CONH(CH2)3-S-, and CONH(CH2)3NHCO(CH2)2S-;where T is an extension group selected from -CO-(C4-alkylene)-NH-, -CO-(C4-alkylene)-[O-(C2-C4-alkylene)]j-NH-, and -COO-(C4-alkylene)-[O-(C2-C4-alkylene)]j-NH-, where j is an integer from 1 to 5; b is an integer from 0 or 1; g is 0 or 1; D is a drug fraction of formula (Ia) or formula (Ib), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers, or stereoisomers: or D is a drug fraction of formula (IHa) or formula (IHb), or one of its pharmaceutically acceptable salts, esters, solvates, tautomers, or stereoisomers: (IHa) (IHb) where the wavy lines of (IHa) and (IHb) indicate the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to Li; Ri is CN or OH; R2 is acetyl; R3 is hydrogen or methoxy, preferably hydrogen; Yes-NH-uO-; R4 (if present) is -CH2OH, or -CH2NH2; and Z (if present) is -NH- or -O-.; 76. A compound of formula D-(X)b-(AA)w-(T)g-Li according to claim 72, wherein: 292 Li is a bonding agent of formula: LPQQCn / Lznz / Σΐ / ΥΙΛΙ where: the wavy line indicates the point of covalent bonding to (T)g if any, to (AA)W if any, to (X)b if any or to (D); R19 is -C2-Ce alkylene -; w is 0 or 2, and where w is 2, then (AA)W is of formula (III): (lll) R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, where the wavy lines indicate the point of covalent bonding to (X)b if any, or D (the wavy line to the left) and (T)g if any, to L1 or to a hydrogen atom (the wavy line to the right); X is an extension group selected from -COO-CH2-phenylene-NH-, -COO(CH2)3NHCOO-CH2phenylene-NH, -COO-(CH2)3)NH-, -COO(CH2)3-S-, and -COO-(CH2)3NHCO-(CH2)2S-;where T is an extension group selected from -CO-(C1-C4 alkylene)-NH-, -CO-(C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, and -COO-(C1-C4 alkylene)-[O-(C2-C4 alkylene)]j-NH-, where j is an integer from 1 to 5; b is 0 or 1; g is 0 or 1; D is a drug selected from: or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers; where the wavy line indicates the point of covalent attachment to (X)b if any, to (AA)W if any, to (T)g if any, or to Li.; 77. A compound of formula D-(X)b-(AA)w-(T)g-Li according to claim 72, wherein: L1 is a group of formula: 293 € > Π NCK cu σ σ u where: the wavy line indicates the point of covalent bonding to (T)g if any, to (AA)W if any, to (X)b if any, or to D; R19 is -C2-C5 alkylene w is 0 or 2, and where w is 2, then (AA)W is of formula (III): (Hl) where R22 is isopropyl, R23 is selected from methyl and -(CH2)3NHCONH2, where the wavy lines indicate the point of covalent bonding to (X)b if any, or to D (wavy line to the left) and (T)g if any, to L-ι or to a hydrogen atom (wavy line to the right); X is a -COO-CH2-phenylene-NH- group; T is a -CO-(CH2)2-[O-(CH2)2]4-NH- group; b is an integer of 0 or 1; g is 0 or 1; D is a drug fraction selected from: or one of its pharmaceutically acceptable salts, esters, solvates, tautomers or stereoisomers;where the wavy line indicates the point of covalent bonding to (X)b if there is one, to (AA)W if there is one, to (T)g if there is one, or to L1.; 78. A compound of formula DX-(AA)w-(T)g-Li according to any of claims 72 to 77 selected from: 294 LPQQCn / LZnZ / q / YIAI 79. A compound of formula DX-(AA)w-(T)g-Li according to any of claims 72 to 77 selected from: I CQOCO / 1 7Π7 / 3 / YILI 296 LPQQCn / LZnZ / q / YIAI 80. A compound of formula D-(X)b-(AA)w-(T)g-Li, wherein each of D, X, AA, T, Li, b, gyw are as defined in any one of claims 1 to 70.

81. A drug conjugate according to any one of claims 1 to 71, or a compound according to any one of claims 72 to 80, wherein b+g+w is not 0.

82. A drug conjugate according to any one of claims 1 to 71 or 81, or a compound according to any one of claims 72 to 81, wherein b+w is not 0.

83. A drug conjugate according to any one of claims 1 to 71, 81 or 82, or a compound according to any one of claims 72 to 82, wherein when w is not 0, then b is 1.

84. Use of a drug fraction as described in any one of claims 1 to 23, as a payload in a drug-antibody conjugate.

85. Use of a drug fraction as described in any of claims 1 to 23, in the preparation of a drug-antibody conjugate.

86. A drug conjugate according to any of claims 1 to 71, for use as a medicament.

87. A drug conjugate according to any one of claims 1 to 71 for use in the treatment of cancer and, more preferably, cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric cancer, and ovarian cancer.

88. A pharmaceutical composition comprising a drug conjugate according to any of claims 1 to 71 and a pharmaceutically acceptable vehicle.

89. A method for the prevention or treatment of cancer comprising administering an effective amount of a drug conjugate according to any of claims 1 to 71 to a patient in need.

90. A method for the treatment of cancer according to claim 89, wherein the cancer is selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer.

91. Use of a drug conjugate according to any of claims 1 to 71 in the preparation of a medicament for the treatment of cancer, preferably a cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer.

92. A kit comprising a therapeutically effective amount of a drug conjugate 297 according to any of claims 1 to 71 and a pharmaceutically acceptable vehicle.

93. The kit according to claim 92 for use in the treatment of cancer and, more preferably, a selected cancer from lung cancer, colorectal cancer, breast cancer, pancreatic carcinoma, kidney cancer, leukemia, multiple myeloma, lymphoma, gastric and ovarian cancer.

94. The drug conjugate according to any one of claims 1 to 50, wherein n is in the range of 1-12, 1-8, 3-8, 3-6, 3-5, 1, 2, 3, 4, 5 or 6; preferably 3, 4 or 5 or more preferably 4.

95. A process for the preparation of a drug-antibody conjugate according to any of claims 1 to 71 comprising conjugating an Ab fraction comprising at least one antigen-binding site and a drug D, Ab and D being as defined in any of claims 1 to 71.

96. A process according to claim 95 for the preparation of a drug-antibody conjugate of formula (G) or (G'): LPQQCn / Lznz / SA / YILI (Gj) said process comprises the following steps: (i) reacting a DH drug of formula (IH)-H: r3 where the substituents in the definitions of (IH)-H are as defined in any of claims 1 to 71, with a compound of formula (Dj or (E): 298 LPQQCn / LZnZ / q / YIAI to provide a compound of formula (F) or (Fj), respectively; (ii) partial reduction of one or more disulfide bonds in the antibody to be conjugated to provide a reduced antibody Ab-SH having free thiol groups: Ab reduction of / \ -----------►- Ab-SH S-----S disulfide bonds;and (ii) reaction of the partially reduced Ab-SH antibody possessing free thiol groups with the compound of formula (F) or (Fj) produced in step (i) to provide the desired drug-antibody conjugate of formula (G) or (G j, respectively: 299 LPQQCn / Lznz / SA / YILI (G'); 97. A process according to claim 96, wherein the antibody is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment or an immunologically active portion thereof that is partially reduced in step (ii) using tris[2-carboxyethyl]phosphine hydrochloride, preferably the antibody is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment or an immunologically active portion thereof that is partially reduced in step (ii) using tris[2-carboxyethyl]phosphine hydrochloride, and, most preferably, is Trastuzumab or an antigen-binding fragment or an immunologically active portion thereof that is partially reduced in step (ii) using tris[2-carboxyethyl]phosphine hydrochloride. tris[2-carboxyethyl]phosphine.

98. A process according to claim 95 for the preparation of a drug-antibody conjugate of formula (W) or (Wj): (W') said process comprises the following steps: (i) reacting the antibody with 2-iminothiolane hydrochloride (Traut's reagent) to provide a thiol-activated antibody: 300 LPQQCn / Lznz / SA / YILI (i) reacting the thiol-activated antibody with the compound of formula (F) or (Fj), to provide the desired drug-antibody conjugate of formula (W) or (Wj, respectively.

99. A process according to claim 98, wherein the antibody is selected from Brentuximab, Gemtuzumab, Inozutumab, Rovalpituzumab, Trastuzumab, an anti-CD4 antibody, an anti-CD5 antibody, an anti-CD13 antibody, an anti-CD30 antibody, or an antigen-binding fragment thereof or an immunologically active portion thereof, preferably the antibody is selected from Trastuzumab and an anti-CD13 antibody or an antigen-binding fragment thereof or an immunologically active portion thereof and, most preferably, is Trastuzumab or an antigen-binding fragment thereof or an immunologically active portion thereof.

100. A process according to claim 95 for the preparation of a drug-antibody conjugate of formula (O) or (P): S(CH2)i-3CONH(CH2)i.6OCO-D (O) said process comprising the following steps: 301 (i) either: (a) reacting a drug (DH) of formula (IH)-H: r3 LPQQCn / Lznz / SA / YILI wherein the substituents in the definitions of (IH)-H are as defined in any one of claims 1 to 71, with a compound of formula X2-C(O)-Xi wherein Xi and X2 are leaving groups to provide a compound of formula (B): D^X (B) and the attachment point of the -(C=O)Xi moiety is the free -NH2 group of the compound of formula DH,(b) reacting said drug (DH) of formula (IH)-H as defined above with 4-nitrophenylchloroformate to provide a compound of formula (J): (J) and the attachment point of the (4-nitrophenyl)-O-CO- group is the same as that for the Xi(CO) moiety in (a) above; (ii) either: (c) reacting the compound of formula (B) produced in step (i) with a hydroxy compound of formula HO-(CH2)i-6NHProtNH and removing the ProtNH group from the coupled compound to provide a compound of formula (C): O—(CH2)i-6—NH2 (C) and subsequently,react the resulting compound of formula (C) with a compound of formula Me-SS-(CH2)i-3-CO2H to provide a compound of formula (K) 302 V O-(CH2)i-6-N Π oMe (CH2)l-3 LPQQCn / Lznz / Σΐ / ΥΙΛΙ (K) (d) react the compound (J) produced in step (i) with a compound of formula HO(CH2)i-3SProtSH and remove the ProtSH group from the coupled compound to provide a compound of formula (L): DO(CH2)i-3-SS-(CH2)i-3-O^D (L) (II) react (K) or (L) produced in step (ii) with dithiothreitol under disulfide reduction conditions to provide compounds (M) and (N),respectively: DO(CH2)1-6NH (CH2)i-3—SH (M) O(CH2)i-3-SH (N) (iv) reacting the antibody to be conjugated with succinimidyl-4-(A / maleimidomethyl)cyclohexan-1-carboxylate to derive said antibody into one or more lysine groups with a succinimidyl-4-(A / -maleimidomethyl)cyclohexan-1-carbonite group: O Ab—NH2 SMCC Ab-N H (v) reacting the derived antibody produced in step (iv) with (M) or (N) produced in step (iii) to provide the desired drug-antibody conjugate of formula (O) or (P): 303 S(CH2)1-3CONH(CH2)1.6OCO-D (O) LPQQCn / Lznz / Σΐ / YΙΛΙ, 101. A process according to claim 100, wherein the compound of formula X2-C(O)Xi is Ι,Γ-carbonyldiimidazole.

102. A process according to claim 100 or 101, wherein the hydroxy compound reacted with the compound of formula (B) is preferably HO-(CH2)2-4-NHProtNH, and, preferably, HO-(CH2)3-NHProtNH.

103. A process according to any of claims 100 to 101, wherein the compound reacted with the compound of formula (C) to provide the compound of formula (K) is 3-(methyldisulfanyl)propanoic acid.

104. A process according to claim 100, wherein the compound of formula HO(CH2)i 3SProtSH that is reacted with a compound of formula (J) to provide a compound of formula (L) is HO-(CH2)3SProtSH.